Wet granulated liquisolid drug delivery systems with hydrophobic and hydrophilic drugs by Javaheri, Hoda
Javaheri,  Hoda   (2017)  Wet   granulated   liquisolid   drug   delivery   systems  with 
hydrophobic and hydrophilic drugs. Doctoral thesis, University of Sunderland. 
Downloaded from: http://sure.sunderland.ac.uk/id/eprint/8549/
Usage guidelines
Please   refer   to   the  usage guidelines  at  http://sure.sunderland.ac.uk/policies.html  or  alternatively 
contact sure@sunderland.ac.uk.
Wet granulated liquisolid drug delivery 
systems with hydrophobic and 
hydrophilic drugs
Hoda Javaheri 
PhD November 2017
 
ii 
 
Abstract of Research  
The formulation of hydrophobic drugs into appropriate dosage forms is challenging due 
to the problems associated with those drugs such as low solubility and poor dissolution.  
Using a liquisolid system is a promising method to improve the dissolution of hydrophobic 
drugs and in sustaining the release of hydrophilic drugs, in which solid drugs are 
dispersed in non-volatile liquid vehicles. The aim of this research was to use the liquisolid 
technique to enhance the dissolution rate of glibenclamide, a model hydrophobic drug, 
and to sustain the release of metformin-HCl, as a model hydrophilic drug. The wet 
granulation process was applied to liquisolid powders with the aim of overcoming issues 
of poor powder flowability and compressibility, especially using high viscosity liquid 
vehicles. This process was performed with liquisolid powders prior to compaction into 
tablets. Different liquisolid formulations were prepared using three liquid vehicles 
(polyethylene glycol400 (PEG® 400), Synperonic® PE/L44 and Cremophor® ELP), at 10 
and 30 % w/w drug concentrations for glibenclamide; and 30% and 60% w/w drug 
concentrations for metformin-HCl. Avicel®PH102 was used as a carrier, whilst colloidal 
silicon dioxide was employed as a coating material to convert the wet mixtures into dry 
powders. Potato starch, 5% w/w, as a disintegrant was blended with the mixtures 
manually for 10 minutes and then 0.75% of magnesium stearate as a lubricant was added 
and mixed for 5 minutes. The final powder (depending on its flowability and 
compactability) was then compacted automatically using a single-punch tableting 
machine to give tablets with 4 mg for glibenclamide and 40 mg for metformin-HCl. 
Prepared liquisolid compacts were characterized by using British Pharmacopeia quality 
control tests: uniformity of weight, friability, disintegration, hardness and drug dissolution.  
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It was found, for both drugs, that by application of wet granulation to liquisolid powder 
admixtures, the large-scale production of liquisolid compacts is feasible, which can be 
easily adapted to the pharmaceutical industry. In addition to enhancing the flowability and 
compressibility of the powders, the glibenclamide dissolution was also improved due to 
the enhanced binding of particles and because of the wetting effect of liquid vehicles on 
the hydrophobic drug, which make the drug more available for dissolution.  
For the sustained release preparations of liquisolid metformin-HCl, hydroxyl propyl 
cellulose (HPC) was used as a novel carrier in liquisolid compacts. The results showed 
92% drug release after 12 hours using Cremophor®ELP (with 30% w/w drug 
concentration) which was the best sustained drug release formulation. Additionally, 
Eudragit® RL30D and Eudragit® RLPO have been used to study their effects on drug 
release from liquisolid formulations, examining if they can sustain or give more rapid drug 
release.  Both types of Eudragit revealed immediate release with metformin-HCl rather 
than sustained drug release, with the tablets disintegrating within seconds. This suggests 
formulating orodispersible metformin-HCl tablets using Eudragit® RL30D as a liquid 
vehicle.  
In summary, liquisolid technology has led to promising results, not only in enhancing the 
drug dissolution of hydrophobic drugs, but also in sustaining and promoting the release 
of hydrophilic drugs.  
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Chapter 1 - Introduction 
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1.1. General introduction 
There are several types of routes of drug administration available (Table 1.1) such as: 
oral, rectal, parenteral, nasal, topical, eye and ear routes of drug delivery. However, 
before choosing the right dosage form, special attention must be made to relate the drug 
substance to the clinical complication and factors governing the correct choice of drug 
administration such as bioavailability and solubility which must be taken into 
consideration. Amongst the above-mentioned route of administration, oral drug delivery 
remains the main and most appropriate and commonly employed route of administration 
due to its safety with lowest microbial related restrictions during the manufacturing 
process and high patient compliance due to ease of administration. It is mostly intended 
for systemic effect resulting in drug absorption in the gastrointestinal tract (GIT). The drug 
gets dissolved in the fluid of the mouth or stomach and then gets absorbed into the 
systemic circulation (Alderborn, 2013). However, drawbacks are correlated with the high 
desired route of administration and that is due to the slow onset of action and 
gastrointestinal enzyme secretion which can affect the absorption of the drug into the 
blood stream. 
 
In the field of pharmacy or pharmaceutics, a route of drug administration is the path by 
which a drug is taken into the human body. Additionally, a pure chemical substance must 
be formulated into an appropriate dosage form to be taken by the patient in the chosen 
route of administration. Active ingredients are not the only substances that play a role in 
the manufacturing of medicines, simple solutions to complex drug delivery systems use 
appropriate additives and excipients in the formulation where they provide specialised 
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functions. Nevertheless, the main purpose of dosage form design is to reach and achieve 
a desired therapeutic outcome while maintaining the reproducibility and high quality 
control in the large batch production for the pharmaceutical industry (York, 2013). 
Table 1-1: Routes of administration with different dosage forms (York, 2013) 
Route	of	administration	 Dosage	forms	Oral	 Solutions,	tablets,	capsules	and	powders	Topical	 Ointments,	creams	and	transdermal	patches	Parenteral	 Injections	Rectal	 Suppositories	Nasal	 Solutions	and	inhalations	Respiratory	 Aerosols	and	inhalations	Eye	and	Ear	 Solutions,	suspensions	and	creams	
 
Tablets are known to be the most popular form; tablets can be manufactured by several 
stages where the final stage is the compression of the powder held within a confined 
space. In addition, the use of tablets as dosage forms became of interest to the 
pharmaceutical industry, thus the formulation of tablets with variety of forms such as 
modified release, orodispersible, immediate release, chewable and effervescent were 
formulated. (European Pharmacopoeia , 2017) defines tablets as “solid preparations each 
containing a single dose of one or more active ingredients and obtained by compressing 
uniform volumes of particles”. The secret behind the difference between tablets is in the 
type of excipients used. Pharmaceutical industry uses different excipients, diluents, 
disintegrants and lubricants to ensure that tablets of specified quality are prepared. 
However, one excipient can affect the properties of the tablet. Thus, it can be said that 
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each excipient added has a specific role in the formulation of the oral tablets.  
1.2. Common challenges in the manufacturing of oral dosage forms 
The pharmaceutical industry has been facing challenges in the manufacturing of oral drug 
delivery systems. The major obstacle that concerns the industry can vary from dissolution 
rate to poor aqueous solubility and bioavailability of the active ingredient(s) (Dressman, 
2007)This requires special attention for the pharmaceutical scientists because active 
ingredients in tablets must undergo dissolution before they are available for absorption 
from the GI tract (Javadzadeh, et al., 2007)Therefore, drugs with poor water solubility will 
face problems in the dissolution and absorption into the blood stream. About 40% of the 
newly developed drugs are known to be hydrophobic and thus do not dissolve in water 
and have poor dissolution profiles (Lipinski, 2002). Moreover, the first site of drug 
absorption is the stomach where an oral administration can release its active ingredient 
(Dressman, 2007). Therefore, the dissolution is an essential step before absorption can 
take place from the GI tract to the systemic circulation. According to the Food and Drug 
Administration agency, drugs that are hydrophobic and have poor dissolution profiles can 
cause therapeutic in-equivalence due to low and high variable bioavailability which can 
be vital for patient’s health. 
Dissolution rate in the fluid of the absorption site controls the absorption rate of a poorly 
water-soluble drug. In other words, the rate of absorption is controlled by how fast the 
drug dissolves in the fluid at the site of absorption. Therefore, it can be documented that 
the dissolution rate is the rate limiting step in drug absorption (Javadzadeh, et al., 2007). 
Dissolution rate can be calculated using the Noyes-Whitney equation (Equation 1.1):  
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!"!# = %& ∙ ((*+ − *-)            Equation 1.1 
 
where “D” is the diffusion coefficient, “A” the surface area, “Cs” the solubility of the drug, 
“Cb” the concentration of drug in the bulk solution and “h” is the thickness of the diffusion 
layer around each drug particle (khorshed and Maghreby 2016). Each term has an 
influence on drug dissolution and thus absorption. For example, if the surface area 
increases, the dissolution rate will also increase which then improves drug bioavailability, 
see Figure 1.1 below: 
	
Figure 1.1: Representation of effect of modification of drug surface on particle 
properties. 
 
(Mosharraf & Nystrom, 1995) have reported that “poorly water-soluble drugs can be 
identified as small as 100µg/L solubility”. In addition to that, the biopharmaceutical 
classification system has provided a mechanistic framework to help understand the 
concept of drug absorption by means of solubility across the gastrointestinal (GI) pH 
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range 1-7.5 at 37°C and permeability across the GI mucosa. The drugs can be classified 
into four categories or classes (Figure 1.2) in which the drug's dose, permeability and 
solubility must be known (Helga, 2002) 
	
Figure 1.2: Four classes of Biopharmaceutics Classification Systems (BCS) 
 
1.3. Strategies in overcoming poor solubility and dissolution 
One of the major roles of pharmaceutical industries is to enhance oral bioavailability by 
improving drug solubility and dissolution. High doses of hydrophobic drugs being involved 
to increase plasma concentration to a therapeutic level will result in poor absorption into 
the blood stream, which can lead to accumulation of the drug in the GI tract and as a 
result can lead to toxicity (Savjani, et al., 2012). Consequently, these drawbacks have 
delayed several potential drugs in pre-clinical development. Since hydrophobic drugs are 
difficult to formulate using a conventional tableting method, different techniques have 
been reported in the literature to achieve enhanced drug dissolution rates. Some of these 
methods are: a) Solvent evaporation method (its limitations include: difficulty in 
completely removing the liquid solvent and higher cost of preparation) (Serajuddin, 1999), 
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b) Reducing particle size to increase surface area (particle size reduction using jet mill, 
rotor stator colloidal mill and ball mill. Limitations include: degradation due to thermal and 
physical stress, Takano et al 2004), c) Self-emulsifying drug delivery systems, SEDDS, 
(limitations include: administration in lipid-filled gelatin capsules due to the liquid nature 
of the system in which interaction between the drug and the capsule shell should be taken 
into consideration). Additionally, SEDDS’ administration is not intended for long-term use 
due to possibility of diarrhea effect (Shah, et al., 1994). Also, other attempts have been 
made such as: d) Solid dispersion (Scale up problems, decomposition of the solvent 
during process and dissolution reduction with ageing, Gowardhane et al.2014) e) 
Nanosuspension (limitation includes: the drug needs to soluble in at least one solvent in 
which this solvent must be miscible with the other non-solvents used (Muller, et al., 
2000)). Among the mentioned techniques to overcome poor dissolution, scientists have 
reported in several articles a new and promising method to enhance aqueous solubility 
of hydrophobic drugs known as “liquisolid technology” (Javazadeh , et al., 2005). 
Therefore, the aim of this current work is to introduce and to apply the concept of the 
liquisolid technique. 
1.4. Liquisolid compact technology and its mathematical principles 
The information on liquisolid technique was first introduced by (Spireas & Bolton, 1999), 
several research papers have shown successful results in the use of liquisolid compacts, 
yet, there are currently no liquisolid dosages available in the market. The concept of 
“liquisolid tablets” was evolved from the powdered solution technology where liquid 
medication can be used (Tiong & Elkordy, 2009), (Spireas & Sadu, 1998). The term 
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“liquisolid medication” implies to solid drugs dispersed in non-volatile solvent systems 
with the addition of appropriate powder excipients such as carriers, coatings and 
disintegrants. The incorporation of liquid surfactants into the oral hydrophobic drug allows 
the formation of drug-liquid interaction that helps in the solubility of the nonpolar drug 
molecules. Liquisolid compacts possess acceptable flowability and compactibility 
properties depending on the non-volatile liquid vehicle used. Flowchart, Figure 1.3 shows 
the summary for liquisolid compacts. 
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Table 1-2: Liquisolid mathematical expression and its definition 
Symbol Definitions 
Wliquid Weight of liquid medication 
Wsolid   Weight of carrier and coating material 
Q Weight of carrier powder 
R Ration between carrier and coating 
Q Weight of coating powder 
Lf  Liquid load factor 
ΦCa Flowable liquid retention potential of the carrier powder  
ΦCo 
Flowable liquid retention potential of the coating 
powder  
 
	
Figure 1.3: Flowchart summary of liquisolid powder preparation. 
 
Before using equations (1.3-1.5) and formulating the liquisolid compacts, determination 
of the optimal flowable liquid-retention potential for the carrier and coating used is 
essential, which is the Φ value required for Equation (1.3). This is usually the first step in 
the formulation. This measurement is termed as “angle of slide”, where it evaluates the 
flowability of carrier and coating materials. Then, a graph of angle of slide (Θ) versus the 
Step	1
• Angle of Slide determination ( Ɵ-value)
• Using liquid vehicle with carrier or coating
Step 2
•Addition of carrier, coating and other additives such as disintegrant 
and lubricant 
Step 3
•Compaction of liquisolid powder into tablets
Step 4
• Q and q amounts determination used for manufacturing of [liquid vehicle+drug]--> drug	
admixture	
medication
Step	5
•Lf (liquid	load	factor)
•To	calculate	the	amount	of	carrier/coating	(ΦCa	and	ΦCo)
Step	6
• Based on drug percentage (10%,30% and 60%) and R-value (R=/0	) =20
•Lf (liquid	load	factor)	can	be	determined
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measured Φ value is plotted and hence the load factor is then calculated from the results 
obtained (Figure 1.3; Table 1.2). The Φ value is defined as “the maximum weight of liquid 
(Wliquid) that can be retained per unit weight of the sorbent (Wsolid) yielding a mixture 
with acceptable flowability” ( Spireas , et al., 1992) 
Φ
	
value
	 =
89:0;:<8=>9:<
	
	
             Equation 1.2 
Therefore, several equations are used to calculate the right amount of carrier, coating 
and liquid medication needed for the formulation of the liquisolid compact:  Lf
	
= 	ΦCA
	
+ ΦCO
	
(EF)  Equation 1.3 
 
Where ΦCA is the flowable liquid-retention potential of the carrierand ΦCO is the 
flowable liquid-retention potential of the coating material.  
Lf
	
= 	GH                          Equation 1.4 
Where Lf is the “loading factor” where the maximum amount of drug liquid is loaded onto 
the carrier material. Q is the amount of carrier (such as microcrystalline cellulose, Avicel® 
PH102) and W is the liquid medication (such as: drug in PEG® 400 or Synperonic®PE/L44 
or Cremophor® ELP or Eudragit® RL30D)  
R	 = 	 /J  (R=20)        Equation 1.5
 
The amount of Q can be calculated (Equation 1.4) and applied to equation 1.5 to calculate 
the amount of coating (for example: Silica, Cab-o-Sil® M-5 (q)) required. Hence, after the 
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calculation of Q and q, the formulation of the liquisolid dosage can be initiated. In addition, 
the R value is the ratio between the carrier and the coating and it has been suggested 
that a ratio of 20 will produce a flowable and compactible admixture (Tiong & Elkordy, 
2009). 
The liquisolid tablets that contain the hydrophobic drug are expected to show significant 
increase in the wetting properties and surface area of the drug availability and thus, 
enhance drug dissolution. Also, it is expected to show enhanced drug released 
characterisation profiles. Nevertheless, this new dosage form will benefit the 
pharmaceutical industry in offering the most efficient drugs that can then be released to 
the market to improve patient compliance. With the new dosage form, the patient would 
need a decreased dose that is administered less frequently due to the ability of the 
hydrophobic liquisolid drug to release its contents faster allowing for maximum 
bioavailability. 
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Figure 1.4: Theoretical model of liquisolid system adapted from ( Spireas , et al., 1992) 
 
Figure 1.4 summarises liquisolid tablet formulation. The lipophilic drug gets dissolved in 
a selected non-volatile liquid vehicle. Selected suitable fillers such as microcrystalline 
cellulose act as carrier which carries the drug- liquid admixture. The liquid will then be 
absorbed in the interior of the particles. The addition of coating material such as silica 
powder converts the wet surface to a dry free flowing powder with acceptable 
compactibility. Depending on the amount of coating added, either mono or multilayer can 
be formed ( Spireas , et al., 1992). 
 
Based on literature, liquisolid technology has been widely used to improve the dissolution 
rate of hydrophobic drugs. In liquisolid systems, the wetting properties and surface of the 
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drug available for dissolution is significantly increased. This occurs when the drug is in a 
solubilized, almost molecularly dispersed, state or when held within the powder substrate 
in a solution form. Thus, liquisolid compacts of water- insoluble drug is expected to display 
enhanced drug release properties and instantaneously improves bioavailability (Fahmy & 
Kassem, 2008). Initially the liquisolid technique was implemented in 1998 by Spireas and 
Sadu, whose first formulated liquisolid drug was prednisolone, which was then compared 
to directly compressed tablets (Spireas & Sadu, 1998)As a result, prednisolone liquisolid 
compacts demonstrated significantly higher drug release rates. 
(Javazadeh , et al., 2005) improved the dissolution rate of piroxicam by using liquisolid 
technology. In this study, the development of several liquisolid tablet formulations of 
piroxicam and tween 80 were prepared using different concentrations of tween 80. As a 
result, liquisolid compacts showed significantly higher drug release rates than 
conventional formulations. 
Furthermore, in 2007, Javadzadeh et al. further studied the effects of liquisolid technology 
on carbamazepine. According to the BCS, Carbamazepine belongs to class II category, 
where its bioavailability is limited by its poor dissolution rate in the gastrointestinal tract. 
Different liquisolid formulations of carbamazepine were prepared. In this study, the 
loading factor was increased by the addition of some namely additives such as: 
polyvinylpyrrolidone (PVP), hydroxypropyl methylcellulose (HPMC) and polyethylene 
glycol (PEG 35000) to the liquid vehicle. As a result, compared to directly compressed 
tablets, liquisolid formulations containing PVP, exhibited higher dissolution rates. 
Additionally, increased PVP concentration in liquid medication showed significant 
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increase in the drug dissolution rate in the first 30 min of dissolution. Therefore, these 
additives were realized to have the capability to increase the liquid absorption capacity of 
carrier and coating materials. 
In 2008, Javadzadeh et al. utilized the liquisolid technique as a new approach to sustain 
the release of propranolol hydrochloride from tablet matrices. In this study, propranolol 
was dispersed in polysorbate 80, followed by the addition of a binary mixture of carrier–
coating materials Eudragit RL or RS (carrier) and silica (coating material) to the liquid 
vehicle.  In comparison with conventional matrix tablets, propranolol liquisolid tablets 
exhibited a greater retardation property. Furthermore, (Gubbi & Jarag, 2009), have 
reported the use of liquisolid technique to study the dissolution rate of bromhexine 
hydrochloride and compared it with conventional bromhexidine. Furthermore, using 
Avicel PH102 (carrier), Aerosil® 200 (coating material) and Explotab (disintegrant), 
different liquisolid formulations were developed. The drug release rates of liquisolid 
formulations were significantly (p<0.05) higher as compared to conventional tablets, 
proving the great effect of liquisolid technique on dissolution properties. 
In 2009, Javadzadeh et al. examined the effect of several commercial grades of 
microcrystalline cellulose on flowability, compressibility, and dissolution rates of piroxicam 
liquisolid tablets.  Thus, several formulations were prepared using different MCC grades 
(as carrier); propylene glycol as a non-volatile liquid, silica as a coating material, and 
sodium starch glycolate as a disintegrant. Formulations containing MCC PH 101 and 
PH102 resulted in better tablet properties, while enhanced flowability was observed with 
MCC PH 101 grade. 
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 In 2009, liquisolid technology was also practiced by Tiong and Elkordy, to study the 
effects of liquisolid formulations on the dissolution rate of naproxen. The liquisolid tablets 
were formulated with three different liquid vehicles - PEG® 400, Synperonic® PE/L64 and 
Cremophor® EL, at 20%w/w and 40%w/w drug concentrations. Furthermore, Avicel® 
PH102 was used as a carrier, Cab-o-sil® M-5 (silica) as a coating material and maize 
starch was used as a disintegrant. The dissolution study was performed in simulated 
gastric fluid (SGF), pH 1.2, and simulated intestinal fluid (SIF), pH 7.2, and was further 
compared with conventional naproxen tablets. The results exhibited that naproxen 
liquisolid tablets formulated with Cremophor®EL at 20%w/w (drug concentration) 
produced the best dissolution profile with high release and improved tablet properties. 
Additionally, stability studies showed that formulation prepared with Cremophor® EL was 
negligibly affected by aging; while Differential Scanning Calorimetry revealed that drug 
particles in liquisolid formulations were completely in a solubilised state. 
Furthermore, liquisolid tablets of glipizide was applied by (Mahajan, et al., 2011). 
Liquisolid tablets of glipizide were prepared by using Avicel® PH102 as a carrier, Aerosil® 
200, as a coating material and gellan gum as a disintegrant to increase dissolution rate 
of glipizide. Glipizide liquisolid tablets dissolution profiles were compared with the 
commercial counterparts which exhibited higher dissolution rates of glipizide liquisolid 
tablets in comparison to the marketed tablets. The study also showed that dissolution 
rates increased with an increase in the concentration of non-volatile liquid vehicles and 
the best drug release was achieved by formulations containing polyethylene glycol 400 
(PEG® 400).  
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(Saeedi, et al., 2011) investigated a water insoluble drug, indomethacin, for enhancement 
of drug dissolution rates. They applied liquisolid technology and found that in comparison 
to conventional indomethacin, the liquisolid formulations exhibited significantly higher 
drug dissolution rates. Enhanced dissolution rates of liquisolid indomethacin tablets was 
due to an increase in the wetting properties and surface area of drug particles that are 
available for dissolution. This indicates that, the fraction of molecularly dispersed drug in 
the liquid medication of liquisolid systems is directly proportional to the indomethacin 
dissolution rate.  
In 2016, (Pezzini, et al., 2016)performed a study on the practicality of liquisolid 
technology, not on compact form, but on pellets formation of a model drug, felodipine. 
The study was conducted to record the effects of Kollidon®CL-SF (as a coating material 
and as a disintegrating material) and the type of non-volatile solvents, PEG 400 or 
Cremophor®EL, on felodipine dissolution behaviors. As a result, a higher drug release 
was found in formulations using Cremophor®EL which were more effective in comparison 
to PEG® 400. This is due to the formation of softer and more porous structures. 
Remarkable positive effects were also seen in the amount of Kollidon®CL-SF used. The 
study consists of an innovation of the current liquisolid technology of the development of 
liquisolid pellets and the use of Kollidon®CL-SF as a coating material in liquisolid 
formulations. The promising results revealed that it is feasible to adopt liquisolid pellets 
as novel drug delivery systems to improve the dissolution rate of poorly water- soluble 
drugs. 
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1.5. Liquisolid preparation methodology 
Liquisolid preparation is commenced by blending the calculated amount of hydrophobic 
drug with the non-volatile liquid vehicle. With the use of pestle and mortar, the drug is 
satisfactorily mixed with the liquid to allow the liquid to penetrate between the hydrophobic 
drug particles. The process takes around 5 to 10 min of continuous mixing. The admixture 
is then allowed to rest. This is vital to allow the non-volatile liquid particles to be fully 
absorbed into the interior of the powder particles. Gradually, and in small batches, the 
carrier (usually microcrystalline cellulose) gets added to the admixture. The carrier's role 
is to carry the drug along with the liquid vehicle. The coating (Silica Cab-o-Sil ® M-5) is 
then added to coat any excess liquid particles present in the admixture (Figure 1.3) that 
have not been absorbed into the internal structure of the carrier particles. At this stage, 
the liquisolid system is formed with suitable flowability and compressibility profile. As a 
final stage, 5% potato starch and 1% magnesium stearate (calculated according to the 
weight formation) are added as a disintegrant and lubricant respectively, where starch is 
required in the formulation to break up the tablets into primary powder particles in order 
to increase the surface area of the drug in the GI fluid, thus promoting the dissolution rate 
(Fahmy & Kassem, 2008). Magnesium stearate is added to reduce the friction between 
the punch of the tableting machine and the powder. Additionally, as seen in Figure 1-5, 
before the compaction stage, which is a novel step in this research, a wet granulation 
step was introduced to enhance flowability and compressibility of the liquisolid powder 
especially using highly viscous liquid vehicle such as Cremophor®. 
Evidence suggests that liquisolid tablets using hydrophobic drugs have shown enhanced 
dissolution profile due to an increase in the surface area and wetting properties of the 
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water-insoluble drug particles (Spireas & Bolton, 1999); (Nokhodchi, et al., 2005). During 
the process of liquisolid preparation, heating or drying does not take place; therefore, the 
drug remains embraced by the non-volatile liquid vehicle. Hence, the chosen non-volatile 
solvent must have a high boiling point with inert properties and preferably less viscous to 
maintain even distribution of the drug inside the admixture. In addition, a highly viscous 
liquid vehicle can affect the flowability and compactibility of the final liquisolid powder. 
Therefore it is crucial to select a non-volatile liquid vehicle with good property 
characteristics. Several studies have been conducted using different liquid vehicles such 
as Polyethylene glycol, SynperonicÒPE/L44, Cremophor®ELP and TweenÒ80. Each liquid 
vehicle possesses its own characteristics and behaviours when combined with a specific 
hydrophobic drug, therefore, there is no common single liquid vehicle suitable for use in 
liquisolid preparation for a wide range of non-polar drugs. Additionally, the carrier must 
have a porous nature to be able to absorb more liquid and the coating must have 
adsorptive properties to coat the admixture and form a thorough dry powder (Elkordy, et 
al., 2013). 
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Figure 1.5: Schematic diagram of the preparation of liquisolid tablets. 
 
1.6. Mechanism of enhanced drug release from the liquisolid system: the 
advantages and limitations of such system: 
Numerous mechanisms of enhanced drug release have been developed for liquisolid 
technology to understand the dissolution theory of such a system. Improved wetting 
properties, enhanced aqueous solubility and increased surface area of the hydrophobic 
drug are the three principal mechanisms which have been suggested by several studies 
(or groups or researchers). (Nagabandi, et al., 2011) , (Spireas & Sadu, 1998), (Darwish 
& El-Kamel, 2001), (Akinlade, et al., 2010). Besides, the liquid vehicle acts as a surface 
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active and surface tension lowering agent. In return, the wettability of the liquisolid 
particles can be enhanced. Such a theory is demonstrated by the determination of lower 
contact angles and shorter water rising time resulting in an increase in aqueous solubility. 
In addition to the above-mentioned mechanism of drug release enhancement, it is 
expected that the solubility of the hydrophobic drug can be increased with liquisolid 
systems. The increased drug solubility phenomenon of liquisolid system suggests that a 
small amount of liquid vehicle in a conventional manner is not enough to solubilize the 
total amount of drug; however, if the liquid vehicle acts as a co-solvent, it is possible that 
this small amount of liquid vehicle diffusing from the total amount out of a single liquisolid 
particle together with the drug molecules is sufficient to increase the aqueous solubility of 
the drug at the solid liquid interface. Lastly, as the surface area of the drug increases, the 
dissolution rate of the drug with the liquid vehicle also increases (Balaji, et al., 2014). 
1.6.1. Advantages of liquisolid technique include: 
• Numerous hydrophobic solid drugs can be formulated into liquisolid systems. 
• Bioavailability improvement can be achieved as compared to conventional tablets. 
• Liquisolid preparation is a straightforward method and similar to that of 
conventional tablets preparation and industrial production is applicable. 
• When compared to soft gel capsules, the production of liquisolid compacts are 
considerably economical and affordable. 
• Liquisolid system is not limited to the dissolution enhancement of hydrophobic 
drugs, but also can be used to modify the release of highly water-soluble drugs 
with the addition of certain surfactants known as sustaining agents. 
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1.6.2. Limitations of liquisolid technique includes: 
• Small amount of active ingredient used in the liquisolid compacts, because as the 
weight of the drug increases, this leads to an increase in the weight of the liquid 
vehicle, carrier, coating materials and will yield a large tablet which can be difficult 
to swallow and causes reduction in patient compliance. To solve this problem, 
several suggested theories have been made in literature by which to select a 
suitable liquid vehicle to which its loading factor would be high. Increase in loading 
factor means a decrease in tablet weight (Elkordy, et al., 2013); (Nagabandi, et 
al., 2011), ( Spireas , et al., 1992) (karmarkar, et al., 2009).  
• High specific surface area and adsorption properties are required to be shown in 
the used surfactants. 
• Increasing the amount of silica Cab-o-Sil®M-5 (coating material) in the formulation 
can affect negatively on drug release, due to the hydrophobicity of silica Cab-o-
Sil®M-5 (coating material), which can delay drug release if added in high quantities 
(Spireas & Bolton, 1999). 
• Depending on the liquid vehicle used, the liquid being squeezed out of the tablet 
is possible during the compression process resulting in improper hardness and 
even loss of shape (Javaheri et al 2014) 
• Due to the use of highly viscous liquid vehicles, desired tablets cannot be achieved 
into a suitable compression force, hardness and shape. However, wet granulation 
as used in this research can overcome some of this limitation. 
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1.7. Pharmaceutical wet granulation:  
Most pharmaceutical industries recognize wet granulation as a widely-used method of 
tablet processing. It is no longer required to depend on the intrinsic properties of the drug 
and the excipients used because via wet granulation process it has become feasible to 
produce well-formed tablets. The granulation method is divided into two parts: dry 
granulation, in which no liquid is used, and wet granulation, which incorporates the use 
of liquid binder. The granulation mechanism can be defined as the process in which 
primary powder particles agglomerate. In other words, the particles in the powder form 
adhere in a way that they form larger multi-particle entities called granules. These 
pharmaceutical granules have different sizes that can range between 0.2mm to 0.4mm 
(Summers & Aulton, 2013). The reasons behind the use of granulation technique in 
pharmaceutical industry are as follows: 
• Segregation prevention of the constituents of the powder mix. Pharmaceutical 
industries look for the ideal granule which contains all the constituents of the mix 
in a proportional manner. 
• Improvement of powder flow properties. Poor flowability will result in wide weight 
variation in the final product due to the irregular shape and small size of the 
powder. Granulation process with aid of liquid binder adds weight to the particle 
and enhances the flowability. 
• In addition to the above advantages, granulation is used to improve the compaction 
characteristics of the powder mix. This is due to the adhesive properties within the 
granules. Additionally, as the particle size gets evenly distributed using the 
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granulation process, this leads to increased density of the powder and 
enhancement of its compactibility and compressibility. 
• Toxic materials can be turned into granules using non-friable and suitable 
mechanical strength granulation processes, reducing the hazard associated with 
handling of toxic powders.  
• Wet granulation can also be used to modify and improve drug release. 
 
In the wet granulation process, the liquid solution known as the “liquid binder” gets added 
to the dry primary powder to produce bonded particles via capillary forces that remain 
adherent and strong enough to lock particles together (Summers & Aulton, 2013). The 
liquid binder or the granulating fluid, must be non-toxic and volatile in nature in order to 
be evaporated or removed by drying. Examples of such fluids include ethanol, water and 
isopropanol. Water is widely used for its economic and ecological benefits. However, the 
disadvantage of using water as a granulating fluid is that it may affect drug stability and 
show adverse effects. Additionally, water requires longer drying time which can affect the 
stability of the drug due to the extended exposure to heat.   
Granulation process is known to be a simple method depending on the characteristics of 
the powder and equipment used. Using traditional wet granulation method, the liquid 
added to the dry powder gets distributed evenly through the powder particles using 
mechanical agitation, which yields to particle adherence. Furthermore, wet granules are 
formed using pharmaceutical grade sieves with desired sizes, by wet powder mass being 
forced through which are then dried subsequently. A screening stage is then performed 
to break granules agglomerates. There are five primary particle bonding mechanisms in 
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granulation process which include the following: (Kienkens, et al., 2000) 
• Adhesion and cohesion forces between individual particles of the powder. As 
the contact area between particles increases, this causes a decrease in their 
interparticulate distance strengthening and increasing the bond among those 
particles. This can happen only when sufficient liquid is added to the powder to 
form a thin and immobile layer. 
• Solid bridges formation upon solvent evaporation. This can be achieved using 
three steps: crystallization of dissolved substances, partial melting and 
hardening binders. 
• Interfacial forces in mobile liquid films within the granules. The added liquid 
during wet granulation gets distributed as films among and across particles of 
the powder mix to form mobile films.	
• Mechanical interlocking adhesion can occur when an adhesive enters into the 
pores of the adhered surface of a substrate, and locks to the surface 
mechanically. 
• Attractive forces between solid particles. Solid bridges get formed using binding 
agents in the absence of liquid. Electrostatic forces and Van der Waals forces 
are the two main kinds of forces that run between particles.	
1.7.1. Mechanism of granule formation: 
The suggested granulation mechanism can be recognized in the following three stages: 
(Shanmugam, 2015) 
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• Nucleation:  This primary step of granulation process commences with particle-
particle adhesion due to liquid bridges. The even distribution of the liquid binder 
inside the dry powder bed leads to the formation of nuclei granule. 
 
• Transition: The presence of various number of small granules with a broad 
distribution size is what describes the transition stage. Moreover, nuclei can grow 
by either the addition of single particles to the nuclei by pendular bridge, or by the 
combination of several nuclei.  
 
• Ball growth: Depending upon the amount of liquid added and the characteristics of 
the powder being granulated, granule coalescence will continue upon agitation 
which produces an unfeasible and over massed system. The ball growth 
mechanism is illustrated in Figure 1.6 which states the four possible stages or 
mechanism of granule growth (Mirza, et al., 2007); (Summers & Aulton, 2013). 
 
1) Coalescence: Is when several granules join to form a larger granule. 
2) Breakage: The breakage of granules into fragments that can attached to other 
granules. As a result, a layer of material over the surviving granule can be formed. 
3) Abrasion transfer. At this stage, the granule beds get agitated can promote to the 
attrition of material from granules. As a result, due adhesion to other granules, their 
sizes will be increased. 
4) Layering. Layering occurs when an extra batch of powder mix is being added to a 
bed of granules, the powder then coheres to the granules and forms a layer over 
the surface in which as a result, a rise in their size will occur. 
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Figure 1.6: Ball growth mechanisms during granulation process (Summers & Aulton, 
2013). 
 
1.8. Poly vinyl pyrrolidone (PVP) as a liquid binder in the wet granulation process:  
Soluble polyvinylpyrrolidone or poly-[1-(2-oxo-1-pyrrolidinyl) (see Figure 1.7) was the 
first polymerisation product of N-vinylpyrrolidone in water using hydrogen peroxide or 
using an organic peroxide as initiator (Bühler, 2005). Moreover, Polyvinylpyrrolidone is a 
free-flowing white or yellowish-white powder that comes in different particle sizes. The 
method of synthesis determines the odour of individual product. Table 1.3 below lists 
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the official names and abbreviations of PVP that are specific to the pharmaceutical 
industries. 
Table 1-3: Soluble polyvinylpyrrolidone official names and abbreviations (Bühler, 2005). 
Povidone Current valid Pharmacopoeias (e.g. USP 26, Ph.Eur. 5, JP 14) 
Polyvidon(e) Former editions of Pharmacopoeias (e.g. Ph.Fr. IX) 
Povidonum Pharmacopoeias (e.g. Ph.Eur. 5) 
Polyvidonum 
solubile Former edition of the DAC (1986) 
Poly(1-vinyl-2-
pyrrolidon) Deutsches Arzneimittelgesetz 1984 
PVP General abbreviation, commercial name for cosmetics/tech- nical grade 
 
In addition to that, PVP polymers are obtainable in different viscosity grades and can 
range from low to high molecular weight. The viscosity of aqueous solutions of PVP 
depends on its average molecular weight. Additionally, polyvinylpyrrolidone is a stable 
polymer which can be safely used in liquid and solid dosage forms. PVP possess very 
useful application in the field of pharmaceutical industry. The feature that distinguishes 
PVP is its excellent solubility in water. This is an advantageous property in almost all 
dosage forms such as in wet granulation (for tablet production), oral solutions, and 
injectable medications. Nevertheless, its fundamental adhesive and binding influence 
allows it to be distinctive in the wet granulation and direct compression of tablet 
manufacturing making it a good material to use in this research as a liquid binder. The 
other feature that makes PVP a unique polymer is its wettability enhancement and these 
important characteristics can improve the rate of dissolution of hydrophobic drugs if 
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tablets being formulated using PVP. Research article by (Javaheri, et al., 2014), has 
shown dissolution enhancement of poorly water soluble, glibenclamide, when PVP has 
been used as a liquid binder in wet granulation of liquisolid tablets. Nevertheless, as the 
molecular weight of PVP increases, its dissolution rate decreases while the viscosity and 
adhesive power still increases. Therefore, according to the properties of the molecular 
weight, the optimum grade for individual dosage form can be provided in order to acquire 
the best outcome. Other studies have also shown tablet quality enhancement after the 
use of PVP, where wet granulation using PVP showed better flow properties, harder 
granules, lower friability and enhanced dissolution results when compared with cellulose 
derivatives (Bühler, 2005). Moreover, a study performed by (HIlton & Summers, 1986) 
was conducted on a poorly water-soluble drug known as Indomethacin in different solid 
dispersion formulations to test the drugs dissolution profile using PVP with different chain 
length. Consequently, it was noticed that dissolution rate was slower in tablets containing 
longer chain length of PVP and was higher in shorter chain ones. 
	
Figure 1.7: Poly vinyl pyrrolidone (PVP) Struc ture (Sigma Aldrich) 
 
1.9. Wet granulation and liquisolid tablets:  
Several scientists in the field of pharmaceutics, specifically in the formulation of high 
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quality tablets with enhanced dissolution, have challenged the use of liquisolid technique 
in their studies. Additionally, many have implemented new ideas in the manufacturing of 
liquisolid tablets. Amongst the newer generation ideas was the use of wet granulation in 
liquisolid preparation (Javaheri, et al., 2014). Wet granulation using PVP was applied on 
liquisolid system using glibenclamide (hydrophobic drug) with three different non-volatile 
liquid vehicles PEG®400, Synperonic®PE/L44 or Cremophor® ELP at 10 %w/w. The 
study proved the advantages of using wet granulation when used in liquisolid preparation 
not only enhances the solubility of glibenclamide, but also improves the flowability and 
compactibility of the liquisolid powder. Another study by (Javadzadeh, et al., 2007), has 
included polyvinylpyrrolidone (PVP) as an extra additive to the liquisolid systems to 
enhance the release of the hydrophobic carbamazepine in dissolution media. As a result, 
it was shown that the liquisolid tablets prepared with PVP improved dissolution rate in 
comparison with other formulations. The reason behind the success in drug dissolution 
enhancement is the ability of PVP to prevent drug retention in the spaces of porous 
surfactant, thereby enhancing the release of the hydrophobic drug into the dissolution 
medium. 
1.10. Liquisolid technique based sustained release formulations 
Development of sustained-release oral delivery systems are beneficial to achieve 
therapeutically effective concentrations of the desired drug at a constant and 
predetermined rate over a period of time which can be an optimal therapy in terms of 
patient compliance, efficacy and possible side effects reduction. (Wadher, et al., 2011). 
The most commonly used method of modifying the drug release is to use hydrophilic 
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matrix systems. A research on sustaining nicorandil release was performed by (Reddy, 
et al., 2003). Hydroxypropyl methylcellulose (HPMC) was used as a hydrophilic matrix 
agent. However, it was concluded that HPMC alone could not control the release of 
nicorandil release over 24 hours effectively. Therefore, several different techniques of 
sustaining the release of the drug over a desired time to deliver a constant concentration 
of drug have been performed. Nevertheless, it has been suggested by several researches 
that liquisolid technique has the potential to produce sustained release tablets by the 
reduction of drug dissolution rate of water soluble drugs such as trimetazidine. (Pavani, 
et al., 2013) investigated the release of trimetazidine dihydrochloride in polysorbate 80 
and it was demonstrated that the use of polysorbate 80 can prolong the release of the 
used hydrophilic drug.  In 2008, Javadzadeh et al. successfully used liquisolid technique 
to sustain the release of the water-soluble propranolol hydrochloride. Additionally, 
polysorbate 80, EudragitÒ RL and RS grades were used as non-volatile liquid vehicles 
along with carrier and coating materials to prepare a liquisolid system with prolonged 
release mechanism. The importance of liquisolid technology on the ability to improve the 
dissolution of the hydrophobic drug or lower the rate according to the excipients used was 
understood. (Gonjari, et al., 2009) declared that the use of hydrophobic carriers such as 
EudragitÒ RL or RS is likely to be a more efficient in the formulation of liquisolid prolonged 
release tablets. These hydrophobic carriers can lead the liquisolid compact to poor 
wettability, resulting in slower disintegration and slower drug release. In the case of 
hydrophobic carriers being ineligible for use, it is suggested to use hydrophilic carriers 
with the caveat that the hydrophilic carrier can be used only by the incorporation of a 
retarding agent such as hydroxy propylmethyl cellulose (HPMC). Depending on its 
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molecular weight, HPMC can either form a hydrated matrix layer or swells as it gets in 
contact with the gastrointestinal fluid which then allows the drug to erode and slowly 
dissolve. The dissolution of such systems is controlled by diffusion mechanism and the 
gel type formation of the HPMC acts as a protective barrier to the influx of water and efflux 
of the drug (Wadher, et al., 2011). 
Till date, a limited number of drugs and sustaining agents have been formulated into 
liquisolid sustained release tablets. For instance, hydroxy propyl cellulose (HPC-H) has 
not been used in the any liquisolid research study as an agent to prolong the release of 
the water-soluble drug. Therefore, one aim of this work was to use liquisolid system with 
HPC to sustain metformin-HCl (a model drug) release. Glibenclamdie and metformin-HCl 
are used in this research as model drugs to be formulated into liquisolid tablets. 
1.11. Glibenclamide properties and characteristics 
Glibenclamide is an oral antidiabetic drug of the second-generation group known as 
“sulfonylurea”. It is used to treat non-insulin dependent patients with type II diabetes 
mellitus. It works by inhibiting the ATP-dependent potassium channels. It lowers blood 
glucose level by stimulating the insulin release from pancreatic b-cells and by enhancing 
the sensitivity to insulin by peripheral tissues (Manimaran, et al., 2010). In the b-cells of 
the plasma membrane, the KATP channels have receptors that give high affinity to 
glibenclamide to bind on to and stimulates the release of insulin. The drug is 
manufactured into low doses of 2.5mg and 5 mg and is excreted readily from the body. 
Also, due to glibenclamide’s active metabolites, hypoglycemic effects can be one of its 
adverse effects. Moreover, several research papers have witnessed low dissolution rate 
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behavior of glibenclamide due to the poor solubility and wettability characteristics. As a 
result, this can cause a reduction in its bioavailability. As seen in Figure 1-8, glibenclamide 
is a weak acid with a pKa of 5.3 and thus it is a pH dependent of the medium (Gianotto, 
et al., 2007). Several methods have been reported to enhance the poor solubility 
properties of glibenclamide and in this work liquisolid technique was used to formulate 
glibenclamide tablets into 4 mg dose. By this way any possible adverse effects may be 
minimised, yet maintaining the enhanced dissolution properties by the aid of the liquisolid 
system. 
	
Figure 1.8: Glibenclamide structure (Royal Society of Chemistry-ChemSpider 
 
1.12. Properties of Metformin-HCl 
Metformin hydrochloride (dimethylbiguanide) has an empirical formula of C4H11N5•HCl 
and its molecular weight is 165.63. Additionally, its structural formula can be seen in 
Figure 1.9. Metformin-HCl belongs to the biguanide class of oral antidiabetics. For over 
15 years, metformin-HCl has been the first line of treatment for the treatment of non-
insulin dependent type II diabetes mellitus. Prolong use of metformin to control blood 
glucose decreases myocardial infarction and coronary diseases seen in overweight 
diabetic patients (Block, et al., 2008). Metformin-HCl works by inhibiting the glucose 
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absorption from the intestine and suppressing the hepatic gluconeogenesis. Metformin-
HCl is associated with gastrointestinal side effects such as nausea, diarrhea and 
abdominal discomfort which make a small percentage of patients intolerable to it. The 
bioavailability of metformin-HCl is about 40% to 60% (approximately 30% unchanged 
metformin-HCl excreted in urine) with a complete ingestion of approximately 6 hours and 
a plasma half-life of 1.5-4.9 hours (Nanjwade, et al., 2011). It is absorbed in the small 
intestine and partially in the stomach and negligible absorption is seen in the large 
intestine. The therapeutic dose that is currently available in market is 500 mg and up to 
1.5 g, which is a large tablet to formulate and it is sometimes difficult to swallow, thereby 
discouraging patient compliance. Multiple dosing and big tablets can be a potential 
problem to the pharmaceutical market and pharmacy world. Pharmaceutical industries 
face formulation challenges when formulating metformin-HCl due to its poor 
compressibility and high dose. According to the Biopharmaceutical Classification System 
(BCS), metformin-HCl falls into the Class III of the BCS. It is a highly water-soluble drug 
with low permeability (Nicklin, et al., 1996) resulting in the need to administer high 
therapeutic doses to reach the desired plasma level. The other challenge that industries 
face in metformin-HCl formulation is direct compression because of poor characteristics 
of the drug, which can be a great problem on large-scale production. Metformin 
hydrochloride is a white crystalline powder with PKa of 12.4. It is practically insoluble in 
acetone, chloroform and ether. Nevertheless, the pH of a 1% aqueous solution of 
metformin hydrochloride is 6.68. 
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Figure 1.9: Metformin.HCl Structure (Sigma Aldrich) 
 
The above mentioned challenges make metformin-HCl a good drug candidate for 
liquisolid system for enhancement of its properties. Therefore, not only highly water-
soluble drug to be formulated as sustained release formulations, but also liquisolid can 
be useful to overcome problems such as low permeability. 
1.13. Aims and objectives: 
   The primary aim of this research project is to use the liquisolid technique to enhance 
the dissolution rate of glibenclamide tablets, model hydrophobic drug. The second aim is 
to study the release and behavior of the water-soluble drug, metformin-HCl from 
immediate and sustained release tablets in a liquisolid system to confirm the different 
application of this technique and to evaluate its importance in powder technology. 
Furthermore, a novel application of “Wet Granulation” conjointly with liquisolid technique 
was achieved.  It is used to overcome issues of poor powder flowability and compactibility 
especially with using high viscosity liquid vehicles. Thus, this new technique was 
performed as a last step upon preparation of liquisolid powders and before the automatic 
compaction into tablets. The third aim of this research is to enhance the permeability of 
metformin-HCl using liquisolid technique. Due to poor compactibility problem of 
metformin-HCl, it was thought to improve and overcome the challenge using liquisolid 
systems with and without granulation to observe the results. 
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The objectives of this research are as follows:  
• Preparation of ungranulated and granulated liquisolid tablets of 
Glibenclamide (4mg unit dose) as a hydrophobic model drug using three 
liquid vehicles PEG®400, Synperonic®PE/L44 and Cremophor®ELP, at 10 
%and 30 %w/w drug concentrations. 
• Characterisation of tablets via B.P. quality control tests. The tests include 
uniformity of weight, friability, disintegration, drug content uniformity and 
dissolution tests. 
• Preparation of liquisolid tablets of metformin-HCl (40mg unit dose) as a 
hydrophilic model drug using three liquid vehicles PEG®400, 
Synperonic®PE/L44 and Cremophor®ELP, at 30% w/w and 60 %w/w 
concentrations. 
• Investigating the effect of wet granulation process in combination with 
liquisolid systems, in terms of flowability, compactibility and dissolution of 
drugs. 
• Using Eudragit®RL30D as a non-volatile liquid vehicle with metformin-HCl 
to study its influence on drug release behaviour (either sustain or 
immediate release) thereby adding a new non-volatile liquid vehicle to 
literature. 
 
• Sustaining liquisolid metformin-HCl formulations using hydroxylpropyl 
cellulose (HPC) as a carrier.  
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• Studying the permeability of immediate release metformin-HCl using Franz 
cell diffusion with male Wistar rat biological gut membrane. 
 
For sustained release preparations of liquisolid metformin-HCl, hydroxypropyle cellulose 
(HPC) was used as a carrier instead of normal carrier. To our best knowledge, preparation 
of sustained release liquisolid metformin-HCl using HPC is a new study and no 
publications have been found on the uses of HPC in liquisolid technology. Therefore, 
many challenges were experienced in using this new excipient. Additionally, 
Eudragit®RL30D, as non-volatile liquid vehicle and Eudragit®RLPO as a carrier, were 
used to prepare liquisolid metformin-HCl as immediate release tablets. However, this 
study has showed that not all excipients work similarly on all drugs. Several publications 
suggest the usage of Eudragit®RL as sustaining agent, however, when Eudragit®RL30D 
and Eudragit®RLPO were used in this study to prepare liquisolid metformin-HCl, results 
showed immediate release with fast disintegration time (within seconds), which can be a 
new promising discovery for metformin-HCl as orodispersible tablets. 
1.14. Structure of the Thesis 
Chapter One: Introduction and Literature review to give a background for the application 
and importance of liquisolid technology to improve drug performance either to enhance 
or sustain the drug release characteristics.  
 
Chapter Two:  Materials and methodology applied in this current research. 
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Chapter Three:  Glibenclamide liquisolid preparation with the application of wet 
granulation technique. Glibenclamide was used as a model hydrophobic drugs with the 
aim to enhance its release profiles.  
Chapter Four: Application of liquisolid technology using wet granulation on metformin-
HCl: Immediate release and permeability studies. Based on the results of liquisolid 
technology on glibencalmide release, another model drug - but it is water soluble – 
metformin-HCl was chosen to compare and contrast the effects of liquisolid technology 
on release behaviors of different drugs. 
Chapter Five: Preparation and characterisation of sustained release liquisolid metformin-
HCl formulations using Hydroxypropyl Cellulose (HPC-H).  
Chapter Six: Orodispersible liquisolid preparation of metformin-HCl immediate release 
using Eudragit®RL-30D as a non-volatile liquid vehicle: A Novel discovery.  
Chapter Seven: Conclusion and future work. 
Chapter Eight: References. 
Figure 1-10 shows the liquisolid preparations in this research. 
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1.15 Novelty of the current research work 
The novelty of this work can be summarised in the following points: 
• Liquisolid technique with the application of wet granulation prior to 
compaction stage. 
• Effect of liquisolid technique on metformin-HCl permeability with 
Cremophor®ELP as a non-volatile liquid vehicle. 
• Liquisolid compacts using Eudragit®RL30D as a non-volatile liquid vehicle to 
produce orodispersible metformin-HCl tablets. 
• Sustained release preparation of metformin HCl using hydroxypropyl cellulose 
(HPC). 
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Figure 1.10: Flowchart of liquisolid preparation work 
Liquisolid compact preparation
Model drugs for immediate drug release
Glibenclamide, Metformin-HCl
Angle of slide determination (q-value) determination for
carrier: Avicel®PH102
coating: Cab-O-Sil®M-5
Liquid load factor(Lf value) determination
Drug powder admixture with liquid vehicle
PEG®400 Synperonic®PE/L44 and
Cremophor®ELP
Q,q(carrier to coating)amount
R=20 Carrier: Avicel®Ph102
Coating: Cab-O-Sil® M-5
Mixing of drug powder, liquid vehicle,carrier,coating, disintegrant and lubricant 
in adjustable amount based on mathematical calculation 
Powder admixture
wet granulation with 10%PVP
Automatic compaction
No granulation
Manual compaction
Metformin-HCl
Angle of slide determination (q-value) 
determination for carrier: Avicel®PH102, 
Avicel®PH102:Eudragit®RLPO (7:3)
coating: Cab-O-sil®M-5
Liquid load factor (Lf value) 
determination
Drug powder admixture with liquid 
vehicle
Eudragit®RL30D
Q,q (carrier to coating) amount
R=20 Carrier: Avicel®PH102,
Avicel®PH 102 :Eudragit®RLPO (7:3)
Mixing of drug powder, liquid 
vehicle,carrier,coating, disintegrant 
and lubricant based on mathematical 
calculation
Powder admixture=>wet granulation 
using Eudragit®RL30D
Automatic compaction
Model drug for sustained 
drug release 
Metformin-HCl
Lf value  pretermined from literature 
Drug powder admixture with liquid 
vehicle 
(PEG®400,Synperonic®PE/L44, 
Cremophor®ELP)
Q,q (carrier to coating) amount
R=20 Carrier: HPC-H
Coating:Cab-O-Sil®M-5
Mixing of drug, liquid vehicle, carrier, 
coating and lubricant in adjustable 
amount based on mathematical 
calculation
Powder admixture ==>wet 
granulation using 10% PVP
Automatic compaction
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Chapter 2 - Materials and Methods 
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2.1. Materials 
 
Pure glibenclamide and metformin-HCl hydrochloride were obtained from Sigma-Aldrich 
UK.  
 The following excipients were provided by different companies: Microcrystalline cellulose 
(Avicel® PH102) (FMC Corp., Philadelphia, USA), colloidal silicon dioxide (Cab-o-sil® M-
5) (cabot Corporation, Werk Rheinfelden, Germany), potato starch (BDH laboratory 
supplies, Poole England), Polyethylene glycol 400(PEG®400)(Sigma- Aldrich, Poole, 
UK), (Synperonic®PE/L44) (ICI surfactants, Everberg, Belgium), polyoxyl 35 castor oil 
(Cremophor®ELP) (BASF Aktiengesselschaft, Ludwigshafen, Germany), 
Polyvinylpyrrolidone (Sigma Aldrich, used for wet granulation) and magnesium stearate 
(MEDEX, Morthants). Sodium Hydroxide pellets (Sigma-Aldrich, UK) were used. In 
addition, buffer tablets pH= 4.0(BDH Chemical Ltd., England) and Buffer tablets pH=7.0 
(Asons Laboratory reagent, UK) are used for calibrating Jenway 3505 pH meter. 
For the purpose of sustaining metformin-HCl hydroxypropyl cellulose HPC-H (high grade) 
was used and was obtained from NISSO Japan. Also, Eudragit®RL30D and 
Eudragit®RLPO were obtained from Evonik for use in metformin-HCl formulations.  
For metformin-HCl permeability study; 28 male Wistar rat stomach were used (Charles 
River Laboratory, UK), there was no need for the ethical approval (Appendix for Chapter 
4). Hydrochloric acid (0.2 M HCl) from Fisher Scientific, UK. In addition, Tyrode Buffer 
was prepared fresh daily and ingredients were obtained from Fisher Scientific,UK. An 
American pharmacologist “Maurice Tyrode” invented an isotonic with interstitial fluid 
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which is used in physiological experiments called Tyrode’s solution (buffer). It contains 
the following ingredients: 
Sodium chloride(NaCl), Glucose, Sodium Hydrogen carbonate (NaHCO3), Calcium 
Chloride (CaCl2), Potassium chloride (KCl), Magnesium Chloride (MgCl2) and Sodium 
dihydrogen phosphate (NaH2PO4). All materials used were either analytical or 
pharmacological grade. In addition to that, the equipment used were calibrated. 
2.2. Pre-formulation studies  
2.2.1. Calibration curve of glibenclamide 
A calibration curve is needed to calculate the concentration of the drug in the liquisolid 
formulations in the in vitro dissolution study. 
2.2.1.1. Solvent preparation (0.2 M Sodium hydroxide) Mw=40 
Pure sodium hydroxide pellets were weighed (8.0 g) in a beaker and then dissolved in 1L 
distilled water to make 0.2M sodium hydroxide solution (which is used for complete 
dissolving of the drug). The pH meter was calibrated using two different solutions at pH= 
7.0 and pH=4.0 before each measurement.  
2.2.1.2. Preparation of stock solutions 
Glibenclamide was weighed (5.0 mg) using a digital weighing balance (PJ Precisa 
Junior, Swiss quality, Switzerland)	and dissolved in 100 ml of 0.2 M NaOH solution. The 
stock solution was mixed until the drug completely dissolved. By applying a suitable 
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dilution, the solution was scanned between 200 nm and 300 nm wavelengths with a 
bandwidth equals to 1.5 nm by a double beam UV/Vis spectrophotometer (Nicolet 
Evolution 300, Thermo electron corporation with Vision pro version 2.03 software) to 
indicate the suitable drug wavelength using the stock solution. The glibenclamide peak 
wavelength was 229nm.	
2.2.1.3. Serial dilution preparation 
Furthermore, Equation (2.1) was used to calculate the exact volume required to produce 
the needed concentrations:  
!"#"
	
= 	!&#&      Equation 2.1 
Serial dilutions were prepared by taking 0.5 ml, 1ml, 3 ml, 5 ml, 7ml and 10 ml and 12 ml 
from the stock solution and added them to 50 ml volumetric flask and was made up to 
50ml using 0.2M NaOH solution. The following were the concentrations of the resulting 
serial dilutions: 0.5 mg/l, 1 mg/l, 3 mg/l, 5 mg/l, 7 mg/l and 10 mg/l and 12 mg/l 
respectively. The calibration curve construction was repeated five times (Figure 2.1). The 
same line equation was obtained for the calibration plot of the drug in phosphate buffer 
pH 7.6.  
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Figure 2.1: Calibration curve of glibenclamide 
2.2.2. Calibration curve of metformin-HCl  
2.2.2.1. Preparation of stock solution 
 Pure metformin-HCl (500 mg) was weighed and dissolved in 500 ml of distilled water. 
The solution was then scanned between 200 nm and 400 nm wavelengths by double 
beam UV/Vis spectrophotometer (Model M501, Camspec Ltd., Cambridge, UK) to 
determine the maximum wavelength peaks for the stock solution. The maximum peak 
wavelength was at 233 nm, hence the absorbance of all metformin-HCl samples was 
measured at 233nm. 
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2.2.2.2. Serial dilution preparation 
Serial dilutions were prepared by taking 0.2 ml, 0.4 ml, 0.5 ml, 0.6 ml, 0.7ml and 0.8 ml 
from the stock solutions and add them to 100 ml volumetric flask and was made up to 
100 ml with distilled water. The resulting concentrations were: 2mg/l, 4 mg/l, 5 mg/l, 6 
mg/l, 7 mg/l and 8 mg/l, respectively. The calibration curve construction was repeated five 
times (Figure 2.2). 
	
Figure 2.2: Calibration curve of metformin-HCl, standard deviation values are included 
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2.2.3. Flowability studies and determination of flowable liquid retention 
2.2.3.1. Determination of the angle of slide for Avicel® PH 102 and Cab-o-
sil® M-5 (fumed silica)  
Flowchart figure 2.4 reveals the steps for liquisolid compacts preparation. Angle of slide 
is also referred to as the “optimal flowable liquid-retention potential” was measured (to 
evaluate the flow properties of the excipients used): the angle of slide was obtained using 
different liquid vehicles with Avicel®PH102 and Cab-o-sil® M-5 (fumed silica). Initially, 10g 
of the carrier and the coating (separately weighed) were weighed and then 2g of the liquid 
vehicle were added slowly in increasing intervals. This was then mixed which is known 
as the admixture and placed on a polished metal plate. The plate was tilted gradually until 
the admixture powder was about to slide. Then, the angle (Figure 2.3) that was formed 
between the plate and the horizontal surface was measured “angle of slide (θ)”. This was 
repeated several times with different amount of liquids to observe the flow properties of 
the powder with the liquid vehicle. This then showed that the flow properties differed from 
one excipient to the other, which was due to difference in adsorption of the liquid vehicle 
(PEG®400, Synperonic® PE/L44 and Cremophor®ELP). From there, Equation 2.2 was 
used to calculate the flowable liquid- retention potential (Φ- value) of each liquid/powder 
admixture:  
Φ- value = weight of liquid/weight of solid (Avicel® & Silica®)     Equation 2.2 
Eg: Weight of liquid= 4 g Weight of Solid= 10g Φ= 4/10= 0.4  
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Figure 2.3: Diagrammatic representation of angle of slide 
 
(Tan x = Opp/adj x = inverse Tan; x= θ. Thus θ represents the angle of slide of the 
admixture in the plate)  
 
With the aid of graphing, the liquid load factor of the vehicle was determined, by plotting 
the θ values on a graph against the corresponding flowable liquid-retention values (Figure 
2.5). Thus, the Φ value, which corresponds to an angle of slide of 33°, represents the 
flowable liquid-retention potential of Avicel®PH102 (ΦCA) and Cab-O-Sil®M-5 (fumed 
silica, (ΦCO). An angle of slide of 33° represents optimum flow (Javadzadeh, et al., 2007).
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Figure 2.4: Summary of liquisolid preparation work
Liquisolid compact preparation
Model drugs for immediate drug release
Glibenclamide, Metformin-HCl
Angle of slide determination (q-value) determination for
carrier: Avicel®PH102
coating: Cab-O-Sil®M-5
Liquid load factor(Lf value) determination
Drug powder admixture with liquid vehicle
PEG®400 Synperonic®PE/L44 and
Cremophor®ELP
Q,q(carrier to coating)amount
R=20 Carrier: Avicel®Ph102
Coating: Cab-O-Sil® M-5
Mixing of drug powder, liquid vehicle,carrier,coating, disintegrant and lubricant in 
adjustable amount based on mathematical calculation 
Powder admixture
wet granulation with 10%PVP
Automatic compaction
No granulation
Manual compaction
Metformin-HCl
Angle of slide determination (q-value) 
determination for carrier: Avicel®PH102, 
Avicel®PH102:Eudragit®RLPO (7:3)
coating: Cab-O-sil®M-5
Liquid load factor (Lf value) 
determination
Drug powder admixture with liquid 
vehicle
Eudragit®RL30D
Q,q (carrier to coating) amount
R=20 Carrier: Avicel®PH102,
Avicel®PH 102 :Eudragit®RLPO (7:3)
Mixing of drug powder, liquid 
vehicle,carrier,coating, disintegrant and 
lubricant based on mathematical 
calculation
Powder admixture=>wet granulation 
using Eudragit®RL30D
Automatic compaction
Model drug for sustained drug 
release 
Metformin-HCl
Lf value  pretermined from literature 
Drug powder admixture with liquid 
vehicle (PEG®400,Synperonic®PE/L44, 
Cremophor®ELP)
Q,q (carrier to coating) amount
R=20 Carrier: HPC-H
Coating:Cab-O-Sil®M-5
Mixing of drug, liquid vehicle, carrier, 
coating and lubricant in adjustable 
amount based on mathematical 
calculation
Powder admixture ==>wet granulation 
using 10% PVP
Automatic compaction
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Figure 2.5: The angle of slide of various mixtures of powder excipients (i.e. Avicel®PH 
102 and Cab-o-Sil®M-5) with Synperonic®PE/L44 and Cremophor® ELP 
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by following those steps.  
            !"	 = 	%&'	 + 	%&)	(1/-)                                           Equation 2.3 
 
Where ΦCA  is the flowable liquid-retention potential of the carrier 
and      ΦCO is the flowable liquid-retention potential of the coating material. 
         
                   !"	 = 	//0                                                           Equation 2.4 
      
Where Lf is the “loading factor” where the maximum amount of drug liquid loads on the 
carrier material. 
           Q is the amount of carrier (Avicel®PH102) 
 and     W is the liquid medication (PEG®400/Synperonic®PE/L44/Cremophor®ELP) 
  
                   -	 = 	0/1															(- = 20)																																															           Equation 2.5 
              
 
Lf can be calculated by substituting the flowable liquid retention potential of the carrier 
(ΦCA,) and flowable liquid retention potential of the coating material (ΦCO), see below for 
an example calculation, into Equation 2.3. As it was mentioned before the R is the ratio 
between the carrier and the coating material which in this case is 20. By knowing the Lf 
value and the liquid medication (W), it is then possible to calculate the amount of carrier 
“Q” and coating “q” using Equations (2.4) and (2.5). Ultimately, the final admixtures were 
compacted manually or automatically depending on its flow properties on a 10mm flat-
faced punch and die set using a single punch tableting machine (type 3, Manesty 
Machines Ltd., Liverpool, UK). For high unit dose weight, each sample unit was divided 
into 2 or 4 tablets so that they contain 40mg of metformin dose. This is to ensure that 
tablet is within a practical hardness and size. Different formulations had different 
compression force (to obtain tablets with suitable hardness of 47N) depending on various 
factors in the formulation such as the tablet weight and the preparations and the use of 
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the non-volatile vehicle. It is important to mention that non granulated glibenclamide and 
metformin-HCl were compressed manually due to poor powder flow. Also, sustained 
release metformin-HCl using HPC-H, 30% metformin-HCl using PEG®400 and 
Synperonic®PE/L44 were automatically compressed without the aid of granulation. 
Therefore, only 30% and 60% Cremophor®ELP and 60% PEG and Synperonic®PE/L44 
were granulated using PVP (see section 2.4.1). 
 
Example calculation for glibencalmide unit dose per tablet with 
Synperonic®PE/L44 as a liquid vehicle: 
From Figure 2.5 and Equation 2.3, !"		 = 	0.26	 + 	0.12	(1/20) 	= 	0.266 
From Equation 2.4, W for 10% drug in liquid vehicle (the dose of the drug is 4mg) = 4mg 
drug+36mg Synperonic®PE/L44 = 40, hence 0.266 = 40/Q; Q = 150.4mg 
Thus from Equation 2.5, q can be determined; q = 7.5mg 
2.2.3.2. Determination of the angle of slide for Eudragit®RLPO and 
Eudragit®RL30D as a liquid vehicle (used in metformin-HCl) 
For the purpose of choosing the best liquid vehicle, three different grades of dispersion 
of Eudragit®RS30D, NS30D and RL30D were screened. According to the optimum 
flowability test Eudragit®RL30D was chosen as a liquid vehicle. Then angle of slide was 
performed using Eudragit®RLPO and Eudragit®RLPO: Avicel®PH102 (3:7) as carrier 
systems. The best flowability results were obtained using Eudragit®RLPO with 
Avicel®PH102 (3:7) and Eudragit®RL30D as a non-volatile liquid vehicle.  
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2.3. Preparation of Liquisolid powders and compacts 
2.3.1 Glibenclamide and Meformin-HCl (immediate release) 
Flow chart Figure 2.4 shows the steps for liquisolid powder preparation. Glibenclamide 
granulated liquisolid formulations denoted as G1 to G6 (Table 2.1) including conventional 
liquisolid and metformin-HCl ungranulated liquisolid denoted as M1 to M6 (Table 2.2) 
including conventional liquisolid powder and F1 to F6 (Table 2.2) granulated liquisolid 
metformin-HCl were prepared using PEG®400, Synperonic®PE/L44 and Cremophor®ELP 
as liquid vehicles, with 10% and 30% drug concentration (gibenclamide) and 30% and 
60% (metformin-HCl). From Table 2.1 and Table 2.2, the exact amount of drug and 
excipients were measured using a digital weighing balance (PJ Precisa Junior, Swiss 
quality, Switzerland). Batches of 100 tablets were prepared. The drugs were dispersed in 
the liquid vehicle (PEG®400, Synperonic®PE/L44 and Cremophor®ELP) with continuous 
mixing using pestle and mortar. The mixing process was performed for around 5 min until 
no drug particles is seen undispersed. This was then followed by the gradual addition of 
the appropriate amount of carrier which was Avicel®PH102. Again, the time of mixing was 
between 5 to 10 min until proper paste has been formed. Following that, the Silica which 
acts as a coating material was added to convert the wet mixture into dry powder under 
continuous mixing (refer to Figure 1.4). The Avicel®PH102 and Cab-O-Sil®M-5 were used 
at a fixed powder ratio (R) 20. Finally, a 5% w/w of potato starch which acts as a 
disintegrant was added into the admixture and mixed for 10 min. Then the magnesium 
stearate 0.75% was added at the end. The above steps were repeated with each liquid 
vehicle and drug concentration.
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Table 2-1: Formulation of Liquisolid systems of Glibenclamide granules 
Liquisolid		
system	
Non-volatile		
liquid	
vehicle	
Drug	
Concetration	in		
liquid	medication	
	(%w/w)	
Carrier:	
Coating	
(R)	
Liquid	
load		
factor	
(Lf)	
Liquid	
vehicle	
(mg)	
Active		
ingredient	
(mg)	
Carrier	
(Q)	(mg)	
Coating	
(q)	(mg)	
Disintegrant	
(maize	starch)	
(mg)	
Lubricant	
(mg)	
Unit	
dose	
(mg)	
G1	 PEG®	400	 10	 20	 0.17	 36.00	 4.00	 238.10	 11.90	 15.40	 2.31	 308	
G2	 PEG®	400	 30	 20	 0.17	 9.33	 4.00	 79.30	 3.97	 5.10	 0.77	 102	
G3	 Cremophor®	ELP	 10	 20	 0.52	 36.00	 4.00	 76.90	 3.80	 6.40	 0.96	 128	
G4	 Cremophor®	ELP	 30	 20	 0.52	 9.33	 4.00	 25.60	 1.28	 2.10	 0.30	 42	to	250mg	
G5	 Synperonic®	PE/L44	 10	 20	 0.27	 36.00	 4.00	 150.40	 7.50	 10.50	 1.60	 210	
G6	 Synperonic®	PE/L44	 30	 20	 0.27	 9.33	 4.00	 50.10	 2.50	 3.50	 0.52	
70	to	
250	mg	
Conventional	 _	 _	 _	 _	 _	 4.00	 238.10	 11.90	 13.50	 2.00	 270	
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Table 2-2: Formulation of Liquisolid systems of immediate release metformin-HCl (M=no granulation; F= with granulation) 
Liquisolid	
system	
Non-volatile	
liquid	vehicle	
Drug	
Concetration	in	
liquid	medication	
(%w/w)	
Carrier:	
Coating	
(R)	
Liquid	
load	
factor	
(Lf)	
Liquid	
vehicle	
(mg)	
Active	
ingredient	
(mg)	
Carrier	
(Q)	
(mg)	
Coating	
(q)	
(mg)	
Disintegrant	
(maize	
starch)	(mg)	
Lubricant	
(mg)	
Unit	
dose	
(mg)	
M1	 PEG®	400	 30	 20	 0.17	 93.30	 40.00	 794.00	 40.00	 51.00	 8.00	 1026.30	
M2	 PEG®	400	 60	 20	 0.17	 26.70	 40.00	 397.00	 20.00	 26.00	 4.00	 513.70	
M3	 Synperonic®	PE/L44	 30	 20	 0.27	 93.30	 40.00	 501.00	 25.00	 35.00	 5.20	 699.50	
M4	 Synperonic®	PE/L44	 60	 20	 0.27	 26.70	 40.00	 251.00	 13.00	 18.00	 2.60	 351.30	
M5	 Cremophor®	ELP	 30	 20	 0.52	 93.30	 40.00	 256.00	 12.80	 21.00	 3.20	 426.30	
M6	 Cremophor®	ELP	 60	 20	 0.52	 26.70	 40.00	 128.00	 6.40	 11.00	 1.60	 213.70	
Conventional	 _	 _	 _	 _	 _	 40.00	 397.00	 20.00	 24.20	 3.60	 485.00	
F1	 PEG	400®	 30	 20	 0.17	 93.30	 40.00	 794.00	 40.00	 51.00	 8.00	 1026.30	
F2	 PEG	400®	 60	 20	 0.17	 26.70	 40.00	 397.00	 20.00	 26.00	 4.00	 513.70	
F3	 Synperonic®	PE/L44	 30	 20	 0.27	 93.30	 40.00	 501.00	 25.00	 35.00	 5.20	 699.50	
F4	 Synperonic®PE/L44	 60	 20	 0.27	 26.70	 40.00	 251.00	 13.00	 18.00	 2.60	 351.30	
F5	 Cremophor®	ELP	 30	 20	 0.52	 93.30	 40.00	 256.00	 12.80	 21.00	 3.20	 426.30	
F6	 Cremophor®	ELP	 60	 20	 0.52	 26.70	 40.00	 128.00	 6.40	 11.00	 1.60	 213.70	
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2.3.2. Liquisolid metformin-HCl using hydroxypropylcellulose (HPC) as a 
sustained release carrier and Eudragit®RL30D as a non-volatile liquid vehicle 
Similarly, the above steps (Section 2.2.3.1) were used to prepare sustained release 
metformin-HCl liquisolid using HPC (the sustaining agent) as a carrier instead of 
Avicel®PH102 at two drug concentrations 30% and 60% (HPC1-HPC6) (Table 2.3). The 
powders were then automatically compressed using the single punch tableting machine. 
Additionally, Eudragit®RLPO (carrier powder) and Eudragit®RL30D as non-volatile liquid 
vehicle were used to prepare liquisolid metformin-HCl in 30% and 60% drug 
concentrations and are denoted as LSS1 to LSS4 (Table 2.4). Metformin-HCl was 
weighed, followed by the addition of the liquid vehicle Eudragit®RL30D. All four liquisolid 
preparations (LSS1-LSS4) have the same liquid vehicle Eudragit®RL30D, however 
different carriers were used in LSS1 and LSS2, the carrier was Avicel®PH102. In LSS3 
and LSS4, 3:7 of Eudragit®RLPO:Avicel®PH102 was used as a carrier system, after 
mixing for obtaining a homogenous carrier mix, in a turbular mixer (WAB Turbula, system 
Schatz, Willy A. Bacheofen machine, AG Maschinenfabrik, Glen Creston Ltd., 
Switzerland) and then were added to the drug and liquid vehicle admixture. Followed by 
the addition of coating (Cab-O-Sil®M-5), disintegrant (potato starch) and lubricant 
(magnesium stearate). Using wet granulation process (See section 2.4) the liquisolid 
powders were turned into granules using Eudragit®RL30D as a liquid binder and were 
compacted automatically into desired hardness tablets (refer to flowchart Figure 2.4 for 
details).
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Table 2-3: Liquisolid formulations of sustained release metformin-HCl using hydroxypropylcellulose high grade (HPC-H) 
Liquisolid	system	 Non-volatile	liquid	vehicle	
Drug	
concentration	in	
liquid	
medication		
(%w/w)	
Carrier:	
Coating	
(R)	
Liquid	
load	
factor	
(Lf)	
Liquid	
vehicle	
(mg)	
Active		
ingredient	
(mg)	
Carrier	
(Q)	(mg)	
HPC-H	
Coating	
(q)	(mg)	
Disintegrant	
(maize	starch)	
(mg)	
Lubricant	
(mg)	
Unit	
dose	
(mg)	
HPC1	 PEG® 400 30 20 0.17 93.30 40.00 794.00 40.00 51.00 8.00 1026.30 
HPC2	 PEG® 400 60 20 0.17 26.70 40.00 397.00 20.00 26.00 4.00 513.70 
HPC3	 Synperonic® PE/L44 30 20 0.27 93.30 40.00 501.00 25.00 35.00 5.20 699.50 
HPC4	 Synperonic® PE/L44 60 20 0.27 26.70 40.00 251.00 13.00 18.00 2.60 351.30 
HPC5	 Cremophor® ELP 30 20 0.52 93.30 40.00 256.00 12.80 21.00 3.20 426.30 
HPC6	 Cremophor® ELP 60 20 0.52 26.70 40.00 128.00 6.40 11.00 1.60 213.70 
Conventional	 _ _ _ _ _ 40.00 397.00 20.00 24.20 3.60 485.00 
Table 2-4: Liquisolid formulation of metformin-HCl using Eudragit®RLPO as a carrier and Eudragit®RL30D as a non-volatile liquid 
vehicle. 
Liquisolid	system	 Non-volatile	liquid	vehicle	
Drug	
Concetration	in	
liquid	
medication		
(%w/w)	
Carrier:	
Coating	
(R)	
Liquid	
load	
factor	
(Lf)	
Liquid	
vehicle	
(mg)	
Active		
ingredient	
(mg)	
Carrier	
(Q)	(mg)	
Coating	
(q)	(mg)	
Disintegrant	
(maize	starch)	
(mg)	
Lubricant	
(mg)	
Unit	
dose	
(mg)	
LSS1	 Eudragit RL 30D 30 20 0.80 93.30 40.00 166.60 8.33 16.40 2.50 327.00 
LSS2	 Eudragit RL 30D 60 20 0.80 26.70 40.00 83.30 4.17 8.18 1.20 164.00 
LSS3	 Eudragit RL 30D 30 20 0.20 93.30 40.00 666.50 33.30 44.20 6.60 884.00 
LSS4	 Eudragit RL 30D 60 20 0.20 26.70 40.00 333.35 16.67 22.10 3.30 442.00 
Note: * Eudragit®RLPO:Avicel®PH102 (3:7) = carrier 
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2.4. Wet granulated liquisolid formulations 
2.4.1. Wet granulation using Polyvinylpyrrolidone (PVP) 
The liquisolid powder (with glibenclamide and metformin-HCl) were formed into granules 
using 10% Polyvinylpyrrolidone (PVP). The PVP was prepared by weighing 10g of PVP 
and 90g of distilled water, and then was placed in water bath at 60 °C to dissolve the PVP 
in water. Furthermore, the required amount of PVP was added to the prepared liquisolid 
powder in intervals and mixed for approximately 2-3 minutes until a so wet mass reached 
by feeling the wet mass. The correct moisture content was reached when the powder felt 
like an agglomerated mass. The next step was to perform the “agglomerate mass 
experiment” (Leuenberger, 2011), which is to take a hand full of wet mass and form an 
agglomerate mass and drop it into a tray from half a meter above the surface, when the 
agglomerate breaks into large pieces or only cracks, means the correct amount of 
moisture was added to the wet mass. Finally, the wet mass was then sieved using two 
mesh sizes 500μm-710μm. The formed granules were placed to dry at 45 °C for 120min. 
It is important to mention that the granulation step was performed after the formulation of 
the liquisolid powders and just before the compaction step, therefore, it was done as a 
final step before tablet formation (as shown in flowchart Figure 2.4). 
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2.4.2. Wet granulation of liquisolid powder admixtures using Eudragit®RL30 D as 
a liquid binder 
 
 Similarly, the liquisolid metformin-HCl powders (flowchart Figure 2.4) using the liquid 
vehicle (Eudragit®RL30D), at two different drug concentrations (30 and 60%) undergone 
wet granulation process using Eudragit®RL30D as a non-volatile liquid vehicle as well as 
a liquid binder. The experiment was also used to achieve the end point of the granulation 
step, along with same temperature and time constants as above-mentioned granulation 
using PVP (Section 2.4.1).  
      
Furthermore, due to poor compressibility/compactibility of HPC liquisolid formulations, 
wet granulation step with 10% PVP has been applied as well for formulations containing 
Cremophor®ELP, Synperonic®PE/L44 (liquid vehicles) where good quality tablets were 
produced. 
2.5. Pre-compression study characteristics 
2.5.1. Determination of flow and packing properties of the prepared liquisolid 
powders 
The powder flow and packing properties of each prepared liquisolid compact was 
determined using tap volumeter (J. Engelsmann AG, Ludwigschafen, Germany). The 
liquisolid powder was weighed then poured into a 100ml-measuring cylinder. The volume 
of the poured powder was recorded as Vb and the tapped volume (after sufficient taps), 
which recorded to give a constant volume on a tap density apparatus, was noted as Vt. 
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Hence, from the recorded volumes, the density of the liquisolid formulation was calculated 
using the below eq. to give the bulk density (pb) and tapped density (pt) in g/mL.pb = 
Weight of powder/ Vbpt = Weight of powder/Vt  
From there, the compressibility index (CI %) of the formulations was calculated using 
Equation 2.6 to investigate the flowability of the powders:  
!"	%	 = 	100	(	(*+,**-.
	
– 	*0123)/	*+,**-. (Albertini, et al., 2008)     Equation 2.6 
 
According to the British Pharmacopoeia (2017), the smaller the value of CI% the better 
the flow properties of the powder. Thus, CI% below 25 represents passable flow 
properties and anything-above 40% are indicative of poor powder flow. The powders were 
then compacted manually (non-granulated liquisolid powder) or automatically (liquisolid 
granules) depending on their flow properties on a 10mm flat-faced punch and die set 
using a single punch tableting machine (type 3, Manesty Machines Ltd., Liverpool, UK). 
Different formulations had different compression force depending on various factors in 
the formulation such as the tablet weight. For G4 and G6 (refer to Table 2.1) due to the 
small unit dose, extra Avicel® PH102 was added as a filler to increase the tablet weight 
to 250mg unit dose and to get a stronger and bigger tablets. 
2.5.2. Fourier transform infrared (FT-IR) spectroscopy  
The FT-IR spectra were performed on all relative excipients, materials and formulations 
(refer to Tables 2.1-2.4). Using Spectrum BX FTIR Spectrophotometer (Perkin–Elmer, 
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Cambridge, UK). The frequency ranged from 4000 cm-1 to 550 cm-1 at 1.0 cm-1 
resolution. Small amount of individual sample was loaded into the system just to cover 
the diamond and the peaks were obtained for reading and analysis. 
2.5.3. Differential scanning calorimetry (DSC) 
Using DSC Refrigerated Cooling System (Model Q1000, TA Instruments, UK), the DSC 
thermograms of glibenclamide, metformin-HCl and all relative excipients and formulations 
were analysed. DSC aluminium pans were used to weigh samples of about 3-6 mg and 
then were hermatically sealed and transferred into the equipment for analysis. Prior to 
running the samples, the instrument was calibrated with sapphire and indium. Thus, the 
thermal behavior of each sample was studied at a scanning rate 10°C/min, from 0° C to 
300°C. 
2.5.4. Scanning electron microscopy (SEM) 
Electron microscope (model: Hitachi S3000N, Hitachi High-Technologies UK-Electron 
Microscopes, Wokingham Berkshire, UK) was used to perform SEM on glibenclamide, 
metformin-HCl and all relative excipients and formulations used. 
The samples were prepared by adding a small amount of each sample to 15mm diameter 
aluminium specimen stubs that has double sided carbon adhesive tabs (Mikrostik 
adhesive, Agar Scientific). Prior to examination, a thin layer of gold/palladium mixture 
coated the samples for electric conductivity. The samples were then exposed to argon 
atmosphere at 10 Pa and were then coated at current of 18-20mA for 3x15s. 
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2.6. Characterisation of liquisolid tablets (quality control tests) 
The liquisolid compacts were evaluated via quality control tests in accordance to the 
British Pharmacopoeia, 2017 specifications. 
 
2.6.1 In-vitro dissolution studies for immediate release formulations 
In vitro dissolution studies were performed for each batch of liquisolid formulation (refer 
to Tables 2.1 and 2.2 for details), pure drug and conventional tablets for glibenclamide 
and metformin-HCl immediate release and for liquisolid formulations using 
Eudragit®RL30D (LSS1-LSS4, refer to Table 2.4) using USP dissolution apparatus II 
(Caleva Ltd., Dorset, UK); distilled water (glibenclamide and metformin-HCl) and 
phosphate buffer, pH 7.6 (glibenclamide), were used as dissolution media. According to 
British Pharmacopoeia 2017, the liquisolid tablets were placed in dissolution medium of 
900mL at a temperature of 37± 0.10C and stirred at a paddle speed of 100rpm. Ten 
millilitres samples were collected at intervals of 5, 10, 15, 20, 25, 30, 45, 60 and 90 min 
and were replaced by 10 ml of the dissolution medium to maintain a constant volume. 
The collected samples of glibenclamide and metformin-HCl were then analysed using 
UV/Vis spectrophotometer single beam at 229nm (glibenclamide) and 233 nm 
(metformin-HCl) for determination of drug content using the calibration curve (Figures 2.1 
and 2.2). The dissolution experiment in triplicate was achieved to compare the percentage 
drug release of liquisolid tablets, pure drug and conventional tablets. Dissolution for 
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placebo tablets was performed (to be used as blanks) to eliminate any absorbance 
interference from excipients.   
 
2.6.2. In-vitro dissolution studies for sustained-release metformin-HCl tablets 
(HPC-H) using flow through cell method  
A USP apparatus 4 (CE 7 Smart with CP7 piston pump, Sotax AG, Switzerland) with 22.6 
mm flow through cells was used during the dissolution study, hence the sink condition 
was maintained. Each cell was prepared by placing a 5-mm ruby bead in the apex of the 
cone to protect the inlet tube, and roughly 1 spoonful of 1 mm glass beads were added 
to the cone area to form a glass bead bed. The temperature of the flow cell unit was 
37.0±0.5°C. The flow rate of the liquid (distilled water) was set to 10 ml/min. Because this 
is an open loop flow though cell, the washed solution was collected as waste in a separate 
reservoir. The open-loop configuration is shown in Figure 2.6  
Furthermore, the sample analysis was performed by following the solution absorbance 
(Agilent 8453 spectrophotometer, Santa Clara, California 95051, United States). 
Metformin-HCl samples were analysed at 233 nm with a 0.5 cm cell. All samples for 
analysis were filtered through glass microfiber filters (Whatman, GF/ D). The dissolution 
run was set to 12 hours, taking samples at, 10, 15, 20, 25, 30, 45, 60, 90, 120, 240, 360, 
480, 600 and 720 min. Before analysis, calibration curve using serial dilutions was 
prepared and entered into the system to get E value, which was then used, for percentage 
drug release calculation. The UV reader was blanked with distilled water before running 
the process. The “flow-through” method allows constant optimal sink conditions. This is 
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due to the continuous flow of fresh solvent and continuous sampling. It uses large volume 
of solvent and that poor sink can avoid non-sink condition. Therefore, it is an ideal 
apparatus to show an improved in-vitro/in-vivo correlation tests particularly for poor 
soluble and modified release drugs forms.
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Figure 2.6: Flow through cell (open loop) dissolution station 
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2.6.3. Uniformity of tablet weight 
Twenty tablets were selectively chosen from each formulation and weighed individually. 
The average mass of the twenty tablets was calculated and the percentage deviation of 
each tablet was determined.  
2.6.4. Tablet hardness  
Six tablets were selected from each formulation of the two drugs and the force in Newton 
needed to crush them was examined using the hardness tester (Model 2E/205, 
Schleuniger and Co., Switzerland). In addition to that, before the test was performed.   
2.6.5. Friability 
The friability tester (FRV 1000, Copley Scientific, UK) was used to measure the friability 
of 10 selective tablets from different formulation. The weight of the tablets was recorded 
before and after using the tester. The drum was rotating at 25rpm for 4 min. The weight 
difference was recorded and the percentages of friability were calculated using Equation 
(2.7).  
%	#$%&'%(%)*	 = 	 ((-..	-/	0&../%2%)%&(	0&..)	4	100     Equation 2.7 
2.6.6. Disintegration  
The disintegration test was performed on glibenclamide, immediate release metformin-
HCl and metformin-HCl using Eudragit®RL30D. Six tablets from different formulations at 
37± 1 °C in distilled water using the disintegration unit (Manesty Machines Ltd., Liverpool, 
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UK) were used. The time of disintegration of the tablet was recorded when there was no 
residue (soft mass with no palpably firm) in the cylindrical transparent tube, which 
indicated that the tablet has fully disintegrated.  
2.6.7. Drug Content uniformity 
2.6.7.1. Glibenclamide content uniformity 
Tablets containing glibenclamide were weighed and crushed by mortar and pestle in order 
to determine the drug content in classical liquisolid, wet granulated liquisolid and 
conventional tablets. Then, the powder was dissolved in 50 ml 0.2M NaOH to give a 
concentration of 4mg/50ml (80mg/l). The solution was then filtered and diluted as 
appropriate. Finally, the samples were analysed for determining the drug concentration 
using UV spectrophotometer at 229 nm. The percentage of drug content with respect the 
theoretical amount was determined. The experiment was repeated three times to ensure 
accurate results. 
2.6.7.2 Metformin-HCl Content uniformity 
Metformin-HCl tablets, were crushed and placed in 100ml volumetric flask using distilled 
water to give a concentration of 400mg/L. The solution was filtered and diluted with 
distilled water. The samples were prepared for each formulation and the experiment was 
repeated in triplicates and samples were analysed at 233nm using single beam UV-
spectroscopy. 
 
67 
 
2.7 Kinetics model analysis of drug release 
In order to inspect the mechanism of metformin-HCl release from the immediate release 
and sustained release liquisolid three kinetic release models were applied on data 
obtained from dissolution tests. These models are: Zero order, First order and Higuchi 
model of kinetics. With the aid of excel, the graph was conducted to obtain the equation 
of the line and hence the highest square of coefficient of determination (R2) for the 
indication of the most appropriate model to represent the release of metformin-HCl from 
immediate and sustained release liquisolid formulations. Zero order model, is a system 
that all drug particles transfer mechanism to dissolution medium is disclosed to the 
surface area of the system. Hence, the cumulative percentage data of the drug release 
is then plotted against the time. Additionally, first order kinetics drug release is related to 
the drug concentration and can be plotted logarithm of the cumulative percentage release 
of the remaining drug versus the time. Moreover, in Higuchi model, linear plotting of the 
cumulative percentage of the drug release against the square root of time is expected 
(Dash, et al., 2010). 
 
2.8 Stability study of metformin-HCl (immediate release) liquisolids 
The stability of the prepared tablets containing immediate release metformin-HCl and its 
conventional tablet was performed in a stability chamber with 21°C and 75 % humidity for 
12 month period time. 
In vitro dissolution tests, DSC and FTIR analyses were applied after the storage periods 
and the result were compared and evaluated to the fresh sample data.  
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2.9 Statistical analysis 
In the tests of glibenclamide and metformin-HCl tablets evaluation, statistical analysis 
was performed. Paired t-test was used to compare between the permeability test of 
liquisolid formulation contained immediate release metformin-HCl using PEG®400, 
Synperonic®PE/L44 and Cremophor®ELP. Additionally, one-way ANOVA using SPSS 
was used to statistically analyse the dissolution drug release of metformin-HCl and 
glibenclamide liquisolid formulations (Appendix for Chapter 3, 4 and 5). Consequently, 
homogeneity of variance was not significant meaning that data were normally distributed 
and hence ANOVA and T-test were applied in this research. 
2.10. Metformin-HCl permeability test using Franz cell diffuser 
Franz cell (Figure 2.7) diffuser was used to perform metformin-HCl permeability test. The 
membrane used was male Wistar rat gut, cut into thin slice, washed and cleaned using 
Tyrode buffer (prepared as in section 2.1). Individual tablets of each formulation (refer to 
Table 2.2, F1-F6) were crushed and dissolved into 20ml distilled water. The sample was 
then filtered and 1ml was withdrawn using micropipette and injected into the donor 
chamber; the receiver chamber was filled with 14 ml HCl, 0.2M (pH 1.4), and was kept at 
a constant temperature (37 ± 3 °C) (Figures 2.7 and 2.8). Furthermore, using small needle 
and syringe, 1ml sample was withdrawn from receiver chamber every 5 min, 10min, 
15min, 20min, 25min, 30min, 45min, 60 min, 90min, 120min and 2 hours. Then, samples 
were analysed using single beam UV-vis spectrophotometer at 233nm. The withdrawn 
sample was then returned into the receiver chamber to keep constant volume. 
Additionally, the experiment was repeated five times. 
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Figure 2.7: Franz cell diffusion equipment description (Permegear, 2015)  
   
    	
Figure 2.8: Franz cell diffusion apparatus setting 
. 
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Chapter 3 - Glibenclamide liquisolid preparation with the 
application of wet granulation technique 
 
 
(Results and Discussion) 
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3.1. Introduction: 
Via several screening programmes, about 40% of the newly drug synthesis was identified 
to be hydrophobic in nature. Thus pharmaceutical companies in manufacturing similar 
drugs for oral delivery will face challenges with solubility and bioavailability difficulties. 
One of these drugs is glibenclamide, which has been chosen in this research project to 
be the model drug. Additionally, for the preparation of liquisolid compacts, a series of non-
volatile liquid vehicles have been selected such as, “PEG®400, Synperonic® PE/L44 and 
Cremophor®ELP. Several researchers have mentioned the use of the above liquid 
vehicles in the manufacturing of liquisolid immediate release tablets (Tiong & Elkordy, 
2009). However, those authors have not used glibenclamide. PEG®400 (polyethylene 
glycol) is a stable hydrophilic surfactant in solution and has a hydrophilic-lipophilic 
balance (HLB) value of 12. It can be used to form liquid medication with a hydrophobic 
drug that allows miscibility in water. According to Tiong and Elkordy 2009, naproxen 
liquisolid tablets containing PEG®400 and Cremophor®ELP display a higher dissolution 
rate than Synperonic®PE/L44. Therefore, PEG®400 is a good non-volatile solvent to be 
used in preparation of immediate release liquisolid tablets. The second non-volatile liquid 
vehicle used in this section is Synperonic®PE/L44 (Poloxamer 124), which is an ethylene 
and propylene oxide block copolymer. Synperonic®PE/L44 is a water-soluble surfactant 
with an effective wetting properties. Therefore, its application in liquisolid system using 
hydrophobic drugs is ideal. Additionally, it has an HLB value of 12 and is classified as a 
non-toxic substance.  Polyoxyl 35 Hydrogenated Castor Oil, Cremophor®ELP, similarly, 
is a non-volatile liquid vehicle. Its HLB value is 13 and is viscous in nature. Javaheri et al 
2014 (the author of this thesis), demonstrated the use of Cremophor®ELP using 
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glibenclamide and showed the highest dissolution rate than PEG®400 and Synperonic® 
PE/L44. Additionally, some non-ionic surfactants such as Cremophor®ELP can be 
considered as effective pharmaceutical excipients for inhibiting p-glycoprotein function 
and hence promoting the intestinal absorption of different drugs (Shono, et al., 2004). 
Therefore, the uses of the water-soluble surfactants along with their desirable 
physicochemical properties make them suitable for liquisolid technique. 
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Figure 3.1: Flowchart summary of the liquisolid work using glibenclamide as model hydrophilic drug 
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Table 3-1: Formulation of liquisolid systems of glibenclamide granules 
Liquisolid		
system	
Non-volatile		
liquid	
vehicle	
Drug	
Concertation	in		
liquid	medication	
	(%w/w)	
Carrier:	
Coating	
(R)	
Liquid	
load		
factor	
(Lf)	
Liquid	
vehicle	
(mg)	
Active		
ingredie
nt	
(mg)	
Carrier	
(Q)	
(mg)	
Coating	
(q)	(mg)	
Disintegrant	
(maize	starch)	
(mg)	
Lubricant	
(mg)	
Unit	dose	
(mg)	
G1	 PEG	400	 10	 20	 0.17	 36.00	 4.00	 238.10	 11.90	 15.40	 2.31	 308.0	
G2	 PEG	400	 30	 20	 0.17	 9.33	 4.00	 79.30	 3.97	 5.10	 0.77	 102.0	
G3	 Cremophor	ELP	 10	 20	 0.52	 36.00	 4.00	 76.90	 3.80	 6.40	 0.96	 128	
G4	 Cremophor	ELP	 30	 20	 0.52	 9.33	 4.00	 25.60	 1.28	 2.10	 0.30	 42	to	250	mg	with	filler	
G5	 Synperonic	PE/L44	 10	 20	 0.27	 36.00	 4.00	 150.40	 7.50	 10.50	 1.60	 210	
G6	 Synperonic	PE/L44	 30	 20	 0.27	 9.33	 4.00	 50.10	 2.50	 3.50	 0.52	 70	to	250	mg	with	filler	
Conventional	 _	 _	 _	 _	 _	 4.00	 238.10	 11.90	 13.50	 2.00	 270	
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3.1. Determination of the angle of slide for Avicel® PH 102 (MCC) and Cab-o-sil® 
M-5 (fumed silica): 
 
In order to calculate the required ingredient quantities, the flowable liquid retention 
potentials (Φ values) of powder excipients were utilised which are required for the 
calculation of Lf value. The angles of slides for Avicel® PH102 and fumed silica were 
measured with the following liquid vehicles: PEG®400, Synperonic®PE/L44 and 
Cremophor®ELP. The ΦCA value and ΦCO values decide the amount of carrier and coating 
material required to produce a free flowing, non-adherent, readily compactible and dry- 
looking liquisolid formulations. High Φ value is advantageous as it results in smaller sizes 
of the formulated tablets ( Spireas , et al., 1992). It is vital to measure the angle of slide 
because it is the preferred method to determine the flowability of powders with particle 
sizes of less than 150µm ( Spireas , et al., 1992). In this study, as stated by the 
manufacturer, the particle sizes of Cab-o-sil® M-5P and Avicel®PH102 were 133.8µm 
and 0.2-0.3 µm respectively. In addition, Spireas et al (1992) and (Elkordy, et al., 2013) 
clarified that when the drug particle dissolved in the liquid vehicle, the liquid initially 
absorbed into the interior of the particles gets captured by its internal structure, thus 
adsorption of the liquid starts taking place onto the internal and external surfaces of the 
porous carrier particles after saturation state of this process has occurred (Fahmy & 
Kassem, 2008). Furthermore, the coating material (Cab-O-Sil®M-5), which has high 
adsorptive property and large surface area, gives the liquisolid system the desirable flow 
characterisation. Thus determination of the flow properties of the powder excipient and 
liquid/powder admixture is significant to ensure a success in liquisolid formulations.  
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Additionally, the viscosity of the liquid vehicle plays an important role in the formulation of 
the liquisolid compacts. The viscosity of PEG®400 and Cremophor®ELP are 105-130 and 
650-800 mPa s, respectively (Rowe, et al., 2003). (Tiong & Elkordy, 2009), reported that 
the viscosity of the liquid vehicle is inversely proportional to the amount of carrier and 
coating material required in a liquisolid formulation and accordingly the Lf increases with 
increased viscosity of the liquid vehicle.  High viscosity liquid vehicle such as 
Synperonic®PE/L44 and Cremophor®ELP leads to poor powder flowability and 
compactibility of liquisolid admixture even with application of compressibility index as 
described by Spireas ( (Spireas & Bolton, 1999) (Suliman, et al., 2013) studied the 
compressibility index of norfloxacin liquisolid powder using PEG®200 and 
Synperonic®PE/L61 that required the application of an equation described by (Spireas & 
Bolton, 1999). However, this method is very time consuming especially that the equation 
needs to be understood thoroughly before application, which is not convenient for 
manufacturing purposes. The application of compressibility index requires several 
samples as a result loses excessive amount of powder before the liquisolid powders are 
compressed, which is again a great disadvantage to the pharmaceutical industry. 
Nevertheless, although the flowability of liquisolid powder using Synperonic®PE/L61 was 
enhanced using the compressibility index as stated by (Suliman, et al., 2013) it is yet not 
a promising method for enhanced flowability of liquisolid admixtures using high viscosity 
liquid vehicles such as Synperonic®PE/L44 or Synperonic®PE/L61 and Cremophor®ELP. 
Accordingly, wet granulation was applied in this research just before compaction (Flow 
chart Figure 3.1) to overcome these problems, with hope that this process will be 
beneficial for large-scale production in pharmaceutical industry. 
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3.2. Determination of flow and packing properties of the prepared liquisolid 
powders-discussion 
The determination of the powder flowability is important in handling, packing, mixing and 
compression. One major obstacle pharmaceutical industries face is the poor flow 
properties of powders. This affects the uniformity of flow out of the hopper and further 
problems in compaction (Tiong & Elkordy, 2009); ( Spireas , et al., 1992) (Jain, et al., 
2014), because uniform and reliable flow from the hoppers into the die of the compressing 
machine ensures uniform tablet weight and drug content. There are several factors that 
can affect the flow properties of the liquisolid powder including physical, environmental 
as well as mechanical. Therefore, the Carr’s compressibility index was calculated for each 
liquisolid powder to determine its flow properties. This means the flow properties are 
affected by particle shape, particle size, porosity, density, moisture content and surface 
roughness. Additionally, Carr’s compressibility index is a good parameter in reflecting 
interparticle friction. The calculated Carr’s compressibility index of glibenclamide liquisolid 
granules is presented in Table 3.2 and Figure 3.2. It is a good parameter to evaluate the 
flow of the prepared powder. The lower the Carr’s compressibility index is, the better the 
flow of the powder would be. In this research project, as shown in Table 3.2. G1 and G5 
(for composition refer to Table 3.1), conventional liquisolid powders were 12.6%, 8%, and 
18%, respectively, all have CI below 25%. On the other hand, G2 and G3 results showed 
poor flowability with CI% being above 25% (30% and 28% respectively). This can be 
related to the amount, type and property of the liquid vehicle used (PEG®400, 
Synperonic®PE/L44 and Cremophor®ELP). Nevertheless, the flowability results 
obtained were only for granulated liquisolid powder. This is due to the poor flowability 
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properties of the ungranulated liquisolid powder using PEG®400, Synperonic®PE/L44 
and Cremophor®ELP (viscous liquid vehicles). Thus, this shows that the properties of the 
liquid vehicle can interfere with the flow property of the formulation making it better or 
poor flowing. Moreover, in addition to the coating properties of Cab-o-Sil®M-5 (fumed 
silica), it can also act as a glidant (concentration of 0.1-0.5 %) to improve powder 
flowability. Furthermore, these granulated liquisolid powders were compacted 
automatically (electronically) into tablets.  
Table 3-2: Carr’s compressibility index of glibenclamide liquisolid compacts. 
Carr's	index	(Cl%)		
of	prepared	liquisolid	powders	of	glibenclamide	
Liquisolid	system*	 Carr's	index	(Cl%)	 Type	of	Flow	
G1	 12.60	 Excellent	
G2	 30.00	 Poor	
G3	 28.00	 Poor	
G4	 25.00	 Poor	
G5	 8.00	 Excellent	
G6	 16.00	 very	Good	
Conventional	 18.00	 Fair	
* For the composition of each formula refer to Table 3.1. 
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Figure 3.2: Carr’s compressibility index glibenclamide liquisolid granules and 
conventional powder. For formulations’ composition refer to Table 3.1 
 
It can be seen from Table 3.2, that the liquisolid granule formulations using 
Cremophor®ELP (G5) showed best flowability outcome (due to the addition of excess 
Avicel®PH102 (carrier) that was added to increase the weight of the tablet to 250 mg unit 
dose). Therefore, it is clearly visible that granulation with the aid of excess Avicel®PH102 
addition has enhanced the flowability properties of the liquisolid powder using one of the 
viscous liquid vehicle i.e. Cremophor®ELP. On the other hand, liquisolid powders using 
all three vehicles used in this study were not compacted automatically unless formed into 
granules. This is due to poor flowability and compressibility properties of the liquisolid 
powder and due to the elasticity properties of the powders with liquid vehicle used. 
Elkordy et al 2013 experienced two liquisolid formulations using Synperonic® PE/L61 with 
Solutol HS 15 (1:1) at both drug concentrations 10% and 30% which were incompactible, 
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and hence no tablets were formed. The given explanation was linked to the liquid vehicle 
used that lead to elastic behaviour of the powder that caused this incompactibility. The 
powder deformed upon compression and returned to its original shape after removal of 
the compaction force. This is clearly seen in this current research in the case of 
glibenclamide liquisolid with Cremophor®ELP (see Figure 3.3). Compression of 
ungranulated powder admixture was unsuccessful due to the elastic behavior of the 
liquisolid formulation. As it is exhibited in Figure 3.4, the powder not only was not 
compressed into tablets, but also formed a compressed unwanted shape, which is not 
desirable for the industry (Figure 3.4). Therefore, granulation was used to overcome this 
problem. After using granulation, the powder was compressed automatically into tablets 
(Figures 3.5 and 3.6) with no capping or cracking which complied with quality control test 
of the British Pharmacopeia 2017.  
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Before granulation 
 
	
Figure 3.3: Glibenclamide and10% Cremophor®ELP powder without granulation 
 
	
	
Figure 3.4: Glibenclamide and10% Cremophor®ELP without granulation in the tablet 
press. 
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After granulation 
	
Figure 3.5: Glibenclamide and 10% Cremophor®ELP granules after granulation 
 
	
Figure 3.6: Glibenclamide and 10% Cremophor®ELP tablets after granulation 
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In a concentrated suspension (liquid vehicle and drug), weak Van der Waal forces hold 
flocculated particles together. This often results in plastic flow ( (Mahato & Narang, 2012). 
If the shear stress is low, such materials might possess elastic behavior. However, when 
the maximum yield stress is exceeded where the Van der Waal forces are broken, plastic 
flow is exhibited. There must be a balance for plasticity. Although plastic deformation 
helps the solid links to form between particles within the powder mix, excessive plasticity 
leads to the formation of tablets with high extent of hardness. The powder mix produced 
with Avicel®PH101 and the liquid vehicle takes advantage of the elastic properties of the 
liquid vehicle and the plastic properties of Avicel®PH101. Thus, in the current research, 
only few ungranulated liquisolid tablets were manually compressed for the purpose of 
dissolution comparison test study. As shown in table3.1, liquisolid granules using 
Cremophor®ELP (G5) showed best flowability outcome compared to PEG®400 (G1). 
According to (Tiong & Elkordy, 2009), liquisolid naproxen showed best flowability with 
PEG®400 and not with Cremophor®EL (poor flowability). This is due to the high viscosity 
behaviour of the non-volatile liquid and due to load factor being above 0.25. The higher 
the liquid load factor the poorer the flowability characteristics of the liquisolid powder (see 
Table 3.1 for details). This is because there will be fewer amounts of carrier and coating 
available in the formulation and excess amount of liquid vehicle being available leading 
to agglomerates ( (Altememy & Altememy, 2014) (Darwish & El-Kamel, 2001), (Shangraw, 
1989). Also, in this current study, Synperonic®PE/L44 (G3) showed poor flowability 
compared to the conventional powder (fair flow) but both granules were automatically 
compactible. This is clearly linked to the amount of liquid vehicle present that delays the 
flow of the powder. According to (Javadzadeh, et al., 2007) using HPMC or PVP as 
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microsystems can improve flowability. Hence, Avicel®PH 102 was added as an additional 
filler to produce 250mg tablets to improve tablets characteristics. 
The new technique of wet granulation was used in this research. It has shown enhanced 
flowabiity of liquisolid powders that contain viscous liquid vehicles such as 
CremophorâELP. Not only did it enhance the flowability, but it also allowed for automatic 
compression of the liquisolid granules, which was impractical, to achieve without 
granulation. Also, the excipients used play a great role in the flowability and compactibility 
of the liquisolid powder. For example, microcrystalline cellulose (MCC, Avicel®), is a 
widely used excipient in pharmaceutical tableting, because of its good compactible 
properties. This can be explained by the chemical properties of the microcrystalline 
cellulose. The microcrystalline particles are held together with hydrogen bonds, which in 
return affect the strength and cohesiveness of the tablets. Therefore, MCC 
(Avicel®PH102) was used as a filler to increase the tablet size to a medium size tablet of 
250mg unit dose. By the addition of MCC, the tablets were compacted evenly without any 
cracking or capping. Nevertheless, glibenclamide and Cremophor®ELP 10% and 30% 
without granulation were difficult to compact neither manually nor automatically but they 
became elastic and showed an unexpected outcome, they were poorly flowable and were 
cohesive as seen in Figures 3.3 and 3.4.  Therefore, pre-granulation liquisolid powders 
did not undergo flowability test. On the other hand, as seen in Figures 3.5 and 3.6; the 
granulated liquisolid powder of glibenclamide using Cremophor®ELP showed better 
shape with enhanced flowability and thus compactible tablets. 
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Therefore, granulation is a successful technique to convert incompactible elastic powder 
into good flowability and compactability powders with excellent flowability properties 
according to Carr’s compressibility index. 
3.4. Characterisation of liquisolid formulations 
3.4.1 In-vitro dissolution studies 
The dissolution profiles of glibenclamide formulations were performed in both distilled 
water (non-sink conditions) and phosphate buffer (pH 7.6; for sink conditions) to study the 
effect of liquisolid technique on aqueous dissolution enhancement of the drug. The 
dissolution profile of glibenclamide with 30% drug in Cremophor®ELP (Figure 3.7a and b) 
shows highest drug dissolution rate (P< 0.05) (refer to Appendix for Chapter 3) when 
compared to most formulations including the pure drug (which showed no drug release 
at all in water). Also, the liquisolid glibenclamide with granulation showed higher drug 
release than without granulation (P<0.05). It is shown in Figure 3.7, where G1 to G6 (refer 
to Table 3.1 for composition) showed a higher drug release when granulation step was 
performed and inversely, the drug release was to a minimum when manual compaction 
was performed in the non-granulated form. 
 Therefore, it can be concluded that the in-vitro dissolution of liquisolid tablets is greatly 
influenced by granulation and by other three major factors: the type of vehicle, the drug- 
vehicle ratio and type of disintegrant in agreement with (Javadzadeh, et al., 2007); 
(Nokhodchi, et al., 2005). Some carriers could have an effect on the drug dissolution, for 
example in this case, microcrystalline cellulose (Avicel®PH102) was used and from 
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previous research it showed that microcrystalline cellulose (MCC) has disintegration 
property which could facilitate disintegration of tablets and thus dissolution of drug 
(Javadzadeh, et al., 2007). In addition, a study by (El-Gizawy, 2007), suggested that 
single disintegrant has no significant effects on drug dissolution. Also, when explaining 
the dissolution characterisation and the percentage drug release of the formulation better, 
the Noyes-Whitney equation was used. !"!# = 	&. (	("* − ",) 
                                                                                                       
where dC/dt is the dissolution rate of the drug particle; “k” is a constant, which is affected 
by the viscosity of the dissolution medium and experimental conditions; “A” is the surface 
area exposed to dissolution; “Cs” is the saturation solubility of the drug in the diffusion 
layer; “Cb” is the concentration of drug in the bulk solution. Moreover, all dissolution tests 
were done under same paddle speed of 100rpm and same dissolution medium. Thus, the 
factors that will affect the dissolution outcomes of the liquisolid compacts are A and (Cs - 
Cb).   Additionally, there are some factors that can affect the solubility of the solid drug in 
the dissolution medium such as temperature (endothermic or exothermic), dissolution 
medium (acidic or neutral), crystalline structure, presence of solubilising agents and 
molecular structure of the solute.  In this study, the temperature was maintained constant 
at 37±0.10C and the dissolution medium as have been mentioned previously was kept 
constant for all formulation.  Therefore, what could have affected the outcome is the 
presence of other compounds, which are the non-volatile liquid vehicles. As a result, each 
formulation had different dissolution profile (Figure 3.7), depending on its liquid vehicle 
and its wetting property (El-Say, et al., 2010). 
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Figure 3.7a: Dissolution results of glibenclamide granulated liquisolid and conventional tablets (10% drug concentrations) 
in distilled water. 
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Figure 3-7b: Dissolution results of glibenclamide granulated liquisolid and conventional tablets (30% drug concentrations) 
in distilled water. 
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Figure 3.8a: Dissolution results of glibenclamide granulated liquisolid and conventional tablets (10% drug concentrations) 
in phosphate buffer, pH 7.6. 
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Figure 3-8b: Dissolution results of glibenclamide granulated liquisolid and conventional tablets (30% drug concentrations) 
in phosphate buffer, pH 7.6. 
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Basically, enhanced dissolution rate revealed in liquisolid formulations is due to the 
mechanical treatment with the hydrophilic liquid vehicle, which increased the contact 
between the drug, and the dissolution medium which was distilled water (Yadav & Yadav, 
2010). In other words, surfactants increase the wettability of the drug making them more 
available for water molecules to penetrate and thus increase the drug dissolution and 
improve the absorption from the GI tract. Hence, to relate the results to the equation, 
when formulating the liquisolid tablet, the drug particle was dispersed in the hydrophilic 
liquid vehicle which increases the diffusion coefficient of the dissolved drug particle, which 
is affected by the viscosity of the dissolution medium. In this study, PEG®400 behaved 
with glibenclamide differently when compared to other drug in other literature as it showed 
enhanced dissolution (Javadzadeh, et al., 2007), but with glibenclamide no great effect 
was observed (see Figure 3.7). Therefore, not all liquisolid vehicles work to the same 
extent with all hydrophobic drugs. The reasoning behind one formulation having higher 
dissolution rate than another is due to the solubility effect of the liquid vehicle itself. In 
other words, if the drug was soluble in that liquid then it can be predicted that formulation 
will have higher dissolution profile. On the other hand, comparing drug release from 
conventional tablets, the extent of the drug release was about 15% (Figure 3.7) and only 
10% of the drug were released after 10 minutes. For PEG®400 containing liquisolid 
formulations, the drug release was lower (however not significant P>0.05) in the case of 
ungranulated compacts prepared manually. Presence of Synperonic®PE/L44 and 
Cremophor®ELP enhanced glibenclamide release better than PEG®400 did. Hence, 
based on this study, PEG®400 is not a good choice of liquid vehicle to enhance 
glibenclamide dissolution in water. However, higher values were obtained in phosphate 
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buffer.  
Interestingly, Cremophor®ELP containing liquisolid compacts, which was prepared after 
granulation resulted in the highest drug release (>50% after 20 min in dissolution media) 
(Figure 3.7 & Figure 3.8). The same formulation without the wet granulation step could 
not be compacted into tablets even manually (Figure 3.4). On the other hand, as seen in 
Figure 3.7, the granulated liquisolid tablets showed better release and thus higher 
dissolution rate compared to the ungranulated ones. In a similar research paper, 
(Javadzadeh, et al., 2007) used PVP not as a liquid binder to produce granules. PVP was 
used to increase the load factor of the liquisolid formulations and therefore witness an 
increase in dissolution rate with the presence of PVP. Moreover, because of its excellent 
solubility, PVP normally has no delaying effect on the dissolution rate of the pure drug 
and higher rate of dissolution is seen than that of the pure drug. According to Javadzadeh 
et al 2007, the reason behind this enhancement could be due to the “crystal growth 
inhibition”, which refers to one the characteristics of PVP that inhibits the precipitation of 
the drug from the saturated solution. Additionally, as a result of the adsorption of the drug 
on the carrier, this allows the drug to be exposed to the dissolution medium with a larger 
surface area leading to a higher dissolution rate. Thus, wet granulation step has shown 
an advantage to the liquisolid formulation in the release of the hydrophobic drug and 
enhancement of the dissolution rate (Figure 3.7b) which may be leading to improved oral 
bioavailability. 
For choosing the most applicable kinetic model of the drug release in phosphate buffer 
from the granulated glibenclamide liquisolid formulations, goodness of fit test must be 
performed (Refer to Figure 3.9 for examples). The results for coefficient of determination 
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(R²) for glibenclamide liquisolid granulated tablets were revealed that the release of the 
drug was governed by the Higuchi model (Figure 3.8). Higuchi model describes the 
release of the drug from a matrix, in this case the matrix is the carrier mixed with the liquid 
vehicle, as a square root of time, which is linked to Fick’s Law of diffusion (Prabakaran, 
et al., 2003) This means that the driving force for diffusion of metformin-HCl molecule 
from the tablet into the dissolution medium is the drug concentration gradient between 
tablet and dissolution medium (Elkordy, et al., 2013), (Javadzadeh, et al., 2007). Also, 
this can explain the slow diffusion rate of the drug as the distance of diffusion is increased 
which is the Higuchi model (Square root of time). The zero-order model can be best 
described when drug release rate is independent of its concentration. Whilst the first-
order model is when the drug release is dependent on its concentration.  
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Figure 3-9: Kinetic release models of glibenclamide from some granulated liquisolid 
tablets (10% and 30% drug concentrations) in phosphate buffer, pH 7.6. 
3.4.2. Uniformity of tablet weight 
 The permitted weight variation in BP is, not more than two tablets differ from the mean 
by more than 5% if the average weight of the tablet was 250 mg or more, and for less 
than 250 mg, the percentage deviation is 7.5 %. In this case, all prepared formulations 
(Table 3.3), including the conventional tablet except Synperonic®PE/L44 and 
glibenclamide 30%w/w (G4), did comply with British Pharmacopeia (BP) specifications. 
The above uniformity of weight test was performed only on granulated liquisolid tablets 
whilst non-granulated tablets were not tested for any quality control measures due to 
elastic properties of these powders. 
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3.4.3. Tablet hardness  
 Generally, ideal tablet hardness should be produced without applying excessive 
compression force where rapid tablet disintegration and drug dissolution are maintained 
at the same time. In this study, G1 and G6 (table 3.1) showed best tablet hardness (5.93 
Kg/f (58N) and 5.03 kg/f (49 N) respectively) compared to the other formulations. There 
are several factors tablet hardness depends on such as particle size, interparticle force 
and most importantly compression force. Usually, as compression force increased, tablet 
hardness and fracture resistance also increases. Additionally, (El-Say, et al., 2010) found 
a relationship between liquid load factor and the hardness of the tablets in the formulae 
having approximately the same powder excipient ratio. When liquid load factor increased, 
the hardness of the tablet decreased. However, this was not supported in this study; the 
data obtained showed no relationship to the liquid load factor of the liquid vehicle used. 
Our hypothesis is that not only the liquid load factor has an effect on the hardness of the 
tablet, but also granulation process that was performed before compaction (refer to table 
3.3). For example, G3 formulation, although hardness was small (1.8kg), but the tablet 
complied with friability test (<1%).  
3.4.4. Friability 
All the liquisolid and conventional tablets complied with British pharmacopoeia 2017 (BP) 
limits (less than 1%) of the percentages of weight loss in friability tests (Table 3.3). The 
tablets showed no crack, chipped or broken marks during the test. Hence, liquisolid 
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tablets can withstand any handling and packaging attritions applied to them without losing 
their physical properties.   
	
Table 3-3: Summary of results expressed by the average of tablet hardness (N), tablet 
uniformity weight (mg), friability (%) and drug content (%) for all granulated liquisolid 
(G1-G6) and conventional glibenclamide tablets. 
FORMULATION	 HARDNESS	
(N)	
CRUSHING	
LOAD	
(KG/F)	
FRIABILITY	
(%)	
DRUG	
CONTENT	
(%)	
UNIFORMITY	OF	
WEIGHT	(MG)	G1	(GRANULATED)	 58.21	±	11.2	 5.93	±	1.14	 0.60	 107.00	 307	±	7.70	G2	(GRANULATED)	 84.86	±	12.9	 8.65	±	1.32	 0.05	 98.00	 109	±	1.90	G3	(GRANULATED)	 17.82	±	5.63	 1.82	±	0.57	 0.40	 102.00	 211	±	2.80	G4	(GRANULATED)	 23.87	±	3.44	 2.43	±	0.35	 0.23	 85.00	 179	±	15.3	G5	(GRANULATED)	 38.10	±	0.74	 3.88	±	0.08	 0.06	 104.00	 248	±	7.40	G6	(GRANULATED)	 49.38	±	1.34	 5.03	±	0.14	 0.50	 103.00	 251	±	1.30	CONVENTIONAL	 52.32	±	16.5	 5.33	±	1.68	 0.60	 98.00	 256	±	10.1	
3.4.5. Disintegration 
The presence of a non-volatile liquid vehicle is expected to delay the disintegration time 
of the tablet. However, the presence of microcrystalline cellulose (MCC) speeds the 
process of disintegration giving a low disintegration time (Javadzadeh, et al., 2007). In 
addition to that, some literatures suggest that high hardness tablets are associated with 
long disintegration time. Disintegration time can be affected by the type of liquid vehicle 
used and also by other properties such as tablet porosity and pore structures (Tiong & 
Elkordy, 2009). Studies suggest that there is a positive relationship between tablet 
hardness and disintegration time. In other words, when the hardness increases, the 
disintegration time increases (Kitazawa, et al., 1975). Additionally, in this research, G6 
(refer to table3.1 for composition) records the lowest disintegration time of about 9 
seconds and the longest time was seen in G2 (15 min). Figure 3.10 presents the average 
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disintegration time results of the liquisolid and conventional formulations. All formulations 
including the conventional tablets showed disintegration time below 15 min except for G2.  
This proves to some extent that the higher the crushing force, the longer the disintegration 
time. Hence, the relationship between tablet hardness and disintegration time is directly 
proportional. Thus, the way to overcome poor disintegration time is to reduce the 
compression force. Nevertheless, all glibenclamide liquisolid tablets including the 
conventional tablet did comply with BP specification of disintegration time meaning that 
liquisolid technique was successful to produce enhanced disintegrated (hence enhanced 
drug release as shown above) glibenclamide tablets. 
 
	
Figure 3-10: Average disintegration time of glibenclamide liquisolid granulated tablets 
and conventional tablets. (Refer to Table 3.1 for formulations’ composition) 
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3.4.6. Drug content 
British Pharmacopoeia 2017 drug content uniformity criteria suggests an accepted limit 
between 85% and 115% of the average drug content. Accordingly, all liquisolid (G1-G6 
granulated, and G1-G4 ungranulated) (Table 3.3) preparations except conventional 
tablets complied with BP limit test. However the drug content for G4 was less than other 
granulated formulations and this can be explained on the basis of large standard 
deviations obtained from weight uniformity results of G4. Moreover, there are no 
significant differences (p > 0.05) between either granulated and ungranulated as well as 
conventional tablets. In other words, the presence of PVP and different quantities of liquid 
vehicles carrier and coating did not affect the drug uniformity results. Thus, liquisolid 
granules prepared by wet granulation technique using PVP show similar results to non-
granulated liquisolid tablets.  Literature suggests that the adsorptive properties of 
liquisolid system onto the carrier, which increases the surface area, could lead to a 
homogeneous drug distribution within the batch (Fahmy & Kassem, 2008). It was also 
suggested by (Elkordy, et al., 2012), that the large volume of the liquid vehicle, carrier 
and coating being used affects the drug uniformity. Their results showed batches with 
higher liquid vehicle concentration (10% w/w) complied with BP content uniformity 
specifications (Cremophor®EL 20%, Synperonic®PE/L61 20% and CapryolTM 90 20%. 
The reason is that the drug would need larger volume of liquid vehicle to be dispersed in, 
thus a larger amount of carrier and coating would be needed to produce a free flowable 
powder which leads to an even drug content.  
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3.5. Scanning electron microscopy (SEM) 
SEM photomicrographs that show the surface morphology of the liquisolid formulations 
(G1-G6 granulated, G1–G6 ungranulated) including conventional and pure drug are 
displayed in Figure 3.11. Pure glibenclamide powder observed to be crystalline in nature 
with fine particles which consists of flat shape. Also, conventional preparation showed 
crystals on the surface of the carrier material. The scanning electron microscopy of the 
liquisolid particles reveals irregular shapes with some long or rod-like structures which 
usually represents the shape of Avicel®PH102 (Elkordy, et al., 2013). The change in 
shape provides additional surface for deposition of the drug particle into the liquid vehicle. 
Thus, the disappearance of glibenclamide crystals to large extent suggests solubilisation 
of the drug into the liquisolid admixture, as will be confirmed by the DSC data. This may 
be contributed to the enhanced dissolution properties of the drug (Altememy & Altememy, 
2014). Furthermore, as seen in Figure 3.11, the SEM photomicrographs show different 
particle shape between granulated and ungranulated formulations. The granulated 
glibenclamide liquisolid formulations present with joint agglomerates, whereas the 
ungranulated particles appear to be less bonded with rod-like structure shapes. This can 
be indicative of the enhanced flowability using PVP in wet granulation. Liquisolid drug 
particles after granulation become combined into a general sphere like shape that not 
only means the drug has been dispersed well with the carrier and coating materials, but 
also demonstrates the unique flow characteristics associated with this technique. 
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         Pure glibenclamide                                 
 
Conventional glibenclamide 
 
 
G1 (Granulated)                                               
 
G1 (ungranulated) 
 
       G3 (Granulated) 
 
G3 (ungranulated) 
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G4 (Granulated) 
 
G4 (ungranulated) 
 
              G6 (Granulated)                                                 
 
G6 (ungranulated)                                                
Figure 3-11: SEM photomicrographs for pure (x1000) and conventional glibenclamide, 
and glibenclamide liquisolid powders and granules (x500). Refer to Table 3.1 for 
formulations’ composition. 
3.6. Fourier transform infrared spectroscopy (FTIR) 
 
Figures 3.12 illustrate the Fourier transform infrared spectral information of pure 
glibenclamide powder, excipients (Avice®PH102, Cab-O-sil®M-5, potato starch, Mg 
stearate and PVP) and non-volatile liquid vehicles (PEG®400, Synperonic®PE/L44, 
Cremophor®ELP). Additionally, liquisolid formulations (G1-G6) (refer to Table 3.1 for 
composition) in both granulated and ungranulated forms. The characteristics fingerprint 
FTIR peaks between 1500 and 1800 cm-1 for glibenclamide, the C=O stretching region 
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can be seen in Figure 3.12. It shows noticeable change in the IR spectra associated with 
liquisolid preparations. The peaks were either shifted or disappeared with even reduced 
intensity, suggesting interaction between the drug (glibenclamide) and the excipients 
used (Suliman, et al., 2013). Moreover, bands between 1000-1200 cm-1, show reduction 
in percentage transmittance which is the C-O stretching region, implies to an interaction 
between drug and non-volatile liquid vehicles leading to hydrogen bonding between 
glibenclamide and the liquid vehicle. One of the contributing factors that can affect the 
drug’s solubility is the formation of hydrogen bonding between the drug and liquid vehicles 
and thus accelerates dissolution rate (Elkordy et al 2013). Also, the comparison between 
ungranulated and granulated liquisolid glibenclamide do not show any change in their IR 
spectra, both correspond to the same peak number. Thus, the granulation process using 
PVP does not lead to any interaction with glibenclamide. Consequently, FTIR spectra 
analysis complies with DSC results where the crystallinity of glibenclamide was 
decreased leading to the solubilisation of glibenclamide crystals in the liquid vehicles. 
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G1 
 
PEG®400, Synperonic® PE/L44 and 
Cremophor® ELP 
G3  G5 
Figure 3-12: FT-IR spectra of pure glibenclamide powder, liquisolid formulations (G1, G3 
and G5) in powder and granules form and excipients used (PEG®400, 
Synperonic®PE/L44 and Cremophor®ELP. Refer to Table 3.1 for formulations’ 
composition. 
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3.7. Differential scanning calorimetry (DSC) 
The DSC thermograms of pure glibenclamide, granulated and ungranulated liquisolid 
glibenclamide including conventional powder should be in the range of the melting 
temperature of glibenclamide in order to define the effect of liquisolid and wet granulation 
on the drug. The presence of any change or shift in the melting temperature indicates the 
outcome of PVP in wet granulation as well as the effect of liquid vehicles and other 
excipients. Formulations G1-G6 (refer to Table 3.1 for composition), the excipients, pure 
glibenclamide and conventional DSC thermograms are shown in (Appendix for Chapter 
3) and Table 3.4 exhibits the DSC transition temperatures. The thermogram of pure 
glibenclamide clearly shows a melting temperature of 175.9 0C and an enthalpy value of 
91.5 J/g. At the 175.9 0C, the drug was in melting state with a sharp peak, which 
corresponds to the crystalline form of the drug (Baskaran, et al., 2016). Furthermore, in 
the liquisolid formulations (PEG®400, Synperonic®PE/L44 and Cremophor®ELP), the 
sharp endothermic peak at the drug melting point was either disappeared from granulated 
liquisolid containing PEG®400 (G1 and G2), and Cremophor®ELP (G3 and G4) liquid 
vehicles (which corresponds to the solubilisation of the drug in the liquid vehicle or 
causing change to the amorphous state of glibenclamide which was reflected in enhanced 
drug release as shown above in Figure 3.7a and b) or broadened with reduced enthalpy 
with granulated liquisolid containing Synperonic®PE/L44 (G5 and G6). In addition to that, 
no interaction between drug and excipients were shown in the DSC thermograms but 
compatibility was shown.  In more detail, PVP granulated liquisolid formulations 
thermograms display small changes at a temperature range of 110-130 0C in their 
endothermic peaks compared to the ungranulated formulations. The probable reason 
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could be that the interaction between the non-volatile liquid vehicles and drug particles 
are much larger than that between PVP, excipients and glibenclamide. Nevertheless, a 
slight shift in the endothermic peaks in all granulation methods is evident compared to the 
ungranulated formulations. Also, (Albertini, et al., 2004), debated whether the appearance 
is due to drug interaction with PVP or with other excipients. It can be concluded that the 
enhanced dissolution rate of glibenclamide is not only due to the interaction between the 
drug and the excipients or reducing the crystallinity of the drug, but also due to the 
wettability of the drug particles in the liquisolid systems by the aid of the liquid vehicle, 
this is in agreement with the study by (Javadzadeh, et al., 2007). 
 
Table 3-4: DSC transition temperatures of pure glibenclamide conventional powder, 
drug liquisolid granulated and ungranulated formulations (G1 – G6). 
Composition*	 Transition	temperature	(0C)	Pure	glibenclamide	 175.88	Conventional	 109.38,	small	peak	at	about	176	G1	(granulated)	 110.19	G1	(ungranulated)	 130.47	G2	(granulated)	 118.56	G2	(ungranulated)	 117.87	G3	(granulated)	 131.79	G3	(ungranulated)	 133.94	G4	(granulated)	 127.27	G4	(ungranulated)	 136.17	G5	(granulated)	 111.69,	193.26	G5	(ungranulated)	 106.70,	141.08,	189.85	G6	(granulated)	 127.64,	small	peak	at	174	G6	(ungranulated)	 139.27	
* Refer to Table 3.1 for formulations’ composition. 
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3.8 Conclusion 
Liquisolid technique changes the properties of glibenclamide by inclusion of the drug 
particles (10%w/wand 30%w/w) in non-volatile liquid vehicles (PEG® 400, 
Synperonic®PE/L44 and Cremophor ®ELP). Wet granulation of prepared liquisolid 
powders successfully produced automatically compactible tablets using the above-
mentioned liquid vehicles. The best dissolution enhancement was seen with combination 
of Cremophor® ELP with glibenclamide (10%w/w). However, the viscous behavior of 
Cremophor ®ELP makes the flowability and automatic compaction of liquisolid powders 
containing Cremophor® ELP very challenging. Using the new technique of wet 
granulation developed in this study, those problems were resolved and well compressed 
tablets were developed that were in compliance with B.P standards. Therefore, it can be 
concluded, that the problem with liquisolid compacts, which is flowability and 
compressibility, has been resolved by the introduction of wet granulation system to 
liquisolid powder admixture before compression. This new technique enhances not only 
the dissolution of the hydrophobic drug, but also the formation of wet tablets into strong 
well-compacted tablets with no lamination or capping. The liquisolid system can use any 
type of viscous liquid vehicles in its composition and by application of wet granulation 
technique liquisolid powders can be compacted into tablets. 
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Chapter 4 - Application of liquisolid technology using wet 
granulation on metformin-HCl: Immediate release and 
permeability studies 
 
 
 
 
 
 
Results and discussion
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Figure 4.1: Flowchart summary of immediate release metformin-HCl liquisolid preparation 
Liquisolid compact preparation
Model drugs for immediate drug release
Metformin-HCl
Angle of slide determination (q-value) determination for carrier: Avicel®PH102
coating: Cab-O-Sil®M-5
Liquid load factor(Lf value) determination
Drug powder admixture with liquid vehicle
PEG®400 Synperonic®PE/L44 and Cremophor®ELP
Q,q(carrier to coating)amount
R=20 Carrier: Avicel®PH102 Coating: Cab-O-Sil® M-5
Mixing of drug powder, liquid vehicle ,carrier,coating, disintegrant and lubricant in adjustable amount based on mathematical
calculation 
Powder admixture
wet granulation with 10%PVP
Automatic compaction
No granulation
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4.1. Introduction 
The main goal in diabetic patients is to achieve controlled blood glucose levels with the 
aid of insulin or antidiabetic drugs such as metformin-HCl. However, successful use of 
metformin-HCl therapy is challenged due to the high incidence of associated 
gastrointestinal symptoms such as diarrhoea and abdominal discomfort (BNF 73, 2017). 
Additionally, metformin-HCl has a multiple dosage regimen of 500mg two to three times 
daily or 850 mg once or twice per day. Therefore, such complications are not desirable 
and should be avoided to maintain patient compliance. Moreover, metformin-HCl presents 
other formulation challenges such as poor compressibility and poor permeability 
(Nanjwade, et al., 2011). According to the biopharmaceutical classification system (BCS), 
metformin-HCl belongs to class III with high water solubility and low permeability 
properties and due to metformin-HCl’s poor compressibility properties, direct 
compression is difficult on the commercial scale. This leads to poor content uniformity as 
well as poor weight content uniformity, hardness and friability (Nanjwade, et al., 2011).  
The aim of the work presented in Chapter 4 is to utilise liquisolid-based formulations of 
metformin-HCl as immediate release preparations whereas in the following chapter the 
formulation of metformin-HCl as a sustained release drug will be discussed. By use of 
liquisolid technique, a reduction in drug dosage was successfully achieved for both 
release types, meaning less costs for pharmaceutical industry and fewer side effects for 
patients. For both metformin-HCl liquisolid immediate and sustained release formulations, 
PEG®400, Synperonic®PE/L44 and Cremophor®ELP were used as non-volatile liquid 
vehicles. Additionally, wet granulation using PVP was applied to both systems in order to 
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achieve acceptable powder flowability and compressibility. Also tested and discussed in 
this chapter is the immediate release liquisolid metformin-HCl tablets used to perform 
permeability test using FRANZ Diffusion Cell to study the permeability release of 
immediate release metformin-HCl through Wistar rat stomach membrane.  
4.2. Determination of the angle of slide (θ) for determination of flowable liquid 
retention potential (Φ values) for Avicel®PH102 (MCC) and Cab-O-sil®M-5 (fumed 
silica)  
Flowchart Figure 4.1 shows the newly designed procedure. (Spireas & Sadu, 1998) 
claimed that the liquisolid technology theory indicates that drug, upon dissolving in the 
liquid vehicle, becomes merged into the carrier material. The carrier (Avicel®PH102), has 
entangled fibres as cellulose in its interiors and also has a porous surface where 
adsorption and absorption occurs. In other words, the non-volatile liquid gets absorbed in 
the interior of the particles where then the saturation of this procedure leads to the 
adsorption of the liquid onto the internal and external surface of Avicel®PH102 (carrier). 
Thus, the adsorptive coating material and its large surface area offers the desirable flow 
properties to the liquisolid system. Additionally, the angle of slide is used to determine the 
flowable liquid-retention potential in order to calculate the Lf (as explained in sections 1.4 
and 3.1). According to Spireas et al 1992, angle of slide is the preferred technique to 
obtain the flowability of small particle size powders (less than 150μm.) The chosen non-
volatile liquid vehicles were PEG®400, Synperonic®PE/L44 and Cremophor®ELP. The Φ 
values for Avicel®PH102 (MCC) and Cab-O-sil®M-5 using the three liquid vehicles were 
obtained. Drugs in liquisolid formulations, with lower concentration require more liquid 
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vehicles, carriers and coating materials to produce larger tablets. Additionally, literature 
values show that the liquid load factor (Lf) is inversely proportional to the amount of carrier 
and coating used, and it increases with high viscosity liquid vehicles (refer to section 3.1 
for more details). Table 4.1 reveals results for Lf value.
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Table 4-1: Formulation of liquisolid systems of immediate release metformin-HCl (m=no granulation; F= with granulation) 
Liquisolid	
system	
Non-volatile	
liquid	vehicle	
Drug	
Concetration	in	
liquid	medication		
(%w/w)	
Carrier:	
Coating	
(R)		
Liquid	
load	
factor	
(Lf)	
Liquid	
vehicle	
(mg)	
Active		
ingredient	
(mg)	
Carrier	
(Q)	(mg)	
Coating	
(q)	(mg)	
Disintegrant	
(maize	
starch)	(mg)	
Lubricant	
(mg)	
Unit	
dose	
(mg)	
M1	 PEG®	400	 30	 20	 0.17	 93.30	 40.00	 794	 40.00	 51.00	 8.00	 1026.30	
M2	 PEG®	400	 60	 20	 0.17	 26.70	 40.00	 397	 20.00	 26.00	 4.00	 513.70	
M3	 Synperonic®	PE/L44	 30	 20	 0.27	 93.30	 40.00	 501	 25.00	 35.00	 5.20	 699.50	
M4	 Synperonic®	PE/L44	 60	 20	 0.27	 26.70	 40.00	 251	 13.00	 18.00	 2.60	 351.30	
M5	 Cremophor®ELP	 30	 20	 0.52	 93.30	 40.00	 256	 12.80	 21.00	 3.20	 426.30	
M6	 Cremophor®	ELP	 60	 20	 0.52	 26.70	 40.00	 128	 6.40	 11.00	 1.60	 213.70	
Conventional	 _	 _	 _	 _	 _	 40.00	 397	 20.00	 24.20	 3.60	 485.00	
F1	 PEG®	400	 30	 20	 0.17	 93.30	 40.00	 794	 40.00	 51.00	 8.00	 1026.30	
F2	 PEG®	400	 60	 20	 0.17	 26.70	 40.00	 397	 20.00	 26.00	 4.00	 513.70	
F3	 Synperonic®	PE/L44	 30	 20	 0.27	 93.30	 40.00	 501	 25.00	 35.00	 5.20	 699.50	
F4	 Synperonic®	PE/L44	 60	 20	 0.27	 26.70	 40.00	 251	 13.00	 18.00	 2.60	 351.30	
F5	 Cremophor®	ELP	 30	 20	 0.52	 93.30	 40.00	 256	 12.80	 21.00	 3.20	 426.30	
F6	 Cremophor®	ELP	 60	 20	 0.52	 26.70	 40.00	 128	 6.40	 11.00	 1.60	 213.70	
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4.3. Flowability and packing properties of the prepared liquisolid powders 
Powder flowability plays a crucial role in handling, packing, mixing and producing of 
pharmaceutical dosage forms where a set of tablets with even drug distribution is required 
to be compressed. Uniform powder fed through the hopper is required to maintain 
uniformity of tablet weight and drug content (Ekordy et al 2012, British Pharmacopoeia 
2017, (Mahato & Narang, 2012). Additionally, several factors such as physical, 
environmental as well as mechanical aspects can affect the liquisolid powder flowability 
properties. Therefore, to determine the flowability of powder, Carr’s compressibility index 
(Cl%) is used. It is a suitable parameter to compare between bulk and tapped densities 
of powder mass, which provides a measure to the reflecting interparticulate friction, and 
thus is used to measure the flowability of all liquisolid powders. The calculated Carr’s 
compressibility index of metformin-HCl liquisolids before and after granulation is 
presented in Figure 4.2. Generally, in accordance to British Pharmacopoeia 2017, any 
formulation with CI% below 15% indicates good flowability and CI% above 25 % suggests 
formulation with poor powder flowability.  
Therefore, the powder flow properties of the prepared granulated and ungranulated 
liquisolid metformin-HCl were evaluated using CI%. However, liquisolid formulation using 
Cremophor®ELP powder flow was very poor due to its high viscosity properties, hence no 
CI% was obtained before wet granulation stage. The calculated CI% results show that 
granulated liquisolid formulation have better flow properties than ungranulated ones (F1: 
24.5%, F2: 18.6%, F3: 15.7%, F4: 14.6%, F5: 24.2%, F6: 24.5%, refer to Table 4.1 for 
composition) as well as conventional metformin-HCl showed better flow properties in the 
granulated form (18%, Figure 4.3). 
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Figure 4.2: Carr’s compressibility index of metformin-HCl Liquisolid before granulation. 
F5 and F6 powders were sticky and hence they were not flowable at all. 
 
	
Figure 4.3: Carr’s compressibility index of metformin-HCl liquisolid after granulation. For 
formulations’ composition refer to Table 4.1. 
 
This can be related to the amount, type and property of the liquid vehicle used (PEG®400, 
Synperonic®PE/L44 and Cremophor®ELP) and the effect of wet granulation on the 
enhancement of powder flow using PVP as a liquid binder. The ungranulated liquisolid 
metformin-HCl showed fair flowability for F1 and F2 (24.5% and 23.1% respectively) and 
poor flowability was seen in Synperonic®PE/L44 liquisolid powders with CI% of 28.3% 
and 27% for F3 and F4 respectively. Also, CI% for F5 and F6 was not calculated due to 
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its unflowable powder characteristics (Figure 4.1). Thus, this shows that the properties of 
the liquid vehicle can interfere with the flow property of the formulation making it better or 
poor flowing.  
 Literature ( Spireas , et al., 1992), (Alderborn, 2013), (Javadzadeh, et al., 2007), 
(Javazadeh , et al., 2005), (Nokhodchi, et al., 2005) mentioned that the amount of carrier 
and coating materials in the liquisolid system can play a great role in determination of 
powder flow property. The liquid vehicle gets adsorbed to the surface of the carrier 
allowing the coating material (Cab-O-Sil®M-5) to absorb the excess liquid to form a freely 
flowable powder. Furthermore, only granulated liquisolid metformin-HCl were 
automatically compacted into tablets. This is due to poor flowability and compressibility 
properties of the liquisolid ungranulated powder and due to the elasticity properties of the 
liquid vehicle used, thus powders were manually compressed for the purpose of 
dissolution and drug content uniformity evaluation. According to (Javaheri, et al., 2014), 
ungranulated powder admixtures were uncompactible due to the elastic behavior of the 
liquisolid formulations. The powder not only was not compressed into tablet, but also 
formed a compactible unwanted shape. Similarly, such powder behavior was experienced 
by Elkordy et al 2013, where two liquisolid formulations using Synperonic®PE/L61 with 
Solutol HS 15 (1:1) at both drug concentrations 10% and 30% were incompactible, and 
hence no tablets were formed. The two non-volatile liquid vehicles have a plastic flow 
nature when combined, thus tablet formation was unachievable. In a concentrated 
suspension, weak Van der Waal forces hold flocculated particles together. This often 
results in plastic flow (Mahato & Narang, 2012). If the shear stress is low, such materials 
might possess elastic behavior. 
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 However, when the maximum yield stress is exceeded where the Van der Waal forces 
are broken, plastic flow is exhibited. There must be a balance for plasticity. Although 
plastic deformation helps the solid links to form between particles within the powder mix, 
excessive plasticity leads to the formation of tablets with high extent of hardness. The 
powder mix produced with Avicel®PH102 and the liquid vehicle takes advantage of the 
elastic properties of the liquid vehicle and the plastic properties of Avicel, leading to the 
formation of a powder mix that is mainly elastic (Elkordy et al.2013).  (Javadzadeh, et al., 
2007) suggested using HPMC or PVP as microsystems can improve flowability 
regardless of the liquid load factor being high. Although the flowability measured using 
Carr’s index in this study was fairly poor after granulation, as per their study, HPMC was 
only granulated and not the whole formulations. In the current research project, 
ungranulated F5 and F6 (refer to Table 4.1 for composition) showed the least favourable 
CI% results of all formulations. The suggested explanation is dependent on the high 
viscosity property of the liquid vehicle (Cremophor®ELP with viscosity of 650-800 (Rowe, 
et al., 2003) leading to a non-flowable liquisolid powder admixture. Similarly, (Tiong & 
Elkordy, 2009) claimed the powder flow of liquisolid naproxen with Cremohpor®EL to be 
poor due to the high viscosity of the liquid vehicle and high liquid load factor. In agreement 
with (Javazadeh , et al., 2005), load factor above 0.25 along with high viscosity liquid 
vehicle can induce poor powder flowability. For the reason that, there will be fewer 
amounts of carrier and coating materials available in the formulation and excess amount 
of liquid vehicle being available leading to the formation of agglomerates. As shown in 
Figure 4.2 and Figure 4.3, liquisolid powders show better Carr’s compressibility index 
when formed into granules. 
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 According to (Javaheri, et al., 2014), liquisolid powders before granulation showed poor 
flowability and therefore Carr’s compressibility index was not performed. However, after 
using wet granulation using PVP 10%, enhanced flowabiity of liquisolid powder granules 
was shown even with viscous liquid vehicles such as Cremophor®ELP. Not only did it 
enhance the flowability, but it also allowed for automatic compression of the liquisolid 
granules, which was previously unachievable without granulation. Granulated tablets, 
appeared hard with no capping or cracking and complied with quality control test of the 
British Pharmacopeia 2017. For this reason, wet granulation system, with a suitable liquid 
binder, is a successful technique to convert incompactible elastic powder into compactible 
powders with advanced tablet properties. 
4.4. In-vitro dissolution studies of immediate release metformin-HCl 
The in-vitro drug release (dissolution profiles) from immediate release metformin-HCl 
liquisolid tablets (M1-M4 and F1-F6, refer to Table 4.1 for composition), including 
conventional and pure metformin-HCl were performed in distilled water and are 
graphically presented in Figure 4.4. It was found that, all the prepared granulated liquisolid 
tablets released more than 80% of their metformin-HCl content after 60 min. After 5 min 
in the dissolution apparatus, the percentage released from granulated metformin-HCl 
liquisolid tablets was found to be 37.6, 41.0, 15.8, 16.0, 20.7 and 20.9 % from F1, F2, F3, 
F4, F5 and F6 (refer to Table 4.1 for composition) respectively versus 73.8% and 101% 
from the pure and conventional metformin-HCl respectively. The release for ungranulated 
liquisolid metformin-HCl showed inconsistent drug release (Figure 4.4). This indicates 
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that the addition of wet granulation using PVP as a liquid binder to the liquisolid compacts 
produces a steady with stable release of the drug over the time. Moreover, the extent of 
drug release for F1-F6 liquisolid formulations after 90 min was 102,103, 91, 100, 105 and 
103% for F1, F2 F3, F4, F5 and F6 respectively. Wet granulation process helps in having 
good flowable liquisolid powders with good compaction and also good drug uniformity 
content (Table 4.2).  The uneven distribution of the drug in the tablets for M3 and M2 
causes the drug release to be more than 100% (for M3) and less than 90% (for M2 due 
to high friability of M2 tablets). This confirms that the liquisolid metformin-HCl when 
formed into granules using PVP produced a strong binding effect that released the drug 
gradually. Moreover, the main reason for the stable release of the drug in the presence of 
PVP might be due to crystal growth inhibition, where PVP may serve to inhibit precipitation 
of the drug from the supersaturated solution (Usui, et al., 1997) (Javadzadeh et al.2007).  
According to (Javaheri, et al., 2014), similar outcome was not observed, although 10% 
PVP was also used for wet granulation process. The ungranulated glibenclamide tablets 
showed almost no release (however it is a hydrophobic drug but metformin-HCl is a water 
soluble drug) when compared to the granulated formulations. This can explain, using 
similar excipients does not necessarily give common results, as the drug’s structure and 
characteristics can play a great role in the release profiles (El-Say, et al., 2010). 
Additionally, higher dissolution rate was observed in pure metformin-HCl (Figure 4.4) and 
not for pure gibenclamide; this is basically due to metformin-HCl’s solubility properties in 
water which is not present in the water insoluble drug, glibenclamide. 
 
For the tested liquid vehicles, PEG®400 within granulated liquisolid tablets (30 and 60% 
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drug concentration) showed fast drug release within the first 10 minutes, while 
Cremophor®ELP and Synperonic®PE/L44 delayed the drug release over the time (Figure 
4.4). This can be explained on the basis of viscosities of the two later vehicles which have 
effects on the thickness of the diffusion layer around the drug particles (increased 
thickness) and on the diffusion coefficient (reduce diffusion). Based on the Noyes Whitney 
equation, these will properties cause the drug release to be reduced. This may be 
desirable to enhance drug bioavailability by enhancing the drug permeability for the 
released drug molecules. (Elkordy, et al., 2012).
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Figure 4.4: Dissolution study of immediate release metformin-HCl liquisolid in distilled water (30% and 60% drug 
concentrations). Refer to Table 4.1 for formulations’ composition.  
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Enhanced in-vitro dissolution of the drug from liquisolid compacts can be denoted to 
improved wettability via liquid vehicles Cremophor®ELP, a non-volatile hydrophilic liquid 
vehicle (surfactant) with HLB of 12-14. It is responsible for wetting of drug particles in the 
liquisolid system by decreasing the interfacial tension between particle’s surface and the 
dissolution medium causing an increase in the surface area of drug particles. The choice 
of the carrier can also affect the dissolution of the drug. After exposure to the dissolution 
medium, the drug being present on the surface of the carrier material dissolves, leading 
to an initial burst release of the drug that acts as a loading dose. (Butreddy & Dudhipala 
, 2015). The liquisolid preparations with a higher R value contains a low liquid load factor, 
a higher amount of microcrystalline cellulose (Avicel®) and a lower amount of the coating 
material. This was confirmed by the study performed on griseofulvin liquisolid 
formulations, where the use of microcrystalline cellulose with R-value of 20 resulted in a 
significant higher percentage of drug release compared to a prepared formulation with 
low R value (R=10) (Elkordy, et al., 2012) 
Several liquisolid studies performed on hydrophobic drugs correlate the enhanced 
dissolution rate to the increased wettability and surface availability of the lipophilic drug 
to the liquid medium as a result of drug dispersion within the hydrophilic non-volatile liquid 
such as PEG®400 ( (Butreddy & Dudhipala , 2015). Comparable outcomes were not 
obtained in the current project due to the high water solubility of metformin-HCl, where 
the non-volatile liquid vehicle (PEG®400, Synperonic®PE/L44 and Cremophor®ELP) 
attached their hydrophilic head to the hydrophilic part of metformin-HCl (react differently 
compared to hydrophobic drugs) allowing for a constant release of the drug. However, 
the positive effect of liquisolid technique on metformin-HCl was the possibility of dose 
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reduction (40mg active ingredient) and steady release of the drug by performing wet 
granulation in the final stage while maintaining the specified therapeutic effect of the drug 
(permeability enhancement as will be shown later). Nevertheless, liquisolid metformin-
HCl release has been prolonged by using HPC-high grade which is another great 
advantage of applying liquisolid on hydrophilic instead of lipophilic drugs to produce a 
sustained release formulation (refer to Chapter 5).  
 
Additionally, there are some factors that can affect the solubility of the solid drug in the 
dissolution medium such as temperature (endothermic or exothermic), dissolution 
medium (acidic or neutral), crystalline drug structure, presence of solubilising agents and 
molecular structure of the solute. Moreover, not all liquisolid vehicles work to the same 
extent with all hydrophobic drugs, as they can work differently depending on the solubility 
of the drug. Therefore, the presence of other non-volatile liquid vehicles may have 
affected the outcome. As a result, each formulation had a different dissolution profile 
depending on its liquid vehicle and its wetting property (El-Say et al. 2010) as seen in this 
current study (Figure 4.4). Principally, enhanced dissolution rate seen in liquisolid 
formulations is due to the mechanical treatment with the hydrophilic liquid vehicle, which 
is believed to raise the contact between the drug, and the dissolution medium (Yadav & 
Yadav, 2010). In other words, surfactants increase the wettability of the drug making them 
more available for water molecules to penetrate and thus increase the drug dissolution 
and improve the absorption from the GI tract. However, the opposite can be seen in some 
liquid vehicles. According to (Suliman, et al., 2013), conventional tablets gave a higher 
drug release than the liquisolid formulation using norfloxacin (a hydrophobic drug), this 
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was explained due to the zwitterionic behaviour of the drug in water. This is observed with 
hydrophobic nature drugs. Metformin-HCl behaves differently as it is freely soluble in 
water and results in rapid dissolution from immediate release tablets but this drug is poorly 
absorbed by the stomach (Hu , et al., 2006). The binding properties of the drug to the 
liquid vehicle and other excipients too can play a role as exhibited in Figure 4.4. The 
higher the concentration of the drug (60%) the higher the drug release compared to the 
30% containing drug formulations. Ultimately, the hydrophilic liquid vehicle contains two 
parts, a hydrophilic head and a hydrophobic tail, the tail attracts to the hydrophobic part 
of the drug allowing for water solubility enhancement. However, in this case since 
metformin-HCl is highly soluble in water, the opposite is happening, the hydrophilic head 
binds the hydrophilic part of the drug allowing for gradual release of metformin-HCl 
(Figure 4.4). 
Therefore, it can be concluded that the in vitro dissolution of liquisolid tablets is greatly 
influenced by wet granulation that causes strong binding, and by other factor such as the 
type of liquid vehicle used and whether automatic or manual compaction was performed 
on the powder admixture.  
For choosing the most applicable kinetic model of the drug release from the granulated 
metformin-HCl liquisolid formulations (F1-F6), goodness of fit test must be performed. 
Table 4.2 shows the results after calculation being performed to get the coefficient of 
determination (R²) for metformin-HCl liquisolid granules (F1-F6).  The zero-order model 
can be best described when drug release rate is independent of its concentration. On the 
other hand, First-order model is when the drug release is dependent on its concentration. 
The highest coefficient of determination is usually the most desirable model to be used in 
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which in this case it is the Higuchi model. It describes the release of the drug from a 
matrix, which is usually insoluble as a square room of time, which is linked to Fick’s Law 
of diffusion (Prabakaran, et al., 2003) This means that the driving force for diffusion of 
metformin-HCl molecule from the tablet into the dissolution medium is the drug 
concentration gradient between tablet and dissolution medium. Also, this can explain the 
slow diffusion rate of the drug as the distance of diffusion is increased which is the Higuchi 
model (Square root of time). 
Table 4-2: Kinetic release mechanism of metformin-HCl 
Metformin	Liquisolid	
granules	 Zero	Order	(R²)	 First	Order	(R²)	 Higuchi	(R²)	PEG®400	30%	(F1)	 0.959	 0.869	 0.991	PEG®400	60%	(F2)	 0.872	 0.788	 0.987	Synperonic®PE/L44	30%	(F3)	 0.931	 0.797	 0.988	Synperonic®PE/L44	60%	(F4)	 0.921	 0.790	 0.973	Cremophor®ELP	30%	(F5)	 0.889	 0.743	 0.972	Cremophor®ELP	60%	(F6)	 0.931	 0.797	 0.996	
 
4.5. Tablet hardness, Friability, Disintegration (BP) and Uniformity of drug content 
and Uniformity of tablet weight 
 
A summary of expressed average and the standard deviations results of tablet hardness, 
friability, disintegration and drug content for all metformin-HCl liquisolid (F1-F6) and 
conventional tablets are shown in the Table 4.3. The uniformity of weight test was 
performed on liquisolid tablets with granulation (F1-F6, refer to Table 4.1 for composition) 
whilst non-granulated tablets were not tested for any quality control measures due to the 
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manual compression of the liquisolid powders. Regarding the tablet hardness test, there 
were variations in tablet thickness and hardness due to the compression force applied. 
Generally, ideal tablet hardness should be produced without applying excessive 
compression force where rapid tablet disintegration and drug dissolution are maintained 
at the same time ( (Tiong & Elkordy, 2009), (Fahmy & Kassem, 2008) (Elkordy, et al., 
2013). Tablet hardness depends on particle size, interparticle force, and most importantly, 
compression force. Usually, as compression force increases, tablet hardness and fracture 
resistance increases as well (Bi, et al., 1999). Additionally, El-Say et al. (2010) found a 
relationship between liquid load factor and the hardness of the tablets in the formulae 
having approximately the same powder excipient ratio: when liquid load factor increased, 
the hardness of the tablet decreased. In this study, M1 has the lowest liquid load factor 
(refer to Table 4.1) and as a result showed highest hardness (hardness: 11.8 kg/f, 115.7N) 
and inversely for F1 (8.2kg/f 80.4N), although M1 and F1 have same excipients’ ratio but 
M1 is ungranulated and F1 was prepared from granulated powder mix. The M1 was 
manually compacted. That would be another reason why the hardness is high in this 
formulation as a high force was applied when compacting manually. Therefore, our 
suggestion is that not only the liquid load factor has an effect on the hardness of the tablet, 
but also the granulation process that was performed before compaction can be a factor 
and also the binding substance, PVP, as well. In addition, hydrogen bonding between 
hydrogen groups on Avicel®PH102 molecules can play a role in the strength of the 
liquisolid tablets (Fahmy & Kassem, 2008). This is because microcrystalline cellulose, 
MCC (a crystalline structure) undergoes plastic deformation when compression is applied 
allowing for increased hydrogen bonding through closer contact between the surfaces of 
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the MCC molecules.  
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Table 4-3: Crushing load, hardness, friability, drug content uniformity and uniformity of 
weight for metformin-HCl liquisolid tablets (for formulation compositions, refer to Table 
4.1) 
FORMULATION	 CRUSHING	LOAD	(KG/F)	
HARDNESS	
(N)	
FRIABILITY	
WEIGHT	
(%)	
DRUG	
CONTENT	
(%)	
UNIFORMITY	OF	
WEIGHT	(MG)	
M1	 11.80	±	1.81	 115.70	 0.26%	 103%	 270	±	6.50	
M2	 7.10	±	0.52	 69.60	 10.00%	 101%	 255	±	4.50	
F1	 8.15	±	0.26	 79.90	 1.00%	 99%	 276	±	1.70	
F2	 6.83	±	0.89	 67.00	 0.87%	 99%	 263	±	4.10	
F3	 6.18	±	0.26	 60.60	 0.01%	 94%	 372	±	7.40	
F4	 11.97	±	0.42		 117.40	 0.01%	 94%	 377	±	14.4	
F5	 5.98	±	0.45	 58.60	 0.10%	 96%	 231	±	4.00	
F6	 6.37	±	0.24	 62.50	 0.02%	 99%	 213	±	5.90	
CONVENTIONAL	 4.98	±	0.97	 48.80	 0.80%	 98%	 371	±	30.0	
          
All liquisolid granulated metformin-HCl tablets complied with BP limits of friability test 
(<1%). There was no cracking or breaking of tablets after performing the test. However, 
M2 (refer to Table 4.1 for composition), the ungranulated liquisolid metformin-HCl 
formulation did not comply with BP and showed a very high friability percentage (10%; 
this affects its drug release) (Figure 4.4). Therefore, the granulated liquisolid tablets are 
expected to stay strong and withstand handling, packaging through, transportation.  
Rapid disintegration is important during manufacturing of tablets to ensure fast breakup 
of tablet into small particles, yielding a high surface area for enhanced dissolution 
(Elkordy et al 2012, (Gubbi & Jarag, 2009), (Chebli & Cartilier, 1998)). Disintegration time 
can be affected by several factors such as the type of liquid vehicle used, tablet porosity 
and pore structures (Tiong & Elkordy, 2009). The presence of a non-volatile liquid vehicle 
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is expected to delay the disintegration time of the tablet. However, the presence of MCC 
speeds the process of disintegration giving a low disintegration time (Javadzadeh et al. 
2007). This is because water uptake into pores is enhanced causing pressure in the tablet 
pores eventually breaking down of the tablet into smaller particles. In addition, literature 
suggests a liner relationship between tablet hardness and disintegration time. In other 
words, as hardness increases, the disintegration time also increases (Kitazawa, et al., 
1975). The higher the crushing force, the longer the disintegration time will be. However, 
this finding was not achieved in this study, as seen in Figure 4.4 and Table 4.3, the 
slowest disintegration formula was F3 (refer to Table 4.1 for composition) which took 43 
minutes to disintegrate followed by F4 (32.5 minutes). The strong binding of PVP and 
Synperonic®PE/L44 may cause the delay in the disintegration time. Although, 
microcrystalline cellulose (Avicel®PH102) has disintegration property that can facilitate 
disintegration and dissolution of drug, However, the presence of non-volatile liquid vehicle 
(Synperonic®PE/L44) binds to the liquisolid powder and cause a delaying disintegration 
time (Javadzadeh et al.2007). Therefore, this delay of the disintegration time in F3 in 
addition to the extensive binding properties of PVP, lower dissolution rate (Figure 4.4). 
Nevertheless, F1 and F2 showed a faster disintegration time (13.5 min and 13.6 min 
respectively) compared to F3-F6 (Figure 4.5) and this could be linked to the nature of the 
non-volatile liquid vehicle used (PEG®400 in F1 and F2). Thereby, F1 and F2 
disintegrated within 13.5 min and 13.7 min, respectively and complied with BP 
disintegration test. Thus, the type of non-volatile liquid vehicle, the quantity of the 
disintegrant and the quantity and the type of the carrier are the major time controlling 
factors of the liquisolid tablet disintegration. Taking into consideration, there are no big 
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difference in hardness of F1, F2, F3, F5 and F6 (Table 4.3 and Figure 4.5).  
	
Figure 4.5: Average disintegration time of liquisolid immediate release metformin-HCl. 
Refer to Table 4.1 for composition. 
 
British Pharmacopoeia (2017) specifies the accepted limits of the percentage of the active 
drug in tablets between 85% and 115% (BP 2017). The drug uniformity content was 
performed only on granulated tablets (F1-F6, refer to Table 4.1 for composition) and 
tablets that were manually compactable (M1 and M2). This is due to the lack of good 
flowability and compactibility properties of M3-M6.  Accordingly, all liquisolid formulations 
including conventional tablet complied with British Pharmacopoeia (BP), 2017 drug 
content uniformity. From the drug content result, it can be said that the granulated 
formulation showed uniform drug content.  This is a very important finding that drug 
binding to PVP during granulation allows for better uniformity and distribution in tablets 
when compacted.  According to (Fahmy & Kassem, 2008), the higher the amount of liquid 
medication and carrier used, the more uniform drug distribution is achieved. This is due 
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to the adsorption process of the carrier to the liquid vehicle, which yields a higher surface 
area with a homogeneous distribution of the drug. Moreover, the effect of liquid 
medication and content of carrier did not play a great role and there was no major 
difference in drug content, between 30% and 60% drug content of each batch used. In 
other words, there was no significant differences between liquisolid formulations of 
different liquid vehicles (PEG®400, Synperonic®PE/L44 and Cremophor®ELP) as well as 
conventional tablets. The possible reason can be referred to the amount of the carrier 
excipient in the unit dose of each formulation, which enhances the absorption of the liquid 
medication into the internal part of the carrier, resulting in a homogeneous distribution of 
the active ingredient ( Spireas , et al., 1992), (Akinlade, et al., 2010) (El-Say, et al., 2010) 
(Javaheri, et al., 2014).  
4.6. Fourier transform infrared (FT-IR) spectroscopy 
Within a molecule, the IR-radiation causes the excitation of the vibrations of covalent 
bonds, which can also be the bending and stretching means. Figure 4.6 below illustrates 
the infrared spectra of pure metformin-HCl, pure excipients, conventional and some of 
the liquisolid powders both granulated and ungranulated (M1-M6 and F1-F6). The 
fingerprint region is usually between 500 – 1800 cm-1 and the functional group region is 
between 2000-4000 cm-1. Metformin-HCl IR studies, revealed two typical bands at 3367 
and 3292 cm -1 due to N-H primary stretching and a band at 3156 cm-1 due to N-H 
secondary stretching. Additionally, characteristic bands at 1623 and 1561 cm-1 were 
observed to be denoted for N-H asymmetric deformation. The FT-IR can be indicative of 
shift due to hydrogen bonding interaction between the hydroxyl group of liquid vehicle 
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and metformin-HCl which was observed in liquisolid formulations (F1-F6, refer to Table 
4.1 for composition).  Hydrogen bonding is an important contributing factor that 
determines solubility or dissolution enhancement of the hydrophobic drug. Although 
metformin-HCl is a hydrophilic drug, the conventional metformin-HCl spectra showed a 
complete change in peaks when compared to pure metformin-HCl (Figure 4.6). The DSC 
in Figure 4.7 confirms the rationale behind the FT-IR data of the liquisolids granulated 
and ungranulated. Additionally, there was no band shifting in granulated an ungranulated 
formulations, therefore, this could indicate that PVP as a liquid binder has no negative 
effects on drug release in the neutral dissolution medium and in this situation, PVP will 
not lead to crystallization. The FT-IR results were also consistent with DSC results, which 
confirms the solubilisation of metformin-HCl within the liquid vehicles. (Silverstein, et al., 
1991), (Sheela, et al., 2010). 
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Figure 4.6: FT-IR spectra of pure metformin-HCl, pure excipients, conventional and 
some of the liquisolid powders both granulated and ungranulated (F1, M1, M3, F3). For 
formulations’ compositions refer to Table 4.1.  
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4.7. Differential scanning calorimetry (DSC) 
DSC is the most common parameter to determine the physicochemical properties and 
interaction between the drug and the excipients. Figure 4.7 shows the DSC of pure 
metformin-HCl, pure excipients, conventional and some metformin-HCl liquisolid 
formulations. Pure metformin-HCl thermogram showed a sharp endothermic peak at 
232.99°C with a melting enthalpy of 215.8J/g. This sharp peak indicates that the drug is 
in its crystalline anhydrous state (Murra , et al., 2005) (Fahmy & Kassem, 2008). Very 
broad peaks were displayed in Figure 4.7 for both thermograms of potato starch and 
Avicel®PH102 with mid points of 139.180C and 145°C, respectively. In addition, Cab-o-
sil®M-5 thermogram showed a small peak at 117.770c which indicates the amorphous 
state of the coating material. On the other hand, the DSC thermograms (Figure 4.7) of all 
liquisolid formulations (except M5 and M6; F5 and F6) showed broadened peaks with 
reduced intensities instead of the sharp melting peak of metformin-HCl; meaning 
changing of the drug crystallinity.  This signifies to the large solubilisation of metformin-
HCl in the liquid vehicle as well as the possibility of an interaction between the drug and 
the excipients (Tiong and Elkordy, 2009) or a modification to a secondary amorphous 
forms which were reflected in enhanced dissolution compared to Cremophor® ELP 
containing formulations M5 and M6 (ungranulated powders) and F5 and F6 (granulated 
powders). The thermograms of conventional and pure metformin-HCl showed sharp 
peaks at ~229.290C and conventional metformin-HCl powder revealed a broad peak at 
121.450C corresponding to the Avicel®PH102 broad peak and a sharp one at 235.200C 
which resembles the pure drug melting point, indicating no major changes in crystallinity 
of metformin-HCl in the conventional system.  
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Magnesium stearate 
 
 
Figure 4.7: DSC thermograms of pure metformin-HCl, some liquisolid formulations, 
conventional, and pure excipients used. Refer to Table 4.1 for formulations’ composition. 
 
4.8. Scanning electron microscopy (SEM) 
Figure 4.8 displays the SEM microphotographs of pure metformin-HCl, conventional and 
some liquisolid powders, granulated and ungranulated (M5, M6, F5, and F6). It can be 
noted that the pure metformin-HCl powder shows the drug in crystalline form with particles 
having well defined edges. This can be confirmed by the above results obtained from 
DSC thermograms. On the other hand, the liquisolid powders present with a rod like 
shape structure in which no crystals were seen. According to (Elkordy, et al., 2013) the 
disappearance of the drug crystals indicates that there has been a full inclusion of the 
drug molecule within the carrier, coating and liquid vehicle used. Moreover, conventional 
metformin-HCl shows a more defined, smooth edged shape even though liquid 
medication is not added. Therefore (Elkordy, et al., 2013) findings are confirmed by this 
study. It can be observed from the images below that the granulated liquisolid metformin-
HCl shows a more defined yet smooth edged shape particles compared to the non-
granulated powders. It can be concluded that the SEM results below can be a promising 
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finding for permeability test (Section 4.14) as it indicated that the drug particles are 
integrated in the liquid vehicles and the other excipients used.  
 
 
Pure Metformin powder 
 
Conventional Metformin 
 
   M5  
F5 
 
M6 
 
F6 
Figure 4.8: SEM microphotographs (x1000) of pure metformin-HCl and liquisolid 
powders being ungranulated and granulated. Refer to Table 4.1 for composition of 
formulations. 
 
 
139 
 
4.9. Stability study 
4.9.1. In-vitro dissolution study for stored metformin-HCl liquisolid tablets 
Dissolution stability results of metformin-HCl granulated (F1-F6) liquisolid tablets in figure 
4.9 revealed that there was no significant difference (P > 0.05) between fresh and store 
liquisolid formulations after storage at 250C with 76% relative humidity. This suggests that 
metformin-HCl liquisolid formulations are stable under any stressful condition such as 
high humidity, without affecting the drug properties (as detected from DSC and FT-IR 
data– see below) or cause any changes in dissolution profile, making the production of 
metformin-HCl liquisolid viable for pharmaceutical industrial manufacturing.
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Figure 4.9: Dissolution profiles from stored liquisolid metformin-HCl (F1-F6). For formulations’ composition refer to Table 
4.1 
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4.9.2. Fourier transform infrared (FT-IR) spectroscopy stability study of 
granulated liquisolid metformin-HCl 
The FT-IR results of stored liquisolid metformin-HCl tablets are shown in Figure 4.10. It 
can be observed that there is no significant difference between the fresh and the stored 
liquisolid metformin-HCl tablets. This further confirms the obtained dissolution results of 
stored liquisolid metformin-HCl and that the liquisolid compacts are successful 
formulations that maintain stability under stressful conditions. 
       
 
 F3 and F4                                                          
F5 and F6 
Figure 4.10: Fourier transform infrared (FT-IR) spectroscopy stability study of liquisolid 
metformin-HCl. For composition refer to Table 4.1.       
4.9.3. Differential scanning calorimetry (DSC) of stored liquisolid metformin-HCl 
Figure 4.11 shows the DSC thermograms of liquisolid metformin-HCl (F1-F6) after 
storage (at 76% humidity and 25°C) for 12 months. The thermograms revealed no 
significant difference between fresh (Figure 4.4) and stored metformin-HCl liquisolid 
tablets (Figure 4.9).  
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Figure 4.11: Differential scanning calorimetry (DSC) of stored liquisolid metformin-HCl 
formulations, refer to Table 4.1 for composition. 
4.10. Metformin-HCl permeability test 
The major goal in the design, drug selection and production of drugs intended for 
noninvasive delivery is the prediction of human drug absorption. In different phases of 
drug discovery and development, several techniques were employed to evaluate the 
extent of drug absorption. Screening protocols include a variety of preclinical 
methodologies to evaluate drug absorption such as in-vitro, in-vivo and ex-vivo. To 
assess the absorption of drugs in preclinical studies, animal studies are the gold 
standards despite the fact that this is an expensive and time consuming protocol that may 
not precisely predict the drug in human behavior (Sarmento, et al., 2012). Additionally, in 
the selection of compounds for clinical development, the in-vitro models that mimic the 
mucosa in the human body are most appropriate protocol for absorptions data. The 
presently used techniques for drug absorption and permeability tests other than using 
human volunteers for some particular drugs in clinical trials, cell culture models, which 
offers a highly defined tool, as well as human cell lines are currently considered as 
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convenient models. In order to thoroughly resemble the in-vivo tissues, the in-vitro cell 
based model have been optimized which incorporates more than one single type of cell. 
In an attempt to shorten drug development time, new and improved tissues based in-vitro 
models are used to estimate the drug absorption. An alternative approach to test the 
activity of drug across the biological tissue is the consideration of ex-vivo experiments 
that closely represent human conditions. Based on the in-vitro drug permeation profiles, 
the in-vitro-in-vivo correlation must provide a drug’s in-vivo pharmacokinetics prediction 
(Pelkonen, et al., 2001). The key factor in the absorption and distribution of drugs is the 
permeability across the biological membranes leading to poor absorption across the 
gastrointestinal mucosa and distribution throughout the human body. This can also be 
due to membrane based efflux mechanisms as well as structural features. Additionally, 
the permeability classification can be determined directly by measuring the mass rate 
transfer across the human intestinal or stomach membrane. An alternative method is by 
indirect estimation of the amount of drug absorption in pharmacokinetics studies in 
humans. Several other systems can be used for oral drug absorption prediction in humans 
as well as for classification of drugs according to their permeability, such as intestinal 
perfusion studies (in-situ methods), in-vitro cell cultures (Caco-2), artificial membranes 
and ex-vivo studies using intestinal segments from animals or humans (Balimane, et al., 
2000). In this section, a review on the different types of drug permeability tests used and 
their application in different publication is discussed. The goal of this work is to 
demonstrate the use of prepared liquisolid metformin-HCl tablets in an ex-vivo experiment 
using Franz Cell Diffusion. The permeability test was performed on Wistar male rats 
stomach tissue to compare the absorption between pure metformin-HCl and liquisolid 
 
145 
 
formulations. To the best of our knowledge, no study or publication has been performed 
on the use of liquisolid formulations in permeability test using Franz cell diffusion and 
particularly using stomach tissue. Therefore, all the acquired data are purely based on 
the experiments performed during the laboratory work, and the typical available methods 
of drug permeability test such as Caco-cell based tests were not used. 
4.11. Different permeability studies 
4.11.1 Intestinal permeability test using Single-pass Intestinal Perfusion 
A study by (Song, et al., 2006) used the Single-pass Intestinal Perfusion (SPIP) technique 
to characterize the intestinal transport and mechanism of metformin-HCl in rats. They 
have stated that this procedure is used in anesthetized rats whereby a section of intestine 
is isolated and perfused with a solution of the drug. In the experimental procedures of 
single-pass Intestinal Perfusion, modifications can be made to the length of the perfused 
intestine, concentration of the drug and the flow rate. Additionally, as determined by the 
difference between the inlet and outlet concentrations, the loss of compound is attributed 
to absorption. The preliminary studies may consist of stability studies in the homogenates 
of the intestine and the buffer intestine.  As a result, it was found that metformin-HCl could 
be absorbed from the whole intestine with the main absorption site being the duodenum. 
Metformin-HCl is transported by passive and active carrier mediated mechanisms, which 
is also concentration-dependent. Furthermore, the Peff values obtained, the human 
fraction dose absorbed for metformin-HCl is estimated to be 74%-90% along human 
intestine. Intestinal perfusion studies are closer to in-vivo conditions. Limitations of this 
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method are associated with the technical complexity of studies in anesthetized animals 
making the method very low throughput. The permeability measurement is based on 
disappearance of the drug from the intestinal lumen as the only indication of absorption 
and a large number of animals are needed for a statistical significance  
(Zakeri-Milania, et al., 2007) used SPIP in rats to predict the human intestinal permeability 
and fraction absorbed upon oral dosing. They determined the permeability coefficients in 
anaesthetized rats using fourteen compounds. The appropriate SPIP method used is 
through the perfusion of the drug solution through a single-pass intestinal perfusion 
(SPIP) in phosphate buffered saline (PBS) with 0.21ml/min flow rate. At different time 
points, up to 90min, the samples were taken from outlet tubing. Using HPLC, drug 
concentrations in samples were determined and permeability coefficients (Peff) were 
calculated. In conclusion, the SPIP could be utilized with precision to predict the human 
intestinal permeability. Additionally, this particular technique provides a complete blood 
supply and functional intestinal barrier that simulates a normal physiological state, which 
can be used as a reliable procedure for the prediction of the absorbed dose following oral 
administration in humans. 
4.11.2 In-vivo permeability study of liquisolid formulations using animals such as 
beagle dogs and rabbits  
Khaled et al. 2001, carried out an in-vivo drug permeability test to examine the absorption 
properties Hydrochlorothiazide liquisolid tablets by using six male beagle dogs. The 
liquisolid hydrochlorothiazide was orally and intravenously administered in dogs. 
Moreover, 25mg of a single oral liquisolid and commercial tablets in a randomized two-
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way crossover design was administered on two occasions. The results of the oral 
administration showed significant difference (P < 0.05) between the liquisolid and the 
commercial tablets in the peak plasma concentration, and the absolute bioavailability. 
Additionally, liquisolid tablets showed 15% higher absolute bioavailability than the 
commercial tablets, indicating greater bioavailability of the liquisolid tablets. 
Consequently, the absorption of liquisolid hydrochlorothiazide tablets showed 
significantly higher extent of absorption than the commercial tablets. Thus, upon 
performing the in-vivo test, production of liquisolid formulation has the potential to be used 
for clinical trials on humans to provide large scale production of liquisolid 
hydrochlorothiazide tablets by pharmaceutical industries (Khaled, et al., 2001). 
(El-Houssieny, et al., 2010) studied the bioavailability and biological activity of repaglinide 
liquisolid and its effect on glucose tolerance in rabbits. The rabbits were orally 
administered with liquisolid repaglinide and blood samples were used to determine the 
pharmacokinetic parameters of the liquisolid drug and then compared to pharmacokinetic 
parameters of marketed tablets (Novonorm, 2 mg). For pharmacokinetic studies, high-
performance liquid chromatography was used to determine and validate the concentration 
of repaglinide in the plasma of rabbits. It was found that the relative bioavailability of 
repaglinide liquisolid tablets was significantly increased in comparison to the marketed 
tablets. In regards to insulin levels, the liquisolid repaglinide tablets increased insulin level 
with a significant change of 37.6% while an insignificant change of 3.52% was seen in 
commercial tablets. Additionally, the glucose tolerance test showed a reduction in blood 
glucose level (18.1 % change) upon administration of the commercial whereas the blood 
glucose level percentage change in groups treated with liquisolid formulation decreased 
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29.98%. Consequently, the bioavailability of liquisolid repaglinide was enhanced upon 
oral administration of the drug which showed significant decrease in blood glucose levels 
and more control of blood sugar than in commercial tablets by stimulating the release of 
insulin from the β-cell of the pancreas (El-Houssieny, et al., 2010). 
4.11.3 Effect of Freezing and Type of Mucosa on Ex-Vivo Drug Permeability 
Parameters   
(Caon & Simões, 2011) performed an ex-vivo permeability study of carmabazepine (CBZ) 
and triamcinolone acetonide (TAC) on the porcine esophageal and buccal mucosa with 
different permeabilities and physicochemical properties using a Franz diffusion cell 
system and HPLC as A detection method. The evaluation of freezing effects on drug 
permeability parameters by comparing fresh and frozen tissues was tested. As a result, 
it was found that fresh and frozen esophageal mucosae provided higher permeation of 
triamcinolone acetonide than on buccal mucosae while the permeability parameters 
obtained for carmabazepine were similar on both mucosae. Additionally, involving 
carmabazepine, porcine esophageal mucosa could be used as a substitute for buccal 
mucosa on ex-vivo studies whereas triamcinolone acetonide cannot be used for buccal 
mucosa study. With great care, substitution of frozen tissues could be used instead of 
fresh in both cases with special attention to the results of previous tests due to results 
obtained could differ depending on the tested drug.  Thus, in permeability studies 
involving carmabazepine and triamcinolone acetonide, frozen porcine mucosae could be 
substituted by fresh porcine mucosae. Also, only in ex-vivo experiments comprising of 
carmabazepine, esophageal mucosa could be used as a substitute for buccal mucosa. 
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Consequently, to study the buccal drug permeability, consideration of drug type and its 
physicochemical characteristics are relevant during the development of an ex-vivo mode. 
(Caon & Simões, 2011). 
4.11.4 Caco-2 Model 
Caco-2 cells have been considered the “gold standard” assay for the prediction of 
intestinal absorption, since they are extracted from human colorectal carcinoma (Hidalgo, 
2001). No passive diffusion is constituted in Caco-2. Additionally, intestinal epithelium 
permeability is a vital property that determines the extent and the rate of human 
absorption which eventually affects the bioavailability of drug candidates. Additionally, by 
allowing rapid assessment of membrane permeability, the caco-2 permeability assay rank 
compounds as high, medium and low permeability. Moreover, majority of the 
morphological and functional characteristics of intestinal cells that are responsible for 
absorption are expressed by enterocytes. On the other hand, the permeability of 
hydrophilic drugs are generally low in the Caco-2 monolayer that are transported by the 
paracellular pathway. This is due to the tighter junction of the hydrophilic drugs (Sun, et 
al., 2008) 
4.12. Passive diffusion fundamentals of drug substances	
The main target upon drug administration by extravascular route is the systemic 
absorption followed by distribution to tissues and organs. At the side of action, drug 
receptor interaction usually takes place to exert the pharmacological or toxic effect of the 
drug. The transport of drug molecules across the cellular barrier involves two types of 
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movements or diffusion caused by an external force such as hydrodynamic flow or gravity: 
transcellular (across the cell) and paracellular (inbetween cells). Diffusion in the presence 
of a concentration gradient causes a net transport of molecules. The movement of drug 
molecules from a higher to a lower concentration without the need of energy is known as 
“passive diffusion” and this type of movement or diffusion does not involve a carrier which 
can mediates either transcellular or paracellular transports (Shargel and YU 1999). 
Additionally, according to Cao et al. (2006), about 80-95% of drug are absorbed by 
passive diffusion and is affected by physicochemical properties such as hydrogen 
bonding, pKa and lipophilicity. 
4.13. Franz Cell 
The most common in-vitro release testing (IVRT) method that is currently being used is 
called Franz diffusion cells. There are few studies for orally administered drugs using the 
Franz diffusion cell. Traditionally, they are used with synthetic membranes such as skin 
and only few studies have employed Franz diffusion cells to study drug permeability 
across the stomach or small intestine tissue (Dezani, et al., 2013). The membrane is kept 
between the two compartments that separates donor from the receptor chamber. The 
donor compartment contains the test product and the receptor compartment is filled with 
the collection medium. There are several advantages of using Franz diffusion cells 
including the need for a small amount of drug substance and the minor amount of tissue 
handling and the similarities between rat and human tissues (Cao, et al., 2008). 
 
151 
 
4.14. Permeability study of metformin-HCl using stomach tissue and Franz cell 
The permeability study of liquisolid immediate release metformin-HCl was performed on 
male Wistar rats’ stomach tissue (Refer to Appendix for Chapter 4). The tissue was stored 
in freezer (-80 0 C) and prior to the test, the tissue was defrosted and placed in freshly 
prepared tyrode solution. Throughout the experiment, fresh solutions of tyrode and 0.2M 
HCl were prepared. The tyrode's solution resembles lactated Ringer's solution, but 
contains magnesium, glucose uses bicarbonate and phosphate as a buffer. The isotonic 
solution was invented by an American pharmacologist Maurice Vejux Tyrodeis and it is 
used in physiological experiments and tissue culture. Metformin-HCl liquisolid tablet 
containing roughly 40mg of active ingredient was dissolved in distilled water and filtered 
using 0.2µm size filter. The stomach tissue, upon cleaning the inner lining and cutting into 
appropriate thickness, was placed on the Franz diffusion cell opening designated for the 
membrane. The chamber was filled with 14 ml of HCl, 0.2M solution. The Franz cell was 
kept at a constant temperature over a magnetic stirrer. Using a micropipette,1 ml of the 
filtered metformin-HCl solution was injected in the donor chamber and samples were 
withdrawn from the receiver chamber after specific time intervals. The results of the 
performed permeability study are shown in Table 4.4. 
As an anti-diabetic biguanide, metformin-HCl through a reduction in gluconeogenesis, 
works by suppressing the unnecessary production of hepatic glucose. It has a half-life of 
about 5 hours with a renal clearance rate of 510±120 ml/min. Moreover, metformin-HCl 
is not metabolized and is excreted unchanged only in the urine. The drug is distributed 
into the tissues of the body, liver, kidney as well as intestines by cationic transporters 
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(Gong, et al., 2012). The current performed ex-vivo permeability study on the male wistar 
rat stomach has shown a permeability difference between pure metformin-HCl and 
liquisolid formulations. According to (Caon & Simões, 2011), the difference between fresh 
and frozen tissues were insignificant. Thus, although the results shown in Table 4.4 were 
using frozen tissue, the results obtained were promising and can be performed on 
different types of liquisolid drugs. The possible explanation to the new findings could be 
linked to several factors including: the properties of the surfactants (PEG®400, 
Synperonic®PE/L44 and Cremophor®ELP), the excipients (Avicel®PH102 and Cab-O-
Sil® M-5) and the use of polyvenylpyrolidone (PVP). Volker Bühler (2005) presented a 
work linking the effect of PVP (Povidone) with the bioavailability of different active drugs 
administered via several routes. The oral bioavailability of a nifedipine coprecipitate in the 
rat, phenobarbital coprecipitate in rabbits and upon percutaneous administration of 
hydrocortisone coprecipitate on the human skin was evaluated. Additionally, similar dose 
of the pure active substance without PVP was applied for reference. Interestingly, after 
two hours, the plasma level of the nifedipine coprecipitate reached twice the plasma level 
of pure substance, and in the case of the phenobarbital suppositories, it reached three 
times the level of the pure active substance (Bühler, 2005). Therefore, a strong correlation 
between the effect of PVP on the drug permeability and bioavailability is observed. Thus, 
it is a suggested reason, other than the benefits of liquisolid technique on the 
enhancement of drug bioavailability but also wet granulation by using PVP can contribute 
to the permeability improvement. 
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Table 4-4: Efflux (µg/ml/cm2) of metformin-HCl liquisolid in HCl (0.2M) solution using 
Franz diffusion cell for permeability study. 
0.2M	HCL	 Efflux	(µg/ml/cm2)	
Time	(min)	 PEG	30%	 PEG	60%	 Synperonic	30%	5	 0.87	 1.25	 0.50	10	 0.97	 1.12	 0.51	15	 1.00	 1.09	 0.61	20	 1.02	 1.08	 0.73	25	 1.02	 1.11	 0.84	30	 1.10	 1.13	 0.94	45	 1.18	 1.21	 1.12	60	 1.33	 1.34	 1.31	90	 1.95	 1.46	 1.65	120	 2.64	 1.61	 1.20	
Synperonic	60%	 Cremophor	30%	 Cremophor	60%	 Pure	Metformin	0.61	 0.62	 1.07	 0.31	0.68	 0.71	 0.90	 0.30	0.96	 0.74	 0.75	 0.32	0.99	 0.78	 0.77	 0.35	1.01	 0.77	 0.95	 0.36	1.08	 0.80	 1.43	 0.48	1.15	 0.86	 1.52	 0.57	1.46	 0.97	 1.72	 0.67	1.71	 1.16	 1.79	 0.85	2.03	 1.41	 2.21	 0.93	
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Table 4-5: Percentage of metformin-HCl penetrated from liquisolid formulations using 
Franz diffusion cell for permeability study. 
0.2M	HCL	 Percentage	of	the	drug	permeated	(%)	
Time	(min)	 PEG	30%	 PEG	60%	 Synperonic	30%	5	 0.61	 0.87	 0.35	10	 0.68	 0.78	 0.36	15	 0.70	 0.77	 0.43	20	 0.71	 0.75	 0.51	25	 0.72	 0.78	 0.59	30	 0.77	 0.79	 0.66	45	 0.82	 0.85	 0.78	60	 0.93	 0.94	 0.91	90	 1.37	 1.02	 1.15	120	 1.85	 1.13	 0.84	
Synperonic	60%	 Cremophor	30%	 Cremophor	60%	 Pure	Metformin	0.42	 0.44	 0.75	 0.25	0.47	 0.50	 0.63	 0.21	0.65	 0.52	 0.52	 0.23	0.69	 0.54	 0.54	 0.25	0.70	 0.54	 0.67	 0.25	0.76	 0.56	 1.00	 0.34	0.80	 0.60	 1.06	 0.40	1.02	 0.68	 1.21	 0.47	1.20	 0.81	 1.25	 0.59	1.42	 0.99	 1.55	 0.65	
 
Table 4.4 shows the permeability results efflux (µg/ml/cm2) and Table 4.5 reveals the data 
as percentage. It can be seen that all liquid vehicles used (PEG®400, Synperonic®PE/L44 
and Cremophor®ELP) significantly enhanced the metformin-HCl permeability (P < 0.05) 
(refer to Appendix for Chapter 4), compared to the pure drug, hence they are good 
penetration enhancers. PEG®400 increased the drug permeability by 3-fold, whilst 
Synperonic®PE/L44 and Cremophor®ELP increased it by about 2-3 folds (Table 4.5). 
Those liquisolid preparations are expected to enhance bioavailability if they have been 
tried in-vivo. A study by (El-Houssieny, et al., 2010) reported the improvement of 
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bioavailability of liquisolid Repaglinide upon oral administration of the drug which showed 
significant decrease in blood glucose levels and more control of blood sugar than from 
commercial tablets by stimulating the insulin release from the β-cell of the pancreas. 
Additionally, the permeability of hydrophobic drug via the lipid bilayer of the cell 
membrane could be increased in the presence of surfactants as they can disrupt the lipid 
bilayer arrangement on the cell membrane causing increased drug permeability; they can 
enhance the absorption via the passive transcellular route (Swenson & Curatolo, 1992) 
they (for example Cremophor RH40) can inhibit P-glycoprotein that reduces intestinal 
absorption of hydrophobic drugs by efflux transportation (Elkordy, et al., 2012), Moreover, 
some non-ionic surfactants such as Synperonic®PE/L44 and Cremophor®ELP can be 
considered as effective pharmaceutical excipients for inhibiting p-glycoprotein function 
and hence promoting the intestinal absorption of different drugs (Shono, et al., 2004). In 
addition to the role of surfactants in dissolution rate improvements (Kim, et al., 2000). 
Therefore, the liquid vehicles (PEG®400, Synperonic®PE/L44 and Cremophor®ELP) are 
a good choice of surfactants to be used in this study to improve metformin-HCl 
permeability.  
4.15. Conclusion 
Metformin-HCl is a water soluble drug that gives about 100% drug release for pure and 
conventional formulation after 10 minutes. By using liquisolid technique with different 
liquid vehicles used to enhance dissolution, the drug release has not reached 100% after 
10 minutes (Figure 4.4) due to: the effect of processing technique; the effect of surfactants 
(liquid vehicles) and the interaction of the vehicles with the drug. Accordingly, metformin-
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HCl was chosen as a water soluble model drug to emphasis on the various impact of 
liquisolid technique on hydrophobic and hydrophilic drugs using same liquid vehicles.  At 
present, metformin-HCl is commercially available in high dose tablets, 500 mg; the 
granulated liquisolid formulations may assist in the reduction of this dose. The stability 
studies showed that the dissolution of liquisolid tablets was not affected by ageing 
significantly. Franz diffusion cell has been used to test the permeability of metformin 
liquisolid using Wistar rat stomach tissue. The results have shown promising results in 
using granulated liquisolid metformin-HCl tablets to enhance the bioavailability of 
metformin-HCl. Consequently, liquisolid tablets can be further used in alternative animal 
tests in order to confirm the beneficial use of liquisolid technology on permeability of drugs 
with poor bioavailability. Figure 5-1 summarises the sustained release liquisolid 
metformin-HCl preparation. 
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Chapter 5 - Preparation and characterisation of sustained 
release liquisolid metformin-HCl formulations using 
Hydroxypropyl Cellulose (HPC-H) 
	
Results and Discussion 
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5.1. Introduction  
 
The main goal in diabetic patients is to achieve controlled blood glucose levels with the 
aid of insulin or antidiabetic drugs such as metformin-HCl; however, successful use of 
metformin-HCl therapy is challenged due to the high incidence of associated 
gastrointestinal symptoms such as diarrhoea and abdominal discomfort (BNF 73, 2017). 
Metformin-HCl has a multiple dosage regimen of 500mg two to three times daily or 850 
mg once or twice per day. Therefore, such complications are not desirable and should be 
avoided to maintain patient compliance. Metformin-HCl presents other formulation 
challenges such as poor compressibility and poor permeability (Nanjwade, et al., 2011). 
According to the biopharmaceutical classification system (BCS), metformin-HCl belongs 
to class III with high water solubility and low permeability properties and due to metformin-
HCl’s poor compressibility properties. Direct compression is not desirable on the 
commercial scale as it can lead to poor content uniformity as well as poor weight content 
uniformity, hardness and friability (Nanjwade, et al., 2011). Consequently, there is a need 
to provide once daily dosing formulations that would deliver modified release metformin-
HCl, which would maintain drug plasma levels for 10 to 12 hours when consumed orally. 
By applying sustained release on such drugs, minimised systemic adverse effects and 
greater patient compliance as well as other advantages can be achieved. Thus, 
researchers have used numerous approaches to modify drug release in the form of 
tablets and one of the successful methods from the prospect of this research is the use 
of liquisolid technique. Liquisolid formulations not only have the potential to be optimised 
for the reduction of drug dissolution rate and thereby production of sustained release 
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systems for highly water soluble drugs, but also have the potential to enhance flowability, 
compressibility and permeability of metformin-HCl (Pavani, et al., 2013) (Chandrasekar, 
et al., 2011). The sustaining agent that has been used in this chapter is HPC –high grade. 
HPC is a hydrophilic polymer which is solubilised by hydroxypropyl groups. It swells by 
producing a state of hydrogel in water which then releases the drug slowly over period of 
time with diffusion. 
The aim of the presented work chapter 5, is to utilise liquisolid-based formulations of 
metformin-HCl as sustained release preparations. By the aid of liquisolid technique, 
reduction of dose was successfully achieved, meaning less cost for pharmaceutical 
industry and fewer side effects for patients. For both metformin-HCl liquisolid immediate 
and sustained release formulations, PEG®400, Synperonic®PE/L44 and Cremophor®ELP 
were used as non-volatile liquid vehicles. Additionally, wet granulation using PVP was 
applied to both systems in order to achieve acceptable flowability and compressibility.  
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Figure 5.1: Flowchart summary of metformin-HCl sustained release liquisolid 
preparation using HPC-H 
  
Liquisolid compact preparation
Metformin-HCl sustained release
Model drug for sustained drug release
Lf value  predetermined from literature 
Drug powder admixture with liquid vehicle (PEG®400,Synperonic®PE/L44, Cremophor®ELP)
Q,q (carrier to coating) amount R=20 Carrier: HPC-H Coating:Cab-O-Sil®M-5
Mixing of drug, liquid vehicle, carrier, coating, disintegrant and lubricant in adjustable amount                            
based on mathematical calculation
Powder admixture ==>wet granulation using 10% PVP
Automatic compaction
 
161 
 
5.2 In-vitro dissolution study of sustained release liquisolid metformin-HCl using 
HPC-H 
Several techniques have been defined to produce sustained release formulations. Among 
these techniques, a new and promising method, that is the liquisolid formulation, is 
currently being used in achieving modified release dosage forms. Liquisolid formulations 
may not only help in reduction in the drug dose but also may help in production of 
sustained release metformin-HCl formulations. This part of the project explored the role 
of hydroxypropyl cellulose (HPC-H) as a carrier in liquisolid preparation as well as a 
sustaining agent in preparation of the modified release metformin-HCl. This work is novel 
in the field of liquisolid sustaining systems. Other studies tried to introduce new non-
volatile liquid vehicle (Kollicoat®SR30D) that comprise of sustaining the drug release 
while using hydrophilic carrier (Elkordy, et al., 2012). Nevertheless, in this present work, 
the used non-volatile liquid vehicles are PEG®400, Synperonic®PE/L44 and 
Cremophor®ELP. The carrier (HPC) will be the main focus of this section. The R-value 
was also kept constant (20) as an immediate release, meaning the amount of Cab-o-sil® 
M-5 was kept at 1:20 ratio with the carrier. The dissolution release of metformin-HCl was 
performed in distilled water to comply with the immediate release conditions. Moreover, 
in designing the metformin-HCl sustained release formulation, six liquisolid compacts, 
namely HPC1-HPC6 at 30% and 60% drug concentrations were prepared (Table 5.1). 
Together with conventional metformin-HCl, HPC1-HPC6 dissolution profiles are shown in 
(Figure 5.2) 
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Table 5-1: Liquisolid formulations of sustained release metformin-HCl using HPC-H 
Liquisolid	
system	
Non-volatile	
liquid	vehicle	
Drug	
Concetration	
in	liquid	
medication		
(%w/w)	
Carrier:	
Coating	
(R)	
Liquid	
load	
factor	
(Lf)	
Liquid	
vehicle	
(mg)	
Active		
ingredient	
(mg)	
Carrier	
(Q)	(mg)	
HPC-H	
Coating	
(q)	(mg)	
Disintegrant	
(maize	
starch)	(mg)	
Lubricant	
(mg)	
Unit	
dose	
(mg)	
HPC1	 PEG®	400	 30	 20	 0.17	 93.30	 40.00	 794	 40.00	 51.00	 8.00	 1026.30	
HPC2	 PEG®	400	 60	 20	 0.17	 26.70	 40.00	 397	 20.00	 26.00	 4.00	 513.70	
HPC3	 Synperonic®	PE/L44	 30	 20	 0.27	 93.30	 40.00	 501	 25.00	 35.00	 5.20	 699.50	
HPC4	 Synperonic®	PE/L44	 60	 20	 0.27	 26.70	 40.00	 251	 13.00	 18.00	 2.60	 351.30	
HPC5	 Cremophor®	ELP	 30	 20	 0.52	 93.30	 40.00	 256	 12.80	 21.00	 3.20	 426.30	
HPC6	 Cremophor®	ELP	 60	 20	 0.52	 26.70	 40.00	 128	 6.40	 11.00	 1.60	 213.70	
Conventional	 _	 _	 _	 _	 _	 40.00	 397	 20.00	 24.20	 3.60	 485.00	
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Figure 5.2: The dissolution study of sustained release liquisolid metformin-HCl formulations using HPC-H (refer to Table 5.1 for 
formulations’ composition). Note: Standard deviation is presented but values are very small. 
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The results of dissolution indicated that HPC1, HPC2, HPC3, HPC4, HPC5, HPC6 (Table 
5.1) released 55, 55, 60, 66, 80, and 72%, respectively after 4 hours and released 86, 84, 
75, 88, 85 and 85% respectively after 12 hours (Figure 5.2) which showed good release 
profiles to sustain drug release. In comparison to the immediate release (see Figure 4.4), 
Cremophor®ELP was the best choice of liquid vehicles to produce immediate release 
tablets; meaning that this liquid vehicle reduces the effect of HPC as a sustaining release 
agent. Based on the mathematical calculations the HPC amount (in HPC5, 30% w/w drug 
concentration in Cremophor®ELP) was less compared to that in HPC1, HPC2 and HPC3 
(Table 5.1). On the other hand, PEG®400 (HPC1, HPC2) and Synperonic®PE/L44 (HPC3) 
enhanced the action of HPC to sustain release of metformin-HCl compared to 
conventional tablets which contain no liquid vehicle (Figure 5.2); confirming the interaction 
of the liquid vehicles with the HPC to enhance the drug release sustaining effect of the 
HPC (i.e. conventional tablets contain 397mg HPC similar to drug with PEG®400 
(60%w/w) formula tablets that contains 397mg HPC, hence the liquid vehicle enhanced 
the effect of the HPC). Also, the enhanced sustaining drug release effect of PEG®400 (in 
HPC1, HPC2) and Synperonic®PE/L44 (in HPC3) can be explained by that those liquid 
vehicles equipped the formed HPC pores and hence the dissolution medium can 
penetrate slowly through the pores and accordingly the release of metformin-HCl was 
retarded. 
     
Comparing all independent dissolution parameters for liquisolid tablets showed that there 
were no significant differences between the liquisolid sustained release tablets and 
conventional metformin-HCl (p>0.05) (refer to Appendix for Chapter 5). According to 
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(Diwedi, et al., 2012), a polymer’s ability to retard the drug release rate is related to its 
viscosity. They used HPMC K4M and K15M and K100M which exhibited viscosity values 
of 4000, 15000, 100000 mPa respectively. And therefore, HPMC K4M and K15M released 
the drug faster than HPMC 100M. This theory can be implemented on this study where 
HPC-H has viscosity of 3040mPa.s (Nisso HPC 2012) which showed a retardation effect 
on metformin-HCl liquisolid tablets. The high drug release observed with HPC5 (drug in 
Cremophor®ELP, 30%w/w) could be due to the possible interaction between the liquid 
vehicle and HPC which retarded the drug release over 12 hours and at the same time 
maintained a high release of drug without trapping it in the matrix (the drug could not 
diffuse out of the matrix in a short time). Moreover, the prolonged action of metformin-HCl 
from the sustained liquisolid compacts was due to the concentration and swellable nature 
of HPC-H polymer. HPC-H is responsible for the retardation of drug release and the use 
of HPMC was responsible for the retardation of trandolapril release from liquisolid 
compacts (Butreddy & Dudhipala , 2015). The study showed significant sustained 
dissolution profiles of all liquisolid compacts using HPMC K15 M, where the percentage 
drug release of one of the formulations (containing PEG®400 as a liquid vehicle) was 
97.3% after 14 hours. This is in agreement with this study by using Cremophor®ELP with 
HPC-H 
 
Hydroxypropyl Cellulose (HPC-H) is solubilised by the hydroxypropyl groups that impede 
the hydroxyl group hydrogen bonding of the cellulose. Since HPC is a hydrophilic polymer, 
it can be an effective controlled release agent by swelling and becoming a hydro-gel in 
water, through which the dosage composition is released in dissolution medium (Nisso 
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HPC 2012). The incorporation of HPC in liquisolid formulations demonstrates synergistic 
effect on liquisolid metformin-HCl release retardation as shown in Figure 5.2. The 
presence of HPC in liquisolid formulations decreased the percentage of drug release from 
almost 98% in immediate metformin-HCl release (F5) (see Figure 4.4) to 36% drug 
release (HPC5) within the first hour. However, the amount of HPC being added to the 
liquisolid formulations (Table 5.1) affects the retardation of the drug (as the amount of the 
HPC was different in HPC1 - HPC6, Table 5.1). The amount of HPC added corresponds 
to the amount of carrier being loaded in the liquisolid formulas. This means that the carrier, 
Avicel®PH102, for immediate release preparations (Figure 4.4) was replaced by HPC 
polymer to make this novel discovery of joint use of HPC as a sustaining agent as well as 
a carrier to be used in the liquisolid systems. (Nokhodchi, et al., 2010) showed agreement 
with the present outcome where their results demonstrated the direct effect of HPMC 
concentration on the drug release retardation. As more HPMC was integrated in the 
formulation of liquisolid, a further reduction in drug release rate was seen where the 
HPMC concentration of 10%w/w and 15%w/w gave drug percentage release of 31.3% 
and 26.9% respectively (Nokhodchi, et al., 2010). (Wadher, et al., 2011) displayed the 
relationship between the concentration of HPMC and the rate of drug release to be 
inversely proportional. It is documented that some factors can affect the performance of 
tablets when used with HPC-H. The degree of water solubility and molecular weight of 
the drug as well as the particle size of the used HPC are considering crucial factors in 
drug release performances, where some polymers can work beneficially for certain drugs 
and not for others. 
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Researchers have tested the effect of the concentrations of the hydrophilic sustaining 
agent polymer (HPC) on the percentage drug release e.g. (Nanjwade, et al., 2011). Their 
results suggested that as the increase in concentration of the polyethylene oxide is 
inversely proportional to the release rate of the drug. It is further explained that the highly 
water-soluble drug found in polyethylene oxide matrix leads to faster polymer swelling 
and thus increase in gel thickness which prevents the instant disintegration of the tablet 
(as seen also in the current research with HPC-H), thus sustaining the rate of drug 
release. The current project study focusses on the use of liquisolid technique along with 
wet granulation to possibly reduce the amount of the active ingredient and sustain its 
release while maintaining the therapeutic efficacy level in order to reduce possible side 
effects and promote patient compliance. The results promise regarding sustaining the 
drug release. 
In this study, the effect of liquid vehicle on drug release was not significantly different 
compared to the conventional metformin-HCl (Figure 5.2). A study by Nokhodchi et al 
(2010) showed that liquisolid compacts containing polysorbate 80 revealed slower drug 
release compared to conventional tablets without polysorbate 80. Additionally, they 
examined the effect of coating (silica) to Eudragit ratio and have observed slowest drug 
release when ratio of silica:Eudragit was 1:2 (Nokhodchi, et al., 2010). Hydroxyethyl 
cellulose (HEC) matrices drug release unlike HPC can be a combination of erosion, 
polymer swelling as well as drug diffusion (Sinha & Rohera, 2002). Moreover, HPC 
demonstrates a low drug release rate with effect of lower penetration rate resulting in 
moderate swelling. Javadzadeh et al (2007) also showed that formulation containing 
polysorbate 80 (50%) with Eudragit ®RS as the carrier and HPMC as additive had a low 
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dissolution rate. The possible explanation can be due to the formation of gel around the 
disintegrated particles by HPMC, a barrier is built against diffusion of the dissolved drug 
into the dissolution medium.  
In more details, the process of drug release from hydrogel matrix tablet is divided into four 
stages: water penetration into the hydrogel matrix tablet upon insertion into the dissolution 
medium, diffusion of the drug through the sustained release matrix and its dissolution, as 
well as polymeric excipient erosion (Tack-Oon, et al., 2013). Also, diffusion of water into 
the polymer matrix occurs as soon as the polymer matrices come in contact with water. 
Due to this, an increase in the mobility of the polymer chains is caused by water 
penetration, allowing entangled chains to embrace new configuration, causing the outer 
surface of the polymer to dissolve and erode when becomes in contact with water. High 
molecular weight polymers, such as HPC-H, form a more viscous layer causing a 
decrease in the polymer matrix erosion due to the ability of these polymers to seal pores 
before allowing more liquid to penetrate, resulting in the polymer to swell faster. (Tack-
Oon, et al., 2013) and (Wan, et al., 1991). Moreover, the presence of HPC as a drug 
carrier retards the release of metformin-HCl to a great extent. Since HPC-H swells in 
water forming stiff matrix retarding metformin-HCl release. The metformin-HCl release 
mechanism from the HPC matrix. And this can be compared to the immediate release 
liquisolid metformin-HCl did not show delayed release when Avicel®PH102 was used as 
a carrier instead of HPC. 
 
Additionally, the release of drug from matrix is highly dependent on the amount of polymer 
used as seen in Figure 5.2. This is in agreement with (Tack-Oon, et al., 2013) who 
investigated drug release from hydrophilic polymer matrices such as HPMC with different 
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drug to polymer ratios. It was found that as the concentration of the polymer increased, 
the viscosity of the gel also increased and diffusional path being formed and thus drug 
release rate was reduced by diffusion.  
 
In vitro drug testing is crucial process to study the quality assurance as well as 
determination of stability release properties of drugs over a certain period of time. Thus, 
basket and paddle methods resemble the most popular approaches which operate under 
closed sink condition, yet cannot mimic the GI system. In this study, the dissolution test 
of the liquisolid sustained release metformin-HCl was performed using USP 4 operating 
in open-loop manner. The flow through cell (open-loop) system is greatly beneficial for 
low-solubility drugs as it can easily provide sink conditions by maintaining the continuous 
flow of fresh medium throughout the dissolution period. However, in this project, open 
loop configuration was used for high water soluble metformin-HCl to study its sustained 
effect using this system, where results obtained are expressed as the drug instantaneous 
concentration. Additionally, the open loop configuration (USP4) is strongly proficient in 
simulating the digestive system environment and has the potential to provide in-vitro and 
in-vivo relationship that can be easily applied by laboratories (Gao Z., 2009). 
 
5.3 Drug release mechanism and kinetics for metformin-HCl sustained release 
formulations 
 
To interpret the kinetic release mechanisms of the metformin-HCl from matrix systems 
(sustained release HPC), different Kinetic equations such as zero-order, first-order and 
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Higuchi’s equations were applied. The best plot with higher squared coefficient of 
determination (R2) was found to represent the best kinetic release model formulation 
(Wadher, et al., 2011).Table 5.2 represents the values of the squared coefficient of 
determination for metformin-HCl liquisolid sustained release (HPC1-HPC6, refer to Table 
5.1 for details), using zero order, first order and Higuchi kinetic release models. Different 
kinetic equations were implied on release data in order to describe the kinetics of drug 
release from matrix tablets (Figures are included in the appendix for chapter 5). Kinetics 
analysis of in-vitro release data could be best expressed for all formulations containing 
hydroxypropyl cellulose (HPC1-HPC6) by Higuchi’s equation, as the plot showed highest 
linearity coefficient of determination (R2) of more than 0.97 (Table 5.2). The drug release 
kinetic using Higuchi model describes the release from an insoluble matrix as a square 
root of a time-dependent process based on Fickian diffusion (Pavani, et al., 2013). 
 
Constant drug release, from the beginning to the end, in a zero order kinetic model is an 
ideal matrix system (Pather, et al., 1998). With time, drug release from matrix tablets 
becomes progressively slower. The zero-order kinetics is when the drug release rate is 
independent of its concentration. On the other hand, the first order kinetic model 
describes the release rate is concentration dependent (Wadher, et al., 2011). 
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Table 5-2: Release kinetics of metformin-HCl liquisolid sustained release formulations 
(for composition details, refer to Table 5.1) 
Metformin Liquisolid sustained (HPC) 
formulations 
Zero Order 
(R² ) 
First Order 
(R²) 
Higuchi 
(R² ) 
PEG®400 30% (HPC1) 0.959 0.686 0.999 
PEG® 400 60% (HPC2) 0.965 0.699 0.999 
Synperonic®PE/L44 30% (HPC3) 0.954 0.699 0.998 
Synperonic® PE/L44 60% (HPC4) 0.941 0.656 0.977 
Cremophor® ELP 30% (HPC5) 0.974 0.678 0.998 
Cremophor® ELP 60%(HPC6) 0.944 0.661 0.994 
	
Kinetic models which are more suitable for controlled release formulations are zero order 
and Higuchi kinetic models. (Higuchi, 1963) declared that the drug release from non-
swellable matrices is governed primarily by diffusion. Systems that follow Higuchi kinetic 
model show a decrease as a function of time in the rate of drug release from matrixes 
containing water-soluble drug and a water insoluble carrier. This is due to the increase in 
the drug release diffusional path length with time as the solvent moves towards the center 
of the matrix (Higuchi 1963). Furthermore, drug release from the tablets was primarily 
controlled by polymer swelling followed by drug diffusion through the swollen polymer and 
then slow erosion of the tablet matrix (Nanjwade, et al., 2011). 
	
	
5.4. Tablet hardness, friability and uniformity of weight of sustained release 
metformin-HCl using HPC 
Table 5.3 presents physical information about several quality control tests which include: 
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tablet thickness, hardness, friability test, and drug weight uniformity test for the liquisolid 
tablet formulations of metformin-HCl sustained release including conventional tablets 
using HPC (HPC1-HPC6). The aim of making those tests is to investigate the effect of 
wet granulation using PVP and the use of HPC on the physicochemical characteristics of 
the prepared liquisolid tablets.  All liquisolid tablets except HPC 4 (2.94%) and 
conventional tablets (1.54%) passed and complied with pharmacopeia BP required 
specifications for friability test where the loss of the powder was less than 1%. This 
indicates that the prepared liquisolid tablets were of sufficient strength to endure the 
handling and packing process. The wet granulated liquisolid formulations using PVP as 
liquid binder have a tremendous resistance to any adhesive forces with the wall of the 
friability tester or cohesive forces among the tablets. Furthermore, using compression 
force to produce hardness of 30-45N, liquisolid tablets with the hierarchical thickness of 
3.35 to 4.47 mm were prepared. The thickness uniformity could be considered as a further 
control to the increased reproducibility of liquisolid tablets (El-Say, et al., 2010). Also, the 
acquired results in Table 5.3 show acceptable thickness uniformity for all metformin-HCl 
liquidsolid tablets (HPC1-HPC6). 
Considering the integration of liquid vehicle in the formation of liquisolid metformin-HCl 
sustained release formulation, wet granulation was applied on formulations (HPC1-
HPC6) (Table 5.1) using PVP in order to enhance the flowability and compressibility of 
the liquisolid powder. HPC is freely flowable and therefore due to the absence of non-
volatile liquid in the conventional metformin-HCl no granulation step was performed; 
however, the friability result was >1%. 
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Table 5-3: Thickness, crushing load, hardness, friability and uniformity of weight for 
sustained release metformin-HCl liquisolid tablets using HPC (for formulations' 
composition, refer to Table 5.1.) 
FORMULATION	 THICKNESS	(MM)	
HARDNESS																												
(KG/F)	
HARDNESS	
(N)	
FRIABILITY	
WEIGHT	(%)	
UNIFORMITY	
OF	WEIGHT	
(MG)	
HPC1	 4.06	±	0.06	 4.67	±	0.69	 45.78±6.76	 0.38	 288	±	3.00	
HPC2	 4.47	±	0.01	 5.93	±	0.81	 58.21±7.99	 0.75	 293	±	4.40	
HPC3	 3.56	±	0.28	 1	±	0.00	 9.81	 0.97	 279	±	3.70	
HPC4	 3.34	±	0.01	 1.80	±	0.85	 12.43±5.50	 2.90	 246	±	4.40	
HPC5	 3.55	±	0.17	 <1	±	0.00	 9.81	 0.05	 247	±	4.40	
HPC6	 3.64	±	0.09	 1.12	±	0.12	 10.95±1.15	 0.26	 276	±	2.80	
CONVENTIONAL	 3.35	±	0.02	 4.52	±	0.78	 44.31±7.68	 1.54	 283	±	1.50	
 
 
As the diameters for all tablets have approximately similar values (using same tablet 
press), the cause for variations in the tablet thickness can be explained in terms of the 
dissimilarity in the weights of the tablets which also complied with BP limit specifications. 
Tablet hardness were shown to be good for HPC1, HPC2 and conventional (4.67, 5.93 
and 4.52 kg/F = (45.78N, 58.21 N, 44.31 N) respectively where HPC3 - HPC6 showed 
poor crushing load profile (1kg/f) even though granulation process was applied.  A 
correlation between tablet hardness and its porosity was observed: increasing the 
compression force and hardness of tablets leads to the reduction of porosity among the 
particles in the dosage and reduction in drug release (Figure 5.2 for HPC1 - HPC2). 
Formation of solid bridges among the particles of the tablets can result, leading to a 
decrease in the intermolecular distance (Pavani, et al., 2013). Moreover, a relationship 
exists between tablet hardness and the quantity and type of the non-volatile liquid vehicle 
as well as the amount and type of the carrier and coating that are being used in the 
formulation of liquisolid tablets (Spireas & Bolton, 1999). It was found that a relation can 
be found between tablet hardness and the liquid load factor (Lf), where the relationship 
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is inversely proportional. That is, when Lf increased, tablet hardness decreased and this 
finding is illustrated in Table 5.3. This finding is confirmed by the following data where the 
tablet hardness of HPC1-HPC6 is 4.67, 5.93, 1, 1.80, 1 and 1.12 kg/F respectively with a 
corresponding Lf values of 0.168 (HPC1 and HPC2), 0.266 (HPC3 and HPC4) and 0.52 
(HPC5 and HPC6). The proposed explanation to this inverse relationship is that as the Lf 
value increases, the amount of liquid used also increases causing a reduction in the 
quantity of powder excipients used, causing a drop in the tablet hardness. In a previous 
study by Javaheri et al, 2014, it was found that wet granulation in combination with 
liquisolid system can show positive impact on the hardness of the tablets. However, this 
scientific fact was not seen in the liquisolid formulation of sustained release metformin-
HCl using HPC as carrier and as sustaining agent. The possible explanation could be due 
to the high viscosity property of Cremophor®ELP creating an unfeasible environment in 
having freely flowable powders. Nevertheless, the application of wet granulation has 
shown promising results with such highly viscous non-volatile liquids (Javaheri, et al., 
2014) however, HPC in high grade has a gel type characteristic that makes it unpractical 
to granulate easily using any applicable liquid binders. Therefore, it can be suggested that 
for future, encapsulation of HPC 5 and HPC6 into size zero capsules would be strongly 
recommended. Additionally, in regards to uniformity of weight, all liquisolid metformin-HCl 
tablets were found to be practically within BP limits. Overall, granulated liquisolid 
formulations of sustained metformin-HCl using HPC showed acceptable good tablets 
within limits uniformity of weight, low friability with acceptable thickness and hardness. 
Different liquid binders were tested in this research, and amongst them, only PVP worked 
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appropriately with HPC and was a suitable liquid binder that was used to granulate HPC, 
however, poor friability tablets were obtained. 
5.5. Scanning electron microscopy of sustained release metformin-HCl using HPC 
 
The scanning electron microscope microstructure of liquisolid formulation using HPC 
(HPC1-HPC6) including pure metformin-HCl and pure HPC are shown in Figure 5.3. It 
can be seen from the images that pure drug is different in shape from the liquisolid 
formulations indicating its crystalline nature of metformin-HCl. Generally, the SEM 
photomicrographs of liquisolid powders (HPC1-HPC6) demonstrate the drug particles are 
entrapped onto the surface of the carrier material (HPC) or within them and causes 
surface modification of the drug particle  (Nnamani, et al., 2016); ( (Butreddy & Dudhipala 
, 2015). 
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Pure HPC  
 
Pure metformin (x1000) 
 
HPC1 
 
HPC2 
 
HPC3 
 
HPC4 
 
HPC5 
 
HPC6 
Figure 5.3: SEM microphotographs of pure metformin-HCl and sustained release 
metformin-HCl liquisolid powders using HPC. Refer to Table 5.1 for formulations' 
composition 
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5.6. Fourier transform infrared spectroscopy (FTIR) of HPC formulations 
According to (Silverstein, et al., 1991), the interaction between drug and excipients or 
liquid vehicles cause a shift in the peaks corresponding to the functional groups of the 
drug to different wavenumbers. Additionally, the absorption bands of the functional groups 
arise from stretching and deformation vibrations. 
Figure 5.4. metformin-HCl IR studies, revealed two typical bands at 3367 and 3292 cm -1 
due to N-H primary stretching and a band at 3156 cm -1 due to N-H secondary stretching. 
Additionally, characteristics bands at 1623 and 1561 were observed to be denoted   for 
N-H asymmetric deformation. Furthermore, shifts or reduction in intensity for the FTIR 
bands of pure metformin-HCl and disappearance of the sharp peak of metformin-HCl was 
observed in liquisolid formulations (Figure 5.4) which depict clear change in the structure 
of the drug after the interaction between the liquid vehicle, excipients and metformin-HCl.  
HPC forms a peak at 1046 cm -1 and is clearly seen in all liquisolid formulations including 
conventional powder and the fingerprint regions of liquisolid metformin-HCl and HPC are 
superimposed. The study shows drug concentration has no impact on the FTIR spectra 
and thus no difference appears between 30% and 60% drug concentrations in liquisolid 
properties. 
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Pure metformin 
 
Conventional powder and pure HPC 
 
HPC1 and  HPC2 
 
HPC3 and HPC4 
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Figure 5.4: FT-IR spectra of sustained release metformin-HCl liquisolid using HPC. 
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5.7. Differential scanning calorimetry (DSC) of sustained release liquisolid 
metformin-HCl 
DSC thermograms of metformin-HCl HPC1-HPC6 are shown in Table 5.4. The analyses 
were used in order to investigate the possible solid-state interactions between the 
components (drug and excipients) and compatibility in all the examined liquisolid 
formulations. DSC thermogram of pure metformin-HCl in table 5.4 exhibited a sharp 
endothermic peak at Tm of 232.99 0C (melting point) and enthalpy of 215.8J/g indicating 
fusion and crystallinity of metformin-HCl. The thermograms of all liquisolid metformin-HCl 
(HPC1-HPC6) showed broad endothermic peaks and reduction in melting point (~1-3°C, 
Table 5.4). In comparison with the pure metformin-HCl thermogram, the results of the 
liquisolid formulations displayed shifted endothermic peaks towards the lower 
temperature and greatly reduced the enthalpy, indicative of reduced drug crystallinity in 
HPC and non-volatile liquid vehicles and solid-solid interaction (Nafady, et al., 2014). This 
can also be explained on the bases of diluting effects or that most of metformin-HCl was 
dissolved in the liquid vehicle, thus reducing the number of drug crystals particles in the 
liquisolid formulations, this is in agreement with (Nokhodchi, et al., 2010). Moreover, the 
thermogram of conventional metformin-HCl HPC shows peaks of drug melting point 233 
0C, meaning crystallinity of the drug. For HPC1 to HPC6 (refer to Table 5.1) the drug 
endothermic peak became broader and lost its sharpness, indicating the drug dispersion 
and solubilisation in the liquid vehicle and the rest of the excipients including HPC within 
the liquisolid system. However, the DSC thermograms of HPC1-HPC6 including 
conventional show a second peak with melting point ranging between 99 0C - 117 0C that 
is not seen in pure metformin-HCl thermogram. Thermograms of HPC1-HPC6 have 
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endothermic peaks of 116.7 0C, 115.410C, 110.770C, 112.50C, 98.440C and 99.05 0C, 
respectively with enthalpy of 40.38J/g, 46.30J/g, 45.22J/g, 44.13J/g, 43.7J/g and 
43.74J/g, respectively. Those peaks are due to water evaporation or the presence of 
excipients. In conclusion, the delayed dissolution rate of metformin-HCl liquisolid 
compacts can be linked to the changes in crystallinity of the drug and formation of 
complex between the drug and the excipients. 
 
Table 5-4: DSC thermograms results of pure metformin-HCl and sustained release 
metformin-HCl liquisolid formulations using HPC, for formulations' composition refer to 
Table 5.1. 
Formulation	 Temperature	(0C)	 Enthalpy	(J/g)	Pure	metformin	 232.99	 215.80	HPC1	 116.74,	230.73	 40.38,	09.93	HPC2	 115.41,	231.92	 46.30,	20.24	HPC3	 110.77,	230.66	 45.22,	08.08	HPC4	 112.51,	232.32	 44.13,	22.16	HPC5	 98.44,	229.60	 43.71,	14.78	HPC6	 99.05,	229.69	 43.74,	36.28	Conventional		 98.02,	233.12	 51.20,	23.21	
 
5.8. Conclusion 
Sustained release metformin-HCl was prepared using HPC by the application of liquisolid 
technique. Three different liquid vehicles (PEG®400, Synperonic®PE/L44 and 
Cremophor®ELP) were used with 30% and 60% drug concentrations. Among the above 
mentioned liquid vehicles, Cremophor®ELP using 30% drug concentration showed the 
highest (92%) and the most sustained drug release over 12 hours. HPC shows moderate 
swelling coupled with slower rate of erosion.  Drug release profiles on model fitting 
followed zero order and Higuchi models. Additionally, in this research chapter, the flow-
through method with open loop configuration has been used to perform the dissolution 
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study of the sustained release metformin-HCl. Therefore, USP flow-through cell with open 
loop configuration was a successful dissolution apparatus to study the release of 
metformin-HCl over 12 hours. 
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Chapter 6 – Orodispersible liquisolid preparation of 
metformin-HCl immediate release using Eudragit®RL-30D as 
a non-volatile liquid vehicle: A Novel discovery 
 
 
 
 
Results and Discussion
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Figure 6.1: Flowchart metformin-HCl liquisolid formulation using Eudragit®L30D as non-volatile liquid vehicle summary work. 
Liquisolid compact preparation
Model drugs for immediate drug release
Metformin-HCl
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6.1. Introduction: 
Eudragit®RL30D and Eudragit®RLPO are biocompatible copolymers synthesized from 
acrylic and methacrylic acid esters. The structures of Eudragit®RL differ from the rest of 
the Eudragit polymers only in the extent of the quaternary ammonium substitutions, more 
substitution is seen with Eudragit®RL. Additionally, their water permeability is unaffected 
by pH and water can also permeate more freely into Eudragit®RL due to the relative 
hydrophilicity of the RL polymer (Patra , et al., 2017). This can be linked to the availability 
of ammonium groups as salt, which makes Eudragit®RL more permeable. Eudragit® RL 
has an improved protective and sustained-release performance along with an outstanding 
gastrointestinal tract targeting (Evonik 2015), (Singh & Rana, 2013). 
Liquisolid technique is initially designed to enhance the dissolution rate of poorly water-
soluble drugs and in recent studies has been used to sustain the release of water soluble 
drugs such as metformin-HCl (as shown in chapter 5). However, in this section, liquisolid 
is applied on metformin-HCl, a water soluble drug, using a novel non-volatile liquid vehicle 
(Eudragit®RL30D), to produce tablets with enhanced properties. Eudragit®RL is a 
polymer which is widely used in pharmaceutical industry to sustain drug release instead 
of hydrophilic carrier or retarding agents (such as HPMC) (Azarmi, et al., 2002) in the 
liquisolid formulations. In this current study, it did not have the potential to sustain the 
release of metformin-HCl. Instead, it was capable of producing high yet steady release of 
the drug with high standard quality control properties for the prepared tablets, and an 
excellent fast disintegrating profile that makes them a successful discovery and addition 
to the liquisolid system scheme as an orodispersible liquisolid tablets. This may be due 
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to the interaction between the drug and Eudragit®RL. 
Inability to tablet taking is a common difficulty in most patient groups and predominantly 
for geriatric, pediatric and psychiatric patients that fail in compliance with taking tablets 
due to complications such as hand tremors, dysphasia and immature nervous and 
muscular systems. The physical difficulty of swallowing is a common occurrence which 
leads to poor efficiency of treatment. The emergence of fast dissolving tablets as an 
alternative has resulted in overcoming the aforementioned disadvantages. Fast 
dissolving tablets also known as orodispersible tablets swiftly break and disintegrate in 
the mouth within 60 seconds and liquefy in saliva without the need for chewing or water. 
These uncoated tablets are convenient and provide instant action that make them suitable 
dosing with pronounced patient compliance due to ease of swallowing (Revathi, et al., 
2015), (Salunkhe, et al., 2013).  
 
Flowchart 6.1 summarises the work performed in this chapter. 
 
6.2. Determination of the angle of slide for Avicel®PH102 (MCC), Eudragit®RLPO, 
Eudragit®RLPO: Avicel®PH102 (3:7) (as the carrier) and Cab-o-sil®M-5 (fumed 
silica) using Eudragit®RL30D as a non-volatile liquid vehicle 
In the formulation of liquisolid tablets, determination of angle of slide is one of the primary 
steps of the system preparation. The flowable liquid retention potentials (Φ values) of 
powder excipients were used for the calculation of Lf value. The Lf is used to calculate the 
amount of liquid vehicle (Eudragit®RL30D) to be used in the liquisolid formulation. As 
explained previously, the ΦCA value and ΦCO value determine the amount of carrier and 
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coating materials required to produce a free flowing, non-adherent, readily compactible 
and dry- looking liquisolid formulations (Tiong & Elkordy, 2009). The preferred method 
over other approaches to establish the flowability of powders is the determination of angle 
of slide (θ) of fine powders with particle diameter less than 150μm. Moreover, this method 
was applied due to the small particle sizes of Cab-o-sil®M-5P and Avicel®PH102 (133.8µm 
and 0.2-0.3 µm respectively). Therefore, in order to calculate the required ingredient 
quantities, the flowable liquid retention potential (Φ values) of powder were utilised. The 
values of the flowable liquid retention potential for Avicel®PH102 and 
Avicel®PH102:Eudragit®RLPO (7:3) and Cab-o-sil®M-5 with Eudragi®RL30D (the liquid 
vehicle) were respectively calculated. Furthermore, the loading factor (Lf), the appropriate 
amount of carrier (Avicel®PH102 and Avicel®PH102: Eudragit®RLPO (7:3) (Q) and the 
required quantity of coating material (Cab-O-sil®M-5) (q) to convert a given mass of liquid 
medication (W) into an reasonably flowing and compressible liquisolid admixture were 
calculated using equations mentioned in chapter 2 (section 2.3.1). A sample calculation 
is presented below: 
1) !"	 = 	%&'	 + 	%	&)	(1/-); -	 = 20 !"	 = 	0.8	 + 	0	2	(0.05) è from angle of slide !"	 = 	0.8 
 
2) !"	 = 	5/6    ……. For 30% w/w drug in liquid vehicle 
 6 = 	5/!"		6	 = 	133.3/0.8		6	 = 	166.66	
 5	 = 	309:	(;<=:)è	709:	(?@A=@;	BCℎ@E?C) 
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For 40mg drug/unit dose è liquid vehicle amount in mg will equal 40 ∗ 70/30	 = 	93.39: 
Hence,  5	 = 	40	 + 	93.3	 = 	133.3	9:/IJK?CI 6/A	 = 	20, ℎCMEC	A	 = 	8.339:/IJK?CI 
Table 6.1 shows the calculations’ results and the prepared formulations. 
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Table 6-1: Liquisolid formulation of metformin-HCl using Eudragit®RLPO as a carrier and Eudragit®RL30D as a non-
volatile liquid vehicle. 
Liquisolid	
system	
Non-volatile	
liquid	vehicle	
Drug	
Concetration	
in	liquid	
medication		
(%w/w)	
Carrier:	
Coating	
(R)		
Liquid	
load	
factor	
(Lf)	
Liquid	
vehicl
e	(mg)	
Active		
ingredient	
(mg)	
Carrier	
(Q)	
(mg)	
Coating	
(q)	
(mg)	
Disintegrant	
(maize	
starch)	(mg)	
Lubricant	
(mg)	
Unit	
dose	
(mg)	
LSS1	 Eudragit	RL	30D	 30	 20	 0.80	 93.30	 40.00	 166.60	 8.33	 16.40	 2.50	 327.00	
LSS2	 Eudragit	RL	30D	 60	 20	 0.80	 26.70	 40.00	 83.30	 4.17	 8.18	 1.20	 164.00	
LSS3	 Eudragit	RL	30D	 30	 20	 0.20	 93.30	 40.00	 666.50	 33.30	 44.20	 6.60	 884.00	
LSS4	 Eudragit	RL	30D	 60	 20	 0.20	 26.70	 40.00	 333.35	 16.67	 22.10	 3.30	 442.00	
 
Note: * Eudragit®RLPO:Avicel®PH102 3:7 = carrier 
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Several attempts have been made in order to achieve the optimum flowable retention 
using different Avicel®PH102 to Eudragit®RLPO ratios. A ratio of 1:1 was also used and 
the successful ratio of 7:3 (Avicel®PH102:Eudragit®RLPO) gave optimum flow and good 
compactable tablets. 
6.3. In-vitro dissolution study of immediate release liquisolid metformin-HCl using 
Eudragit®RL30D and Eudragit®RLPO 
In-vitro dissolution tests were performed to study the release behaviours of liquisolid 
formulations in dissolution media (distilled water) (refer to Figure 6.2).  
Dissolution profiles of liquisolid compacts using Eudragit®RL30D as a non-volatile liquid 
vehicle (LSS1-LSS4) are shown in Figure 6.2. It is clear that the percentage of metformin-
HCl release in the distilled water dissolution medium is significantly high in a short time. 
After 10 minutes, the percentage of the drug release was over 85% in all liquisolid tablets. 
In this profile, after 2 hours LSS1 to LSS4 reached 100% release. It is clear from Figure 
6.2 that the tablets prepared by liquisolid technique (LSS1 and LSS2) which contain 
Avicel®PH102 as a carrier show faster drug release rate properties (100% after 1 hour) 
in comparison with LSS4 and LSS5 drug release (93.5% and 87.4%, after 1 hour) matrix 
tablets. The results showed that the percentage of drug release from liquisolid matrices 
containing Eudragit®RLPO and Avicel®PH102 in the ration of 3:7 showed lower release 
rate but (P>0.05). This could be due to difference in water permeability of those two 
polymers as water can permeate more freely into Eudragit®RLPO than into Avicel®PH102 
containing tablets due to the relative hydrophilicity of the RL polymer (Azarmi, et al., 
2002); (Javadzadeh, et al., 2008). Additionally, the drug concentration in liquid medication 
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used was 30% and 60% for all liquisolid tablets. Liquisolid formulations with 30% drug 
concentration (high amount of liquid vehicle) showed insignificant higher percentage drug 
release than 60% drug concentration. Comparably LSS1 and LSS2 have liquid load factor 
of 0.8, thus higher percentage drug release was seen in these two formulations and not 
in LSS3 and LSS4 where their liquid load factors were 0.2. This finding is also confirmed 
by the comparison between LSS4 and LSS5. Higher drug release was seen in LSS4 
(93.4%) with 30% drug concentration than LSS5 (87.4%) which contains 60% 
concentration of drug. Therefore, the increase in the amount of liquid vehicle leads to an 
increase in percentage drug release however insignificant (P > 0.05). 
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Figure 6.2: Dissolution study of immediate release liquisolid metformin-HCl (LSS1-LSS4) using Eudragit®RL30D as a 
novel non-volatile liquid vehicle (refer to Table 6.1 for composition). 
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As can be seen in Figure 6.2, no sustained-release effects were observed with metformin-
HCl LSS1-LSS5 liquisolid tablets which were prepared with Eudragit®RL30D as the non-
volatile liquid vehicle and Eudragit®RLPO as the carrier (in combination with 
Avicel®PH102). Fast dissolution rate was observed using Eudragit®RL30D although 
literature, such as (Boyapally, et al., 2009), suggests sustaining property reported for such 
polymers. This can be attributed to the hydrophilic nature of Eudragit®RLPO, when 
exposed to the dissolution medium, water, diffused into the free spaces of the matrix. 
Upon solvation of the polymer chains due to polymer relaxation, an increase in the 
dimensions of the polymer molecules can be observed. 
 
Additionally, there was no significant difference among liquisolid tablets in their drug 
release (p-value is >0.05). This finding can be related to the drug’s nature and the way it 
interacts with the liquid vehicles and other excipients. Similarly, in a study performed by 
Elkordy et al. (2013), they prepared liquisolid spironolactone tablets using 
Kollicoat®SR30D as the non-volatile liquid vehicle and observed no sustained-release 
effects. The proposed explanation was due to the drug’s interaction with the excipients, 
rapid disintegration of tablets due to poor hardness or insufficient concentration of 
Kollicoat®SR30D to produce sustained release effect. Therefore, this can also be a valid 
explanation to the current results with metformin-HCl, taking into account that metformin-
HCl is highly water soluble and therefore could have reacted differently when being in 
contact with Eudragit®RL30D and Eudragit®RLPO which was confirmed by FTIR and 
DSC results. 
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A study by Javadzadeh et al. (2008) publicised the impact of granulation process on the 
retardation of propranolol liquisolid release. In the same study, the authors claimed using 
conventional tablets without the application of granulation process showed higher drug 
release with Eudragit®RL than RS. However, when wet granulation was applied using 
HPMC as a liquid binder on the same formulations, the results were the opposite; 
Eudragit® RL showed slower drug release rate than those prepared using Eudragit®RS. 
The possible explanation was linked to the use of HPMC in the granulation process and 
its effect on release pattern as a result of drug particle coating containing Eudragit®RL 
and not Eudragit® RS. Moreover, in this current research the use of Eudragit®RL30D as 
the non-volatile liquid vehicle and liquid binder for the process of wet granulation did not 
have any retardation effect on the release of metfromin liquisolid. On the contrary, it 
produced steady and immediate release tablets. Unlike the polysorbate 80 which, is also 
a non-volatile liquid vehicle used by Javadzadeh et al. (2008) along with Eudragit to 
sustain the release of propranolol. One of the interesting properties of polysorbate 80 by 
which it can reduce the glass transition temperature of the polymers in which leads to 
release prolongation of liquisolid tablets due to its plasticity effect. 
A study by (Shah, et al., 2012) performed a study on formulation of microsphere based 
orodispersible tablets of itopride HCL, and in the dissolution profile, where the pH of the 
medium was 1.2, it was observed that within the first 10 minutes, 90% of the drug was 
released. Accordingly, in this current research project, the dissolution study performed in 
distilled water and the result outcome was very interesting. After 10 minutes of dissolution 
run, LSS1 released 91% of liquisolid metformin-HCl, followed by LSS2, LSS3 and LSS4 
where the release was 98%, 87% and 85%, respectively. Therefore, it is expected that as 
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soon as Eudragit® dissolves in the acidic environment of the stomach, the drug will be 
quickly released or even before reaching the stomach i.e. in the mouth (as tablets showed 
fast disintegrating effect). Nevertheless, Javadzadeh et al. (2008) claimed the use of 
granulation has greater impact on sustained release behaviour of liquisolid tablets. 
Conversely, in the current study, wet granulation using Eudragit®RL30D as a liquid binder 
showed no sustaining release behaviour on metformin-HCl Liquisolid tablets(LSS1-
LSS4), instead all tablets showed immediate release with fast disintegration profile (Refer 
to Section 6.4). Moreover, the reason for choosing Eudragit ®RL over Eudragit®RS was 
the published research papers. Javadzadeh et al. (2008) prepared liquisolid propranolol 
as sustained release tablets using Eudragit®RL and Eudragit®RS where they compared 
the retardation effect in the release of propranolol by using both polymers. As a result, 
Eudragit®RS showed a more sustained release effect due to its hydrophobic properties 
which reduces the permeability of water into the matrix. However, upon application of wet 
granulation technique using HPMC, the outcome was reversed. Wet granulation had 
remarkable impact with greater retardation effect on propranolol liquisolid tablets 
containing Eudragit®RL (Javadzadeh, et al., 2008). Yet, after application of the above 
principle, immediate release and fast disintegrating formulations of metformin-HCl 
liquisolid tablets were obtained which adds a new approach and discovery to the liquisolid 
list of achievements. For future work, taste masking excipients can be added to make the 
metformin-HCl orodispersible tablets more customer friendly for patients. 
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6.4. Uniformity of tablet weight, Tablet hardness, friability, disintegration and 
uniformity of drug content 
 
Table 6.2 shows a comparison of the content uniformity, friability, hardness and 
disintegration tests in terms of means and standard deviations between different 
metformin-HCl liquisolids using Eudragit®RL30D, as a non-volatile liquid vehicle, and 
Eudragit®RLPO, as a carrier in conjunction with Avicel®PH102 (3:7) that have been 
granulated using Eudragit®RL30D as a liquid binder. The drug content uniformity results 
show that the all formulations (LSS1-LSS4) are within the British Pharmacopoeia 2017 
specific limits (85%-115%). Moreover, the changing in the quantities or type of carrier 
shows significant effect on the uniformity of the drug in these formulations.  For instance, 
LSS1 and LSS2 show drug content of 110% and 104% where the used carrier was 
Avicel®PH102 (microcrystalline cellulose only). On the other hand, when the carrier 
constitution was made into a mixture of Avicel®PH102 and Eudragit®RLPO with a ratio of 
3:7, the drug content uniformity has dropped to 95% and 87% for LSS3 and LSS4 
respectively.  As a consequence, the wet granulated formulations using Eudragit®RL30D 
liquid binder and Eudragit®RLPO: Avicel®PH102 as carrier do affect the distribution of the 
drug inside the Eudragit®RL30D liquisolid bed systems. The liquid binder 
(Eudragit®RL30D) is compatible with the liquid vehicle (Eudragit®RL30D) and the 
formation of the granules sustain the distribution of the liquid vehicle inside the solid 
framework. 
 In regards to the friability tests, none of the liquisolid formulations reached 1% loss. The 
friability percentage for LSS1-LSS4 are 0.01%, 0.03%, 0.45% and 0.42% respectively. 
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The results fulfilled the demands of the British Pharmacopoeia 2017 criteria that present 
an excellent resistance to handling and packaging of the prepared tablets. 
In this study, the range of hardness is between 6.95kg/f (68.11N) and 9.25 Kg/f (90.65N). 
Using Avicel®PH102 as a carrier for LSS1 and LSS2 and Avicel®PH102 with 
Eudragit®RLPO (7:3) as carriers for LSS3 and LSS4, leads to cover the surface and 
increase solid bridges among particles. Particles undergo deformation and non-reversible 
changes of their shapes as a response to compression forces being applied; therefore, it 
can be said that carriers used in this study are capable of exhibiting plasticity behavior 
(Fahmy & Kassem, 2008). Plastic deformation is a well-known property of Eudragit® 
polymers which also have tendency to coat drug particles. (Apu, et al., 2009) noticed 
highest hardness (216.14 kg/cm2)) in matrix tablets containing Eudragit®RLPO and 
Eudragit®RSPO in ratio of 2:3. They explained that high compression forces can result in 
hard, low porosity tablets that can markedly affect the drug release rate. 
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Table 6-2: Crushing load, hardness, friability, drug content uniformity and uniformity of weight for metformin-HCl liquisolid 
tablets	using	Eudragit®RL30D	as	the	non-volatile	liquid	vehicle	(for	formulation	compositions,	refer	to	table	6.1.).	
FORMULATION	 CRUSHING	LOAD	(KG/F)	 HARDNESS	(N)	
FRIABILITY	
WEIGHT	(%)	
DRUG	
CONTENT	(%)	
UNIFORMITY	OF	
WEIGHT	(MG)	
LSS1	 9.25	±	0.23	 90.74	±	2.30	 0.01%	 110.00%	±	1.17	 174	±	2.10	
LSS2	 7.70	±	0.43	 75.54	±	4.21	 0.03%	 104.00%	±	2.44	 176	±	1.70	
LSS3	 6.95	±	0.21	 68.18	±	2.03	 0.45%	 95.00%	±	1.63	 223	±	2.10	
LSS4	 9.03	±	0.34	 88.62	±	3.38	 0.42%	 87.00%	±	2.40	 239	±	1.80	
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For dissolution processes, rapid disintegration time is crucial due to fast division being 
provided into surface fragments. Furthermore, balancing between disintegration time and 
tablet hardness is an important factor from the industrial perception. According to the BP 
specification of disintegration test, in no less than 15 minutes a tablet must disintegrate, 
in which all liquisolid tablets have complied this specification. The data revealed an 
average time of about 2.6min for the liquisolid formulations (LSS1-LSS4). The results in 
Figure 6.3 show that the disintegration time comply with the BP specifications not only for 
immediate release but also for fast disintegration time (<3min). LSS3 recorded the 
shortest disintegration time of 15 seconds.  Figure 6.3 presents the range of the 
disintegration time of metformin-HCl liquisolid formulation using Eudragit®RL30D. LSS3 
was found to be the fastest formula to disintegrate (16 seconds), followed by LSS4, LSS2 
and LSS1 with disintegration time 2.30, 2.70 and 5.2 minutes, respectively. There are 
fewer variations in the case of the Eudragit®RL30D liquisolid formulations compared with 
the immediate release metformin-HCl using PEG®400, Synperonic®PE/L44 and 
Cremophor®ELP formulations (chapter 4, section 4.5).  
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Figure 6.3: Average disintegration profile of liquisolid sustained release metformin-HCl 
granulated tablets. For formulations’ composition refer to Table 6. 
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Rapid disintegration is important during tablet formation to ensure quick breakage of 
tablets into smaller segments during dissolution process for a larger surface area.  The 
rapid disintegration of liquisolid tablets might be accredited it to the presence of 
Avicel®PH102 in conjunction with Eudragit®RLPO powders (7:3). They facilitate the 
uptake of water into the pores of the tablet initiating an internal pressure which leads to 
breakage of the tablets into fragments empowering rapid disintegration. Therefore, since 
all liquisolid tablets disintegrate within 5 minutes (0.27 minutes in LSS3), these liquisolid 
preparations can be used as fast disintegrating tablets that disintegrate or dissolve 
promptly into the solution. With these changes, patient compliance can be ensured, 
particularly for elderly patients who have difficulty in swallowing tablets or any other oral 
dosage forms that causes a barrier or limitation for their compliance. Due to the effect of 
Eudragit®RLPO on the disintegration time, with highest amount of carrier (666mg 3:7 
Eudragit®RLPO to Avicel®PH102) in LSS3, the LSS3 gave the fastest disintegration time 
(16 seconds), followed by LSS4 (2.3 minutes).  El-Say et al. (2010) found an inversely 
proportional relationship between liquid load factor (Lf) and disintegration time of the 
liquisolid tablets. However, similar findings were not observed in this current study. A direct 
positive correlation was found between the liquid load (Lf) and the disintegration time of 
the liquisolid tablets. This principle was confirmed from the results of the following 
formulae, LSS1 and LSS2 having Lf value of 0.8 with a mean disintegration time of 5.2 
and 2.7 minutes respectively, and LSS3 and LSS4 having Lf value of 0.2 with mean 
disintegration time of 0.16 minutes and 2.3 minutes respectively. Similar findings were 
found in a study by (Egla & Abd Al Hammid, 2017)Lf decrease in two formulations F10 
(containing 2.5 mg zolmitriptan, PG as non-volatile liquid vehicle and 9.3mg of CP a 
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superdisintegrant) and F11 (containing (containing 2.5 mg zolmitriptan, PG as non-volatile 
liquid vehicle and 9.3mg of CP a superdisintegrant) where loading factors where 0.175 
and 0.125 respectively. The wetting time (WT) and disintegration time (DT) of the two 
specified formulations exhibited a proportional link with loading factor, where decrease in 
WT and DT was seen as the loading factor was decreased (Egla & Abd Al Hammid, 2017).  
The possible explanation was due to the reduction in loading factor, leading to an increase 
in the amount of Avicel®PH102 (carrier) used. Furthermore, the high porosity of 
Avicel®PH102 aids in the swelling and disintegration of the orodispersible tablets as a 
result of water diffusion by capillary action into the hydrophilic matrix generating pressure 
for rapid disintegration. On the other hand, (El-Say, et al., 2010) proposed a theory where 
by increasing the liquid load factor the amount of liquid used significantly enhances the 
wetting properties of the drug, thus increasing the accessibility of the drug to be freely 
disintegrated causing a reduction in the disintegration time of the liquisolid tablets is 
incompatible with entire range of liquid vehicles and drugs. In other words, drugs with 
hydrophobic nature can preserve the above findings and show inverse relationship 
between disintegration time and liquid load factor (Lf). Thus, when a hydrophilic drug is 
being used, such as metformin-HCl, this relationship disappears leading to fast 
disintegrant liquisolid tablets using Eudragit®RL30D as the non-volatile liquid vehicle. In 
summary, the quantity of the carrier and the quantity of the disintegrants along with the 
type of the liquid vehicle are the main factors controlling the disintegration time of the 
liquisolid tablets. Wetting time is an indicator of the simplicity of tablet disintegration in the 
buccal cavity. The acceptable time range for disintegration of orodispersible tablets must 
be between 15-30 seconds and 3 minutes according to European Pharmacopoeia (Shah, 
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et al., 2012). 
In most studies, fast disintegrating tablets were achievable by the use of fast disintegrants 
such as crospovidone, (Egla & Abd Al Hammid, 2017). In this study they show the 
importance of a balanced concentration in the orodispersible formulation. An optimal 
concentration of the super disintegrant leads to an increase in the orodispersibility of the 
tablet. Such a theory cannot be applied to the current work due to the fact that no 
superdisintegrant was used, instead only potato starch was added to the liquisolid 
formulation of metformin-HCl along with Eudragit®. Thus, to the best of our knowledge, 
the model which played the role of fast disintegrating agent is believed to be 
Eudragit®RLPO and this has been confirmed by disintegration and dissolution results. 
 
6.5. Fourier transform infrared (FT-IR) spectroscopy 
 
The functional groups absorption bands appear from the stretching, whereas the shape 
and relative intensity of the IR absorption bands are used for assigning the vibrational 
mode characteristics with assignments of bands. FT-IR samples of pure metformin-HCl 
powder, pure Eudragit® and liquisolid metformin-HCl (LSS1-LSS4) granules are shown 
in Figure 6.4. They were subjected to FT-IR spectroscopic analysis at spectral bands of 
550-4000 cm-1. The characteristic absorption bands of pure metformin-HCl are between 
3367 and 3292 cm -1 due to N-H primary stretching and a band at 3156 cm -1 due to N-H 
secondary stretching (Sheela, et al., 2010)). Additionally, characteristics bands at 1623 
and 1561 cm-1 were observed to be denoted for N-H asymmetric deformation (Sheela, et 
 
204 
 
al., 2010). The liquisolid formulations LSS1-LSS4 FT-IR showed complete disappearance 
of the metformin-HCl pure peak, or reduction in intensity of peaks. This change might be 
attributed to the interaction between the drug (metformin-HCl) and the excipients used 
such as Eudragit®RL30D and Eudragit®RLPO.  
 
 
Pure metformin  
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Figure 6.4: FT-IR spectra of metformin-HCl liquisolids using Eudragit® (LSS1-LSS4).For 
formulations’ composition refer to Table 6.1 
 
             
6.6. Differential scanning calorimetry (DSC) 
 
 
Differential scanning calorimetry analysis was performed to determine the crystalline 
nature of the drug and possible incompatibility of the drug with excipients used in the 
liquisolid formulation development.  Figure 6.5 depicts the thermal properties of liquisolid 
formulations of metformin-HCl using Eudrgit®RL30D. DSC thermograms of pure 
metformin-HCl showed a sharp endothermic peak at 232.990C corresponding to its 
melting point with respective enthalpy of 215.8J/g. This sharp endothermic peak indicates 
the crystalline nature of drug. The shifts of endothermic peak of metformin-HCl in the DSC 
thermograms to lower temperatures indicates that the drug is mostly solubilised within 
liquisolid mixture i.e. drug present mostly in a solution form (Butreddy & Dudhipala , 2015).  
The small enthalpies of the drug’s melting point peak in liquisolid thermograms (Figure 
6.4) imply that metformin-HCl in LSS1-LSS4 was mainly dispersed in the metformin-HCl 
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matrices (fast release observed) or the drug mostly exists in an amorphous form. 
(Nnamani, et al., 2016). 
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Figure 6.5: DSC thermograms of metformin-HCl liquisolid formulations using 
Eudragit®RL30D as the non-volatile liquid vehicle (LSS1-LSS4). Refer to Table 6.1 for 
formulations composition details 
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6.7. Scanning electron microscopy (SEM) 
SEM analysis showed pure metformin-HCl of irregular shapes and sizes. The SEM 
microphotographs of all the liquisolid granules (LSS1-LSS4), shown in Figure 6.6, signify 
the complete disappearance of metformin-HCl crystals, a fact that indicates that the drug 
was solubilised in the liquisolid system. The liquisolid formulation hypothesis has been 
proved by the fact that although the drug is in a solid dosage form, it is held within the 
powder substrate in solution and it is observed in the dispersed state. This contributes to 
the idea of free flowing and enhanced drug dissolution properties (Jain, et al., 2014). 
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Figure 6.6: SEM microphotographs of LSS1, LSS2, LSS3 and LSS4 using 
Eudragit®RL30D as the non-volatile liquid vehicle. Refer to Table 6.1 for formulations 
composition details. 
  
 
6.8. Conclusion 
This study demonstrated that the prepared liquisolid metformin-HCl using 
Eudragit®RL30D as a liquid vehicle and Eudragit®RLPO as a carrier can possess fast oral 
disintegrating time, thus shorter dissolution release pattern. Therefore, it can be 
concluded that the rapid disintegration tablets formulated in this manner can easily help 
in administration of liquisolid metformin-HCl in a greater satisfactory form. Hence, such 
formulations can ensure higher patient compliance rate with minimum side effects making 
it a suitable and sought after approach for the pharmaceutical industry. Figure 7-1 shows 
the summary of liquisolid work performed in this research. 
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Chapter 7 - Conclusion and Future work  
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Figure 7.1: Summary of liquisolid work
Liquisolid compact preparation
Model drugs for immediate drug release
Glibenclamide, Metformin-HCl
Angle of slide determination (q-value) determination for
carrier: Avicel®PH102
coating: Cab-O-Sil®M-5
Liquid load factor(Lf value) determination
Drug powder admixture with liquid vehicle
PEG®400 Synperonic®PE/L44 and
Cremophor®ELP
Q,q(carrier to coating)amount
R=20 Carrier: Avicel®Ph102
Coating: Cab-O-Sil® M-5
Mixing of drug powder, liquid vehicle,carrier,coating, disintegrant and lubricant in 
adjustable amount based on mathematical calculation 
Powder admixture
wet granulation with 10%PVP
Automatic compaction
No granulation
Manual compaction
Metformin-HCl
Angle of slide determination (q-value) 
determination for carrier: Avicel®PH102, 
Avicel®PH102:Eudragit®RLPO (7:3)
coating: Cab-O-sil®M-5
Liquid load factor (Lf value) 
determination
Drug powder admixture with liquid 
vehicle
Eudragit®RL30D
Q,q (carrier to coating) amount
R=20 Carrier: Avicel®PH102,
Avicel®PH 102 :Eudragit®RLPO (7:3)
Mixing of drug powder, liquid 
vehicle,carrier,coating, disintegrant and 
lubricant based on mathematical 
calculation
Powder admixture=>wet granulation 
using Eudragit®RL30D
Automatic compaction
Model drug for sustained drug 
release 
Metformin-HCl
Lf value  pretermined from literature 
Drug powder admixture with liquid 
vehicle (PEG®400,Synperonic®PE/L44, 
Cremophor®ELP)
Q,q (carrier to coating) amount R=20 
Carrier: HPC-H Coating:Cab-O-Sil®M-5
Mixing of drug, liquid vehicle, carrier, 
coating and lubricant in adjustable 
amount based on mathematical 
calculation
Powder admixture ==>wet granulation 
using 10% PVP
Automatic compaction
 
211 
 
Conclusion 
Solubility and dissolution are the major factors that affect the bioavailability and in vivo 
performance of the drug.  Moreover, based on literature, most current drugs have high 
lipophilicity and poor aqueous solubility resulting in poor bioavailability. In an attempt to 
improve bioavailability, it is crucial to improve the release behaviors of water insoluble 
drugs. The aim of this research work was to enhance the solubility and dissolution of 
hydrophobic drugs by the application of liquisolid technique. Liquisolid technology has the 
capability to sustain the release water-soluble drugs and allow the development of 
sustained release formulation with desirable release kinetics based on the work 
presented in this research. A further aim was to prepare sustained release metformin-HCl 
using liquisolid technique. 
In chapter three, liquisolid technique changed the properties of glibenclamide, a 
hydrophobic model drug by inclusion of the drug particles (10%w/w and 30%w/w) in non-
volatile liquid vehicles (PEG® 400, Synperonic® PE/L44 and Cremophor ®ELP). Wet 
granulation of prepared liquisolid powders successfully produced automatically 
compactible tablets using the above-mentioned liquid vehicles. The best dissolution 
enhancement was seen with combination of Cremophor® ELP with glibenclamide 
(10%w/w). However, the viscous behavior of Cremophor ®ELP made the flowability and 
automatic compaction of liquisolid powders containing Cremophor® ELP very 
challenging. Therefore, the new technique performed in this study (wet granulation by 
incorporating PVP as a liquid binder) resolved the compactibility issues and produced 
well-compressed liquisolid glibenclamide tablets which complied with B.P. quality control 
 
212 
 
tests. Therefore, the combination of the two methods wet granulation and liquisolid not 
only showed dissolution enhancement of glibenclamide (hydrophobic drug), but also the 
non-compressible tablets due to wet liquisolid powder mass, were formed into strong well-
compacted tablets with no lamination or capping. Simultaneously, incorporation of PVP 
as a liquid binder did not affect the positive behavior of the liquid vehicles and also, 
application of heat in the drying process upon wet massing did not lead to any evaporation 
of the liquid vehicle. Accordingly, liquisolid system can use any type of viscous liquid 
vehicles in its composition and by application of wet granulation technique liquisolid 
powders can be compacted into tablets. The above-mentioned liquid vehicles 
(Synperonic®PE/L44 and Cremophore®ELP) were chosen because there are limited 
literature on their usage in liquisolid technology due to their viscous behavior and this 
current research over-come the undesirable viscosity effects on the properties of the 
liquisolid powders. 
In chapter 4 the use of granulated liquisolid technique to generate stable metformin-HCl 
tablets was tested. Metformin-HCl is a water-soluble drug, which gives about 100% drug 
release for pure drug and the conventional formulation after 10 minutes. By using 
liquisolid technique with different liquid vehicles used, the drug release has not reached 
100% after 10 minutes due to: the effect of processing technique; the effect of surfactants 
(liquid vehicles) and the interaction of the vehicles with the drug. Metformin-HCl was 
chosen as a water-soluble model drug to emphasize on the various impact of liquisolid 
technique on hydrophobic and hydrophilic drugs using same liquid vehicles.  At present, 
metformin-HCl is commercially available in high dose tablets, 500 mg; the granulated 
liquisolid formulations may assist in the reduction of this dose. The stability studies 
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showed that the dissolution of liquisolid tablets was not affected by ageing significantly. 
Franz diffusion cells have been used to test the permeability of metformin-HCl liquisolid 
using Wistar rat stomach tissue. The results have shown promising results in using 
granulated liquisolid metformin-HCl tablets to enhance the drug permeability and hence 
may enhance drug bioavailability. Consequently, liquisolid tablets can be further used in 
alternative animal tests in order to confirm the beneficial use of liquisolid technology on 
permeability of drugs with poor bioavailability. 
In Chapter 5, sustained release metformin-HCl was prepared using HPC polymer by the 
application of liquisolid technique. Three different liquid vehicles (PEG®400, 
Synperonic®PE/L44 and Cremophor®ELP) were used with 30% and 60% drug 
concentrations. Among the above mentioned liquid vehicles, Cremophor®ELP using 30% 
drug concentration showed the highest (92%) and the most sustained drug release over 
a 12 hour period. HPC shows moderate swelling coupled with slower rate of erosion.  
Drug release profiles on model fitting followed zero order and Higuchi models. 
Additionally, the flow-through method with open loop configuration has been used to 
perform the dissolution study of the sustained release metformin-HCl. Therefore, USP 
flow-through cell with open loop configuration was a successful dissolution apparatus to 
study the release of metformin-HCl over 12 hours.  
The final chapter, Chapter 6, demonstrated the work on the preparation of liquisolid 
metformin-HCl using Eudragit®RL30D as a liquid vehicle and Eudragit®RLPO as a carrier, 
which can possess fast oral disintegrating properties, thus a shorter dissolution release 
pattern. Therefore, it can be concluded that the rapid disintegration tablets formulated in 
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this manner can easily help in administration of liquisolid metformin-HCl in a more 
customer friendly manner. Hence, such formulations can ensure higher patient 
compliance rate with minimum side effects. This approach can be considered by the 
pharmaceutical industry. This work discovered a new feature for Eudragit to produce fast 
disintegrating effect with metformin-HCl and accordingly, this part was extended to 
formulate liquisolid tablets with Eudragit. However, further future work is required.  
In conclusion, although numerous techniques to handle solubility related issues already 
exist, the liquisolid technology or powder solution technology is a novel and promising 
technique for modifying the release of active pharmaceutical ingredients and to produce 
pharmaceutically modified drugs with desirable characteristics. As the liquisolid 
technology uses similar production processes as followed to develop conventional 
tablets, this technology aims to improve the release rate of poorly water-soluble drugs via 
a simple and cost effective method to positively improve patient compliance. 
To go over the main points regarding the effect of the three non-volatile liquid vehicles 
used (PEG®400, Synperonic®PE/L44 and Cremophor®ELP), Cremophor®ELP was the 
most promising non-ionic surfactant as it enhances the dissolution of glibenclamide 
significantly and improved the permeability of metformin-HCl. Additionally, it also 
enhances the effect of Hydroxypropylcellulose(HPC) in sustaining the release of 
metformin-HCl. 
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Future work 
The current research project commenced with the investigation of applying the liquisolid 
technique on glibenclamide (hydrophobic model drug) in order to enhance the solubility 
and dissolution as well as flowability properties of the drug. Additionally, liquisolid 
technique was also applied on metformin-HCl (hydrophilic model drug) in order to sustain 
the release of the drug by the use of HPC-H in the aqueous media. The obtained results 
with liquisolid preparations could be further investigated in vivo to check the bioavailability 
of the drugs and to validate its enhancement to the drug solubility and dissolution. 
Furthermore, using HPC-H was successful in sustaining the release of metformin-HCl by 
the use of liquisolid technique can further be applied on other hydrophilic and can also be 
filled into capsules, for more convenience. Additionally, stability test can be performed on 
all liquisolid formulations containing Eudragit®RL30D as liquid vehicle (new 
orodispersible liquisolid tablets) and HPC-H containing liquisolid metformin-HCl for further 
quality control testing that is vital for industrial purposes.  
The use of Eudragit® RL30D as liquid vehicle was a successful formulation to obtain fast 
disintegration tablets in which as a result can be beneficial for elderly and vulnerable 
people who have swallowing difficulties by including some flavor enhancer to mask the 
taste of Eudragit® and make it more pleasant for patients. Also, similar liquisolid 
technique can be applied on other available drugs in order to formulate orodispersible 
tablets using Eudragit®RL30D. 
Finally, the current research work showed promising results in enhancing the permeability 
of metformin-HCl by using liquisolid technique and this test was performed on stomach 
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membrane of Wistar rats. This research can further be continued by using other 
membranes such as small intestine in order to investigate the permeability of liquisolid 
metformin-HCl.  
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Appendix 
 
Chapter 3 
Statistics results for glibenclamide release from granulated liquisolid 
preparations   
 
 
 
																					
Time	(min) %	release	Conventional %	release	of	granulated	Glib	10%	PEG %	release	of	granulated	Glib	30%PEG
0 0 0 0
5 5.698867899 10.44169296 5.291454443
10 9.704406847 12.74716213 2.096145381
15 9.162517902 13.91162574 3.109161793
20 10.81741395 15.85633014 0.111
25 13.23610574 16.18977161 2.291391561
30 13.07318623 15.87783337 1.042256178
45 13.37929179 17.23284525 6.004213042
60 14.30175252 19.96671039 7.625605232
90 14.28095345 21.3437423 7.14204867
T	Test	 0.004351204 0.001448477 0.001448477
%	release	Conventional %	release	of	granulated	Glib	10%	PEG %	release	of	granulated	Glib	30%PEG
vs vs vs
%release	of	granulated	Glib	30%	 %release	of	granulated	Glib	30%	 %release	of	granulated	Glib	30%	
Cremophor	with	excess	avicel Cremophor	with	excess	avicel Cremophor	with	excess	avicel
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%	release	of	granulated	Glib	30%	Synperonic %release	of	granulated	Glib	30%	Cremophor	with	excess	avicel
0 0
6.51700323 0
8.391751478 50.16109238
11.4528666 45.44678985
13.88518877 46.07189941
13.42027191 52.33172807
15.17024265 52.93074958
14.44746957 58.08494742
15.1698552 61.67116112
12.41198555
0.005396878 0.026005073
%	release	of	granulated	Glib	30%	Synperonic %release	of	granulated	Glib	30%	Cremophor	with	excess	avicel
vs vs
%release	of	granulated	Glib	30%	Cremophor %	release	of	granulated	Glib	10%	synperonic
	with	excess	avicel
%	release	of	granulated	Glib	10%	synperonic %release	of	granulated	Glib	10%	Cremophor	with	excess	avicel
0 0
12.71988243 3.988841409
18.0747401 10.94687797
20.10604626 33.526474
21.24673841 45.98409448
23.46577155 54.18281294
23.2550223 52.57479598
25.17967281 51.10274215
23.45457365 54.31200124
22.63262514 54.10310768
0.026005073 0.336853453
%	release	of	granulated	Glib	10%	synperonic %release	of	granulated	Glib	10%	Cremophor	with	excess	avicel
vs vs
%release	of	granulated	Glib	30%	Cremophor	 %release	of	granulated	Glib	30%	Cremophor	with	excess	avicel
with	excess	avicel
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DSC thermograms of G1-G6 as liquisolid powder and liquisolid granules. Pure 
Glibenclamide, market Glibenclamide, Conventional Glibenclamide as well as 
nonvolatile liquid vehicles (PEG®400, Synperonic® PE/L44, Cremophor®ELP) and 
excipients such as Avicel® PH102, Cab-O-Sil® M-5, potato starch, Mg stearate and 
PVP. 
	 	
							G1																																																																																						G1	(ungranulated)	
	
	
			 	
G2																																																																								G2	(ungranulated)	
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G3																																																																						G3	(ungranulated)	
	
			 	
G4																																																					G4	(ungranulated)	
	
		 	
G5																																																																											G5	(ungranulated)	
	
	
		 	
G6																																																																											G6	(ungranulated)	
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Pure Glibenclamide                                          Conventional Glibenclamide 
 
 
 
   
     Market Glibenclamide                                          Avicel PH102 
    
 
     Potato starch                                               PVP 
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      Magnesium Stearate                                    Silica 
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Chapter 4 
	
	
 
PEG	30% PEG	60%
Synperonic 
30% Synperonic 60% Cremophor 30% Cremophor 60% Pure Metformin
0.865 1.246 0.497 0.605 0.624 1.069 0.307
0.973 1.119 0.51 0.675 0.713 0.897 0.294
0.999 1.094 0.6117 0.935 0.739 0.745 0.324
1.018 1.075 0.73 0.992 0.777 0.77 0.354
1.024 1.113 0.84 1.005 0.777 0.953 0.362
1.1 1.132 0.938 1.081 0.802 1.43 0.481
1.176 1.214 1.119 1.145 0.859 1.519 0.574
1.329 1.341 1.305 1.462 0.973 1.722 0.671
1.951 1.456 1.648 1.709 1.157 1.792 0.849
2.636 1.614 1.199 2.027 1.411 2.211 0.933
Significance	(P	value) versus	Pure	metformin	 5.75211E-18 5.6096E-07 0.008418363 0.001222167 0.002606373 0.000550413
amount	penetrated	in	14	ml
12.11 17.444 6.958 8.47 8.736 14.966 4.298
13.622 15.666 7.14 9.45 9.982 12.558 4.116
13.986 15.316 8.5638 13.09 10.346 10.43 4.536
14.252 15.05 10.22 13.888 10.878 10.78 4.956
14.336 15.582 11.76 14.07 10.878 13.342 5.068
15.4 15.848 13.132 15.134 11.228 20.02 6.734
16.464 16.996 15.666 16.03 12.026 21.266 8.036
18.606 18.774 18.27 20.468 13.622 24.108 9.394
27.314 20.384 23.072 23.926 16.198 25.088 11.886
36.904 22.596 16.786 28.378 19.754 30.954 13.062
%	penetrated Time (min) PEG	30% PEG	60%
Synperonic 
30% Synperonic 60% Cremophor 30% Cremophor 60% Pure Metformin
5 0.6055 0.8722 0.3479 0.4235 0.4368 0.7483 0.2149
10 0.6811 0.7833 0.357 0.4725 0.4991 0.6279 0.2058
15 0.6993 0.7658 0.42819 0.6545 0.5173 0.5215 0.2268
20 0.7126 0.7525 0.511 0.6944 0.5439 0.539 0.2478
25 0.7168 0.7791 0.588 0.7035 0.5439 0.6671 0.2534
30 0.77 0.7924 0.6566 0.7567 0.5614 1.001 0.3367
45 0.8232 0.8498 0.7833 0.8015 0.6013 1.0633 0.4018
60 0.9303 0.9387 0.9135 1.0234 0.6811 1.2054 0.4697
90 1.3657 1.0192 1.1536 1.1963 0.8099 1.2544 0.5943
120 1.8452 1.1298 0.8393 1.4189 0.9877 1.5477 0.6531
PEG	30% PEG	60%
Synperonic 
30% Synperonic 60% Cremophor 30% Cremophor 60%
Fold	 Time (min)
Increase 5 2.817589577 4.058631922 1.618892508 1.970684039 2.03257329 3.482084691
10 3.30952381 3.806122449 1.734693878 2.295918367 2.425170068 3.051020408
15 3.083333333 3.37654321 1.887962963 2.885802469 2.280864198 2.299382716
20 2.875706215 3.036723164 2.062146893 2.802259887 2.194915254 2.175141243
25 2.828729282 3.074585635 2.320441989 2.776243094 2.14640884 2.632596685
30 2.286902287 2.353430353 1.95010395 2.247401247 1.667359667 2.972972973
45 2.048780488 2.114982578 1.949477352 1.994773519 1.496515679 2.646341463
60 1.980625931 1.998509687 1.94485842 2.178837556 1.450074516 2.566318927
90 2.297997644 1.714958775 1.941107185 2.012956419 1.362779741 2.110718492
120 2.825294748 1.729903537 1.285101822 2.172561629 1.512325831 2.36977492
3	fold 2	fold 2-3	fold
PEG Synperonic	 Cremophor	
Appendix for Chapter 4 
Statistics results for permeability study of metformin using stomach tissue and Franz cell   	
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Purchased animal tissue (ethical exemption) 
Dear Hoda 
 
Please include the forwarded e mails in the thesis's appendix. 
 
Best wishes 
Amal 
 
________________________________________ 
From: Amal Elkordy 
Sent: 20 April 2016 16:48 
To: Kimberley Moore 
Subject: FW: FW: Hoda Javaheri 
 
Hi Kimberley 
 
I have forwarded Etta' email, we will not need ethical approval. 
 
Many thanks 
Amal 
 
 
 
 
 
________________________________ 
From: Etta Evans [etta.evans@sunderland.ac.uk] 
Sent: 20 April 2016 16:43 
To: Amal Elkordy 
Subject: Re: FW: Hoda Javaheri 
 
I think that you would not need ethics approval if you purchase "dead" animal tissue. Kind regards, Etta 
 
 
On 20/04/2016 16:38, Amal Elkordy wrote: 
Many thanks Etta for your reply 
 
Also, if we are going to buy animal tissue from a company, do we need ethical approval? 
 
Many thanks 
Amal 
 
________________________________ 
From: Etta Evans [etta.evans@sunderland.ac.uk<mailto:etta.evans@sunderland.ac.uk>] 
Sent: 20 April 2016 16:32 
To: Amal Elkordy 
Subject: Re: FW: Hoda Javaheri 
 
Hello Amal, 
 
Michelle asked me a question regarding animal tissue and ethics approval but she did not provide any context 
..... 
 
Cutting things short, obviously you do not need ethics approval for research on animal tissue purchased at a 
local butcher's shop. 
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Sorry for the confusion! 
 
Kind regards, 
Etta 
 
 
-- 
Dr Etta Evans 
 
Chair of the University Research Ethics Committee 
Senior Lecturer in Psychology 
 
University of Sunderland 
David Goldman Informatics Centre 
St. Peter's Campus 
Sunderland, SR6 0DD 
 
Phone: ++44 (0)191 515 2624 
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Chapter 5 
Test of Homogeneity of 
Variances 
Drug release   
Levene 
Statistic df1 df2 Sig. 
.393 6 98 .882 
 
 
ANOVA 
Drug release   
 
Sum of 
Squares df 
Mean 
Square F Sig. 
Between 
Groups 
1321.609 6 220.268 .237 .964 
Within Groups 91242.124 98 931.042   
Total 92563.733 104    
 
 
 
 
 
 
 
239 
 
Post Hoc Tests 
 
For metformin HPC formulations’ compositions refer 
to Table 2.3 
 
Multiple Comparisons 
Dependent Variable:   drug release   
Scheffe   
(I) formula (J) formula 
Mean 
Difference (I-
J) Std. Error Sig. 
95% Confidence Interval 
Lower Bound Upper Bound 
HPC1 HPC2 1.82376 11.14177 1.000 -38.5874 42.2349 
HPC3 .08757 11.14177 1.000 -40.3236 40.4987 
HPC4 -5.22088 11.14177 1.000 -45.6320 35.1903 
HPC5 -8.72320 11.14177 .996 -49.1343 31.6880 
HPC6 -5.48649 11.14177 1.000 -45.8976 34.9247 
conventional 
HPC 
-4.61883 11.14177 1.000 -45.0300 35.7923 
HPC2 HPC1 -1.82376 11.14177 1.000 -42.2349 38.5874 
HPC3 -1.73619 11.14177 1.000 -42.1473 38.6750 
HPC4 -7.04464 11.14177 .999 -47.4558 33.3665 
HPC5 -10.54696 11.14177 .989 -50.9581 29.8642 
HPC6 -7.31025 11.14177 .999 -47.7214 33.1009 
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conventional 
HPC 
-6.44260 11.14177 .999 -46.8537 33.9686 
HPC3 HPC1 -.08757 11.14177 1.000 -40.4987 40.3236 
HPC2 1.73619 11.14177 1.000 -38.6750 42.1473 
HPC4 -5.30844 11.14177 1.000 -45.7196 35.1027 
HPC5 -8.81077 11.14177 .996 -49.2219 31.6004 
HPC6 -5.57406 11.14177 1.000 -45.9852 34.8371 
conventional 
HPC 
-4.70640 11.14177 1.000 -45.1176 35.7047 
HPC4 HPC1 5.22088 11.14177 1.000 -35.1903 45.6320 
HPC2 7.04464 11.14177 .999 -33.3665 47.4558 
HPC3 5.30844 11.14177 1.000 -35.1027 45.7196 
HPC5 -3.50232 11.14177 1.000 -43.9135 36.9088 
HPC6 -.26561 11.14177 1.000 -40.6768 40.1455 
conventional 
HPC 
.60204 11.14177 1.000 -39.8091 41.0132 
HPC5 HPC1 8.72320 11.14177 .996 -31.6880 49.1343 
HPC2 10.54696 11.14177 .989 -29.8642 50.9581 
HPC3 8.81077 11.14177 .996 -31.6004 49.2219 
HPC4 3.50232 11.14177 1.000 -36.9088 43.9135 
HPC6 3.23671 11.14177 1.000 -37.1744 43.6479 
conventional 
HPC 
4.10436 11.14177 1.000 -36.3068 44.5155 
HPC6 HPC1 5.48649 11.14177 1.000 -34.9247 45.8976 
HPC2 7.31025 11.14177 .999 -33.1009 47.7214 
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HPC3 5.57406 11.14177 1.000 -34.8371 45.9852 
HPC4 .26561 11.14177 1.000 -40.1455 40.6768 
HPC5 -3.23671 11.14177 1.000 -43.6479 37.1744 
conventional 
HPC 
.86765 11.14177 1.000 -39.5435 41.2788 
conventional 
HPC 
HPC1 4.61883 11.14177 1.000 -35.7923 45.0300 
HPC2 6.44260 11.14177 .999 -33.9686 46.8537 
HPC3 4.70640 11.14177 1.000 -35.7047 45.1176 
HPC4 -.60204 11.14177 1.000 -41.0132 39.8091 
HPC5 -4.10436 11.14177 1.000 -44.5155 36.3068 
HPC6 -.86765 11.14177 1.000 -41.2788 39.5435 
 
 
 
 
 
 
 
Homogeneous Subsets 
Drug release 
Scheffea   
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formula N 
Subset for 
alpha = 0.05 
1 
HPC2 15 34.9292 
HPC3 15 36.6654 
HPC1 15 36.7530 
conventional 
HPC 
15 41.3718 
HPC4 15 41.9739 
HPC6 15 42.2395 
HPC5 15 45.4762 
Sig.  .989 
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Release Kinetics for HPC metformin liquisolid formulations 
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